data_1n1u_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1n1u _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.44 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 10.4 tp10 . . . . . 0 C--O 1.238 0.496 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.627 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.3 p -110.77 153.54 25.19 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.108 0.48 . . . . 0.0 111.158 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.617 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 21.5 t -121.05 38.91 3.94 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.092 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.9 t -62.93 -40.48 89.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.404 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.1 5.41 83.07 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.849 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.0 11.56 84.34 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.93 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.2 p -148.08 142.42 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.243 0.217 . . . . 0.0 110.745 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.421 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.4 m -103.67 159.41 15.64 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.994 0.426 . . . . 0.0 110.153 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.7 m-80 -81.34 -38.64 26.37 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.463 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.451 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -70.43 125.01 91.87 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.207 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.1 Cg_exo -65.71 136.2 44.85 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.791 2.328 . . . . 0.0 112.013 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 23.88 74.51 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.709 -0.678 . . . . 0.0 113.05 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.04 137.63 36.56 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.3 148.21 23.68 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.4 t -83.8 137.05 33.9 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.43 0.633 . . . . 0.0 111.413 -179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' HG22 ' A' ' 21' ' ' VAL . 30.9 m -144.62 58.95 1.32 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.4 t90 -31.82 127.45 0.32 Allowed Pre-proline 0 N--CA 1.463 0.211 0 O-C-N 124.516 1.135 . . . . 0.0 112.628 -177.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -94.62 28.44 17.2 Favored 'Cis proline' 0 N--CA 1.46 -0.456 0 C-N-CA 123.278 -1.551 . . . . 0.0 114.142 0.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.627 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 12.6 m -126.3 -176.7 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.617 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.8 m -127.77 140.4 52.07 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.994 0.426 . . . . 0.0 111.091 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 40.1 p -132.25 157.26 44.83 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.728 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.412 ' HG2' ' OD1' ' A' ' 25' ' ' ASN . 54.9 ttp85 -147.02 127.8 14.35 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.412 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 7.7 m120 60.16 31.61 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 O-C-N 123.422 0.451 . . . . 0.0 110.768 -178.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.29 14.44 81.91 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.967 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.6 mt -127.41 135.95 28.2 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -60.36 141.53 95.91 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.069 1.846 . . . . 0.0 111.652 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.44 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 20.8 t . . . . . 0 C--N 1.317 -0.805 0 CA-C-O 121.483 0.659 . . . . 0.0 110.189 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.552 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 44.9 tt0 . . . . . 0 N--CA 1.453 -0.295 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.548 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.2 p -101.87 152.21 21.18 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.944 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.0 t -117.58 40.92 2.96 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.841 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.5 t -62.32 -41.22 90.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.587 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.27 12.94 63.07 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.597 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.4 30.24 77.15 Favored Glycine 0 C--N 1.319 -0.392 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.36 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.66 149.24 29.59 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.892 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.422 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 60.2 m -123.56 171.76 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.343 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -88.46 -32.57 18.2 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.406 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.521 HG21 ' HD2' ' A' ' 13' ' ' PRO . 27.7 m -74.08 127.51 87.89 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.521 ' HD2' HG21 ' A' ' 12' ' ' THR . 41.3 Cg_endo -68.33 131.31 23.04 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.195 1.93 . . . . 0.0 111.644 179.299 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.73 29.39 69.53 Favored Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.627 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.48 146.76 24.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.758 0.313 . . . . 0.0 110.477 179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.66 144.88 26.0 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -96.53 130.86 43.62 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.262 0.553 . . . . 0.0 111.592 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.454 ' O ' HG21 ' A' ' 21' ' ' VAL . 59.6 m -131.98 63.13 1.62 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -33.87 127.94 0.44 Allowed Pre-proline 0 N--CA 1.462 0.158 0 O-C-N 124.382 1.051 . . . . 0.0 112.2 -177.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -96.96 33.73 9.54 Favored 'Cis proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.574 -1.428 . . . . 0.0 114.335 0.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.548 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.2 m -129.6 164.25 32.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.268 0.556 . . . . 0.0 112.205 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.552 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 92.2 m -97.06 150.89 20.31 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.872 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.409 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 3.1 p -138.56 141.51 39.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.632 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 33.3 mtm180 -125.77 119.34 27.64 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 57.55 41.62 25.53 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.773 0.671 . . . . 0.0 109.984 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.72 13.29 74.92 Favored Glycine 0 CA--C 1.52 0.395 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.202 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 43.8 tp -112.81 125.01 30.57 Favored Pre-proline 0 C--N 1.326 -0.433 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.409 ' HA ' ' CG2' ' A' ' 23' ' ' THR . 18.9 Cg_exo -63.5 142.31 84.11 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.344 2.03 . . . . 0.0 112.088 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.404 HG11 ' HB2' ' A' ' 3' ' ' GLU . 35.7 t . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.378 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.8 tp10 . . . . . 0 C--O 1.238 0.485 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 46.5 p -107.58 151.74 25.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.011 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.485 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.7 t -119.32 41.81 3.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.022 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.9 t -62.42 -39.63 85.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.694 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.36 12.87 61.54 Favored Glycine 0 N--CA 1.453 -0.222 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.891 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.41 21.87 74.52 Favored Glycine 0 C--N 1.321 -0.301 0 C-N-CA 121.453 -0.403 . . . . 0.0 112.614 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.86 147.66 27.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 110.614 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 15.7 m -114.74 167.01 11.14 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.14 0.495 . . . . 0.0 110.219 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -90.63 -34.71 15.35 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.788 178.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.444 HG22 ' HD2' ' A' ' 13' ' ' PRO . 23.3 m -67.88 126.06 92.15 Favored Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.398 -1.274 . . . . 0.0 111.326 -179.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD2' HG22 ' A' ' 12' ' ' THR . 34.4 Cg_endo -65.88 133.45 33.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.439 2.092 . . . . 0.0 112.137 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 31.63 74.37 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.714 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.96 139.21 34.95 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.615 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.48 149.02 23.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.559 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.4 t -88.88 135.6 33.45 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.27 0.557 . . . . 0.0 111.379 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.569 ' O ' HG23 ' A' ' 21' ' ' VAL . 43.6 m -141.03 59.71 1.52 Allowed 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.402 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.3 t90 -32.01 127.16 0.34 Allowed Pre-proline 0 N--CA 1.464 0.227 0 O-C-N 124.649 1.218 . . . . 0.0 112.496 -177.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.402 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.2 Cg_endo -96.02 31.08 12.91 Favored 'Cis proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.175 0.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.5 m -127.77 175.79 8.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.5 ' HB2' ' CG ' ' A' ' 3' ' ' GLU . 87.3 m -117.37 143.17 46.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.175 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 38.8 p -135.8 159.27 42.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.484 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -150.14 126.47 10.74 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.0 t30 60.03 34.8 21.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.518 0.675 . . . . 0.0 110.193 -178.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.59 14.07 79.87 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.995 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.5 mt -122.89 127.51 25.7 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 14.5 Cg_exo -65.82 142.1 68.15 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.415 2.076 . . . . 0.0 112.188 -179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.544 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.7 t . . . . . 0 C--N 1.317 -0.815 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.493 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.467 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 6.1 tp10 . . . . . 0 C--O 1.238 0.496 0 CA-C-O 121.149 0.499 . . . . 0.0 110.3 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.9 p -107.88 153.0 23.67 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.983 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.408 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.4 t -120.7 40.49 3.51 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.049 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -61.94 -40.13 86.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.585 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.91 12.44 61.86 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.762 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.04 21.61 75.54 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 121.557 -0.354 . . . . 0.0 112.739 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.13 147.12 26.67 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 122.427 0.291 . . . . 0.0 110.939 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 18.5 m -112.07 167.36 10.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.038 0.447 . . . . 0.0 109.953 179.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -88.68 -35.64 16.65 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.472 ' O ' ' HB3' ' A' ' 15' ' ' ALA . 26.9 m -68.7 125.38 91.74 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 114.282 -1.326 . . . . 0.0 111.586 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 15.2 Cg_exo -66.17 133.37 32.79 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.554 2.169 . . . . 0.0 111.447 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.76 31.68 70.36 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.719 -0.673 . . . . 0.0 112.724 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.472 ' HB3' ' O ' ' A' ' 12' ' ' THR . . . -99.54 141.33 32.48 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.85 0.357 . . . . 0.0 110.468 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.1 m -89.45 149.1 23.09 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.656 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -90.81 136.32 33.15 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.279 0.562 . . . . 0.0 110.996 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.571 ' O ' HG22 ' A' ' 21' ' ' VAL . 56.9 m -142.66 60.42 1.43 Allowed 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -32.58 127.89 0.36 Allowed Pre-proline 0 N--CA 1.463 0.213 0 O-C-N 124.627 1.205 . . . . 0.0 112.45 -177.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -94.83 29.27 15.92 Favored 'Cis proline' 0 N--CA 1.46 -0.477 0 C-N-CA 123.238 -1.567 . . . . 0.0 114.22 0.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.0 m -126.88 179.88 3.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.985 0.422 . . . . 0.0 112.095 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.467 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 96.9 m -117.95 148.37 42.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.065 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 13.4 p -131.95 157.03 45.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 0.0 110.74 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.707 ' O ' ' HG ' ' A' ' 27' ' ' LEU . 53.7 ttp180 -150.31 130.56 13.67 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.6 t30 57.71 33.48 23.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 110.938 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.74 16.81 80.41 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.819 -0.628 . . . . 0.0 113.941 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.707 ' HG ' ' O ' ' A' ' 24' ' ' ARG . 3.9 pp -133.88 135.66 25.03 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.404 0.602 . . . . 0.0 109.871 178.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_exo -64.93 141.83 72.64 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.599 2.199 . . . . 0.0 112.722 -178.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 43.9 t . . . . . 0 C--N 1.317 -0.823 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.13 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.602 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.9 tp10 . . . . . 0 C--O 1.239 0.516 0 CA-C-O 121.109 0.481 . . . . 0.0 110.363 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.581 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.1 p -108.44 152.04 25.23 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.863 179.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.6 t -119.0 40.81 3.21 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.098 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -62.23 -40.37 87.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 13.24 62.49 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.728 179.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.5 24.55 73.81 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 121.529 -0.367 . . . . 0.0 112.694 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 147.84 27.68 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 122.459 0.304 . . . . 0.0 110.927 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.5 m -118.28 164.11 15.69 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -88.76 -35.33 16.74 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.091 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.438 ' O ' ' HB1' ' A' ' 15' ' ' ALA . 24.6 m -67.9 125.49 91.45 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 114.574 -1.194 . . . . 0.0 111.361 -179.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.72 133.74 35.24 Favored 'Trans proline' 0 N--CA 1.46 -0.476 0 C-N-CA 122.694 2.263 . . . . 0.0 111.797 179.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.64 27.67 72.13 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.968 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.438 ' HB1' ' O ' ' A' ' 12' ' ' THR . . . -97.71 136.32 38.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.827 0.346 . . . . 0.0 110.31 179.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 149.94 22.82 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -86.16 136.61 33.13 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.299 0.571 . . . . 0.0 111.393 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.602 ' O ' HG23 ' A' ' 21' ' ' VAL . 40.9 m -142.89 59.56 1.42 Allowed 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.334 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.0 t90 -32.08 127.38 0.34 Allowed Pre-proline 0 N--CA 1.465 0.288 0 O-C-N 124.675 1.234 . . . . 0.0 112.598 -177.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -95.6 30.32 14.14 Favored 'Cis proline' 0 N--CA 1.459 -0.506 0 C-N-CA 123.432 -1.487 . . . . 0.0 114.132 0.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.602 HG23 ' O ' ' A' ' 18' ' ' SER . 10.5 m -127.27 176.73 6.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 97.0 m -119.29 140.54 50.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.383 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 39.5 p -130.68 131.93 45.12 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.277 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.4 ttp85 -98.67 106.64 18.93 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.8 t30 60.16 37.68 20.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.552 0.692 . . . . 0.0 109.399 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.26 -12.17 65.41 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.466 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -96.92 111.75 58.55 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 117.239 0.52 . . . . 0.0 110.396 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -49.14 138.47 28.4 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.943 2.428 . . . . 0.0 113.56 -179.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.602 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 44.6 t . . . . . 0 C--N 1.317 -0.834 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.541 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.426 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 14.7 tp10 . . . . . 0 C--O 1.238 0.482 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.3 p -108.22 152.41 24.63 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.134 0.492 . . . . 0.0 111.074 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.433 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.9 t -119.67 39.37 3.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.02 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.8 t -62.48 -40.42 88.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.443 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.05 3.84 84.73 Favored Glycine 0 C--O 1.227 -0.326 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.764 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.446 ' O ' HG23 ' A' ' 9' ' ' THR . . . 78.96 14.61 81.8 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.999 179.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.446 HG23 ' O ' ' A' ' 8' ' ' GLY . 18.6 p -148.35 141.86 25.39 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.148 0.179 . . . . 0.0 110.928 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.7 m -106.19 167.6 9.71 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -90.86 -33.9 15.47 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.645 0.736 . . . . 0.0 109.051 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.464 ' O ' ' HB3' ' A' ' 15' ' ' ALA . 34.9 m -63.88 126.99 91.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 114.834 -1.076 . . . . 0.0 111.018 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.39 128.83 23.54 Favored 'Trans proline' 0 C--O 1.237 0.446 0 C-N-CA 122.549 2.166 . . . . 0.0 112.4 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.38 31.77 79.89 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.186 -0.916 . . . . 0.0 112.781 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.464 ' HB3' ' O ' ' A' ' 12' ' ' THR . . . -89.82 143.34 26.88 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.871 0.367 . . . . 0.0 110.825 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.55 148.01 23.63 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.586 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -91.71 136.12 33.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.201 0.524 . . . . 0.0 110.883 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.8 m -142.34 59.96 1.45 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -32.56 127.91 0.36 Allowed Pre-proline 0 N--CA 1.463 0.186 0 O-C-N 124.625 1.203 . . . . 0.0 112.473 -177.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -94.47 27.76 18.22 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.293 -1.545 . . . . 0.0 114.178 0.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.9 m -124.78 -179.25 2.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.026 0.441 . . . . 0.0 111.959 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.9 m -119.79 150.34 40.58 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.299 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.463 HG21 ' HA ' ' A' ' 28' ' ' PRO . 7.6 p -130.26 154.13 47.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.631 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.445 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 14.7 tpt85 -142.14 124.22 15.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 24.3 t30 57.09 38.94 29.38 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.261 0.553 . . . . 0.0 110.793 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.62 16.97 76.18 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.342 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.1 mt -126.48 131.16 23.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.463 ' HA ' HG21 ' A' ' 23' ' ' THR . 16.7 Cg_exo -63.41 140.83 78.47 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.107 1.871 . . . . 0.0 112.214 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.426 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 33.9 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.814 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.609 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 5.5 mm-40 . . . . . 0 CA--C 1.514 -0.441 0 CA-C-O 121.251 0.548 . . . . 0.0 111.827 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -115.01 147.93 39.48 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.546 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.438 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.2 t -117.71 39.8 3.25 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.222 0.534 . . . . 0.0 110.091 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 32.2 t -64.05 -40.7 89.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.008 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.25 12.68 68.5 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.595 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.438 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 65.8 31.04 78.51 Favored Glycine 0 C--N 1.319 -0.381 0 CA-C-N 115.467 -0.366 . . . . 0.0 112.786 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.79 148.54 28.63 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.602 -0.299 . . . . 0.0 110.971 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 23.5 m -125.2 167.87 14.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.081 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -90.3 -33.62 16.04 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.41 -0.813 . . . . 0.0 109.201 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.532 HG21 ' HD2' ' A' ' 24' ' ' ARG . 18.8 m -68.14 124.27 89.28 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.987 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -64.89 129.53 23.51 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.478 2.119 . . . . 0.0 111.87 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 37.33 86.03 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.488 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.434 ' HB1' ' HB ' ' A' ' 12' ' ' THR . . . -97.08 144.24 27.14 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.927 0.394 . . . . 0.0 110.915 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 150.65 22.49 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.696 178.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.5 t -93.94 135.43 35.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.21 0.529 . . . . 0.0 111.329 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.605 ' O ' HG23 ' A' ' 21' ' ' VAL . 66.9 m -141.63 61.92 1.46 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -32.56 126.99 0.37 Allowed Pre-proline 0 N--CA 1.462 0.159 0 O-C-N 124.554 1.159 . . . . 0.0 112.371 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.5 Cg_endo -97.18 32.77 10.51 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.585 -1.423 . . . . 0.0 114.171 0.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 18' ' ' SER . 8.7 m -130.34 169.95 20.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.609 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 88.7 m -106.51 148.3 28.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.459 HG23 ' HA ' ' A' ' 28' ' ' PRO . 15.7 p -133.44 157.29 45.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.357 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.532 ' HD2' HG21 ' A' ' 12' ' ' THR . 26.9 ttt-85 -150.35 130.54 13.61 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 58.68 31.43 21.13 Favored 'General case' 0 C--N 1.328 -0.354 0 O-C-N 123.509 0.505 . . . . 0.0 110.943 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.98 18.83 80.17 Favored Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.859 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.0 mt -129.41 132.04 24.01 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.459 ' HA ' HG23 ' A' ' 23' ' ' THR . 14.4 Cg_exo -64.83 140.85 68.92 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 122.18 1.92 . . . . 0.0 112.27 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.314 -0.943 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.455 179.391 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.479 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.7 tp10 . . . . . 0 C--O 1.241 0.636 0 CA-C-O 121.317 0.58 . . . . 0.0 110.71 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.653 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.6 p -111.88 152.95 27.38 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.586 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.469 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 33.0 t -115.88 37.54 3.6 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.349 0.595 . . . . 0.0 110.28 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.2 t -64.91 -38.36 82.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.024 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.12 2.48 87.63 Favored Glycine 0 C--O 1.227 -0.321 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.894 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.52 3.01 90.01 Favored Glycine 0 C--N 1.317 -0.489 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.175 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.2 p -146.18 142.57 28.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.635 0.218 . . . . 0.0 110.839 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 m -101.06 160.25 14.54 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.14 0.495 . . . . 0.0 110.571 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -84.49 -37.75 20.93 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.34 178.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.456 ' O ' ' HB1' ' A' ' 15' ' ' ALA . 92.7 m -65.48 125.66 90.02 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.239 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -62.83 133.05 39.87 Favored 'Trans proline' 0 C--O 1.237 0.452 0 C-N-CA 122.787 2.325 . . . . 0.0 112.489 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.4 29.88 71.55 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.278 -0.874 . . . . 0.0 113.092 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.456 ' HB1' ' O ' ' A' ' 12' ' ' THR . . . -98.59 135.81 39.58 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.545 179.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 150.01 22.66 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.804 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.2 t -82.54 135.72 35.02 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.303 0.573 . . . . 0.0 111.444 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.2 m -143.57 59.03 1.39 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -32.88 128.57 0.37 Allowed Pre-proline 0 N--CA 1.462 0.167 0 O-C-N 124.605 1.19 . . . . 0.0 112.793 -177.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -93.05 25.66 22.16 Favored 'Cis proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.072 -1.637 . . . . 0.0 114.242 0.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.653 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.4 m -125.01 -173.79 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.469 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 96.0 m -126.25 144.72 50.68 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.346 -179.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.407 HG23 ' HA ' ' A' ' 28' ' ' PRO . 40.3 p -134.36 153.03 52.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.453 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttp180 -141.11 126.03 18.19 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.8 t30 58.75 36.21 24.73 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.612 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.91 14.23 80.29 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 113.003 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 45.1 tp -123.07 124.24 26.55 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.407 ' HA ' HG23 ' A' ' 23' ' ' THR . 16.9 Cg_exo -63.74 140.62 75.13 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.147 1.898 . . . . 0.0 112.334 -179.472 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.479 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 38.8 t . . . . . 0 C--N 1.314 -0.951 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.21 179.328 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.58 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.6 tp10 . . . . . 0 C--O 1.24 0.555 0 CA-C-O 121.222 0.534 . . . . 0.0 109.95 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.7 p -110.85 151.23 28.09 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.237 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.467 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 12.0 t -118.01 39.26 3.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.979 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.5 t -62.2 -40.8 88.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.473 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.97 13.63 60.79 Favored Glycine 0 N--CA 1.452 -0.298 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.39 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.0 20.96 75.18 Favored Glycine 0 C--N 1.32 -0.324 0 CA-C-N 115.398 -0.401 . . . . 0.0 112.694 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.38 26.26 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.108 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 m -115.16 165.11 13.28 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -86.24 -36.89 19.13 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 28.0 m -61.11 125.54 84.04 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.959 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -63.38 130.93 30.01 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.729 2.286 . . . . 0.0 112.578 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 63.19 33.17 86.53 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.229 -0.896 . . . . 0.0 113.141 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.16 145.98 25.08 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.837 0.351 . . . . 0.0 110.503 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.15 147.55 24.13 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -92.31 135.99 33.56 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.289 0.566 . . . . 0.0 111.074 -179.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.432 ' O ' HG22 ' A' ' 21' ' ' VAL . 41.2 m -143.28 59.82 1.4 Allowed 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -32.14 127.5 0.34 Allowed Pre-proline 0 N--CA 1.463 0.224 0 O-C-N 124.587 1.179 . . . . 0.0 112.572 -177.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -95.18 28.71 16.78 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.402 -1.499 . . . . 0.0 114.157 0.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.584 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.7 m -125.15 177.89 4.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.969 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.58 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 95.3 m -118.67 149.05 42.06 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.216 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.479 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.2 p -132.75 166.06 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.338 0.589 . . . . 0.0 111.368 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -150.31 120.37 7.2 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.374 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.0 t30 57.14 38.48 29.02 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.275 0.56 . . . . 0.0 110.874 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.65 10.6 84.77 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-N 115.83 -0.623 . . . . 0.0 113.522 179.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.0 mt -121.55 131.95 24.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.479 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -62.87 141.66 85.46 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.222 1.948 . . . . 0.0 112.312 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.429 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 48.0 t . . . . . 0 C--N 1.319 -0.731 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.916 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.556 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 25.3 tt0 . . . . . 0 C--O 1.235 0.299 0 CA-C-O 121.092 0.473 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.564 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 47.8 p -103.21 151.98 22.01 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.6 t -117.92 40.12 3.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.215 0.531 . . . . 0.0 109.865 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -62.29 -40.99 89.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.541 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.65 13.31 60.95 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.557 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.81 23.57 74.13 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.559 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 146.84 26.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.624 -0.288 . . . . 0.0 111.058 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.4 m -111.51 167.54 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.831 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -83.73 -34.27 24.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.11 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.443 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.1 m -81.6 128.08 70.7 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.206 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 22.3 Cg_exo -63.43 137.67 61.43 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.714 2.276 . . . . 0.0 111.814 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.95 29.59 66.83 Favored Glycine 0 N--CA 1.453 -0.21 0 CA-C-N 115.868 -0.605 . . . . 0.0 112.714 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.599 ' HB1' HH11 ' A' ' 24' ' ' ARG . . . -93.91 144.97 24.97 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.845 0.355 . . . . 0.0 110.647 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.51 147.88 23.73 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -97.04 136.38 37.67 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.297 0.57 . . . . 0.0 111.208 -179.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.601 ' O ' HG23 ' A' ' 21' ' ' VAL . 49.8 m -142.79 60.64 1.43 Allowed 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.61 127.65 0.36 Allowed Pre-proline 0 N--CA 1.463 0.188 0 O-C-N 124.567 1.167 . . . . 0.0 112.475 -177.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -95.55 29.62 15.27 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.365 -1.514 . . . . 0.0 114.16 0.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 18' ' ' SER . 13.2 m -125.42 175.3 7.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 120.936 0.398 . . . . 0.0 112.007 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.556 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 68.0 m -113.5 148.17 36.53 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.202 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.6 p -128.55 156.88 42.62 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.828 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.599 HH11 ' HB1' ' A' ' 15' ' ' ALA . 7.4 ttp-105 -150.11 128.12 11.89 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 m120 58.75 32.69 22.45 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.668 0.605 . . . . 0.0 110.796 -178.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.68 20.46 79.8 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.849 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -129.37 133.04 24.67 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -64.79 141.09 70.33 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.23 1.953 . . . . 0.0 112.009 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 C--N 1.315 -0.899 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.126 179.909 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.542 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.9 tp10 . . . . . 0 C--O 1.24 0.563 0 CA-C-O 121.378 0.608 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 45.0 p -113.72 153.25 29.31 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.938 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.586 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 16.2 t -121.52 38.9 3.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.241 0.543 . . . . 0.0 110.349 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -63.29 -37.95 80.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.5 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.51 11.56 50.86 Favored Glycine 0 C--O 1.228 -0.232 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.066 179.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.23 2.06 82.41 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.857 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.78 145.43 25.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.576 0.227 . . . . 0.0 110.7 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.7 m -91.86 163.39 14.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.995 0.426 . . . . 0.0 109.869 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 t30 -85.94 -36.21 20.0 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.487 -0.779 . . . . 0.0 108.965 178.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 25.9 m -69.02 124.64 90.81 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.76 132.43 28.58 Favored 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.344 2.029 . . . . 0.0 111.992 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.49 34.44 50.03 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.747 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -110.93 143.11 42.1 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.686 0.279 . . . . 0.0 110.263 179.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.2 148.52 23.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.115 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.2 t -89.7 138.59 31.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.234 0.54 . . . . 0.0 111.509 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.511 ' O ' HG21 ' A' ' 21' ' ' VAL . 43.4 m -146.72 60.1 1.2 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.495 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.7 t90 -32.32 128.19 0.34 Allowed Pre-proline 0 N--CA 1.464 0.261 0 O-C-N 124.515 1.134 . . . . 0.0 112.618 -177.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -94.01 25.88 21.7 Favored 'Cis proline' 0 N--CA 1.46 -0.445 0 C-N-CA 123.196 -1.585 . . . . 0.0 113.957 0.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.8 m -124.49 -174.86 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 O-C-N 122.111 -0.368 . . . . 0.0 111.692 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.586 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 92.6 m -125.6 153.13 44.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.985 0.421 . . . . 0.0 111.277 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.487 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 20.9 p -134.69 162.39 32.48 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.916 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 59.3 ttt180 -150.42 126.03 10.27 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 59.76 31.37 20.78 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.843 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.67 13.25 83.37 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.857 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -117.94 130.52 24.66 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.487 ' HA ' ' CG2' ' A' ' 23' ' ' THR . 13.0 Cg_exo -65.86 139.91 58.94 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.247 1.965 . . . . 0.0 112.576 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.315 -0.901 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.267 179.262 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.512 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.9 tp10 . . . . . 0 C--O 1.242 0.658 0 CA-C-O 121.315 0.579 . . . . 0.0 110.82 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.664 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.8 p -113.1 153.67 27.82 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.824 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.537 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 27.4 t -119.1 37.37 4.15 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.285 0.564 . . . . 0.0 110.223 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.8 t -63.3 -38.34 81.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.216 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.65 10.88 60.81 Favored Glycine 0 N--CA 1.453 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.825 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.54 4.68 85.09 Favored Glycine 0 C--N 1.318 -0.442 0 C-N-CA 121.366 -0.445 . . . . 0.0 112.911 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.79 145.72 25.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.519 0.2 . . . . 0.0 110.744 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -94.26 159.85 14.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.207 0.527 . . . . 0.0 110.267 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -80.05 -39.98 28.65 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.231 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.436 HG22 ' NH2' ' A' ' 24' ' ' ARG . 36.0 m -80.42 121.69 81.79 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.812 179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.62 142.14 76.05 Favored 'Trans proline' 0 C--O 1.235 0.375 0 C-N-CA 122.839 2.36 . . . . 0.0 112.721 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.47 2.26 87.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 121.06 -0.591 . . . . 0.0 113.163 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.3 137.97 31.92 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.05 149.37 23.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.882 0.373 . . . . 0.0 110.002 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -80.51 136.84 36.37 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.29 0.567 . . . . 0.0 111.586 -179.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.492 ' O ' HG21 ' A' ' 21' ' ' VAL . 50.3 m -145.92 59.12 1.24 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -32.63 128.57 0.35 Allowed Pre-proline 0 N--CA 1.463 0.208 0 O-C-N 124.677 1.236 . . . . 0.0 112.657 -177.246 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -92.72 25.35 22.65 Favored 'Cis proline' 0 N--CA 1.461 -0.423 0 C-N-CA 123.108 -1.622 . . . . 0.0 114.231 0.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.664 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.6 m -125.19 -172.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 C-N-CA 120.495 -0.482 . . . . 0.0 112.259 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 76.2 m -128.1 143.63 51.07 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.413 HG23 ' HA ' ' A' ' 28' ' ' PRO . 67.6 p -134.13 145.14 49.01 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.587 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.436 ' NH2' HG22 ' A' ' 12' ' ' THR . 60.9 ttm-85 -111.73 109.49 19.37 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.58 35.84 22.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.34 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.53 -16.48 58.98 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.405 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.0 tp -89.42 119.07 69.6 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 117.112 0.456 . . . . 0.0 109.856 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.413 ' HA ' HG23 ' A' ' 23' ' ' THR . 23.3 Cg_exo -59.28 139.11 88.52 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 122.063 1.842 . . . . 0.0 112.547 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.512 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 41.9 t . . . . . 0 C--N 1.314 -0.936 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.063 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.443 ' CG ' ' HB2' ' A' ' 22' ' ' CYS . 9.8 tp10 . . . . . 0 C--O 1.241 0.636 0 CA-C-O 121.157 0.504 . . . . 0.0 110.479 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.0 p -112.31 152.68 28.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.79 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.533 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 22.6 t -117.2 38.92 3.39 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.209 0.528 . . . . 0.0 110.332 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.28 -39.97 87.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.06 179.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.7 11.77 65.45 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.642 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.26 19.02 75.53 Favored Glycine 0 C--N 1.319 -0.371 0 C-N-CA 121.623 -0.322 . . . . 0.0 112.852 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.12 147.45 27.08 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 122.407 0.283 . . . . 0.0 110.83 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 m -115.4 158.81 21.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.997 0.427 . . . . 0.0 110.315 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -82.12 -38.16 25.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.479 178.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.425 ' O ' ' HB1' ' A' ' 15' ' ' ALA . 98.1 m -64.42 125.27 88.12 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.959 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -64.01 132.68 35.35 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.772 2.315 . . . . 0.0 112.016 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.33 28.36 71.45 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.546 -0.752 . . . . 0.0 112.818 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.425 ' HB1' ' O ' ' A' ' 12' ' ' THR . . . -94.18 136.61 34.29 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.031 0.443 . . . . 0.0 110.521 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -89.36 147.74 23.9 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.568 179.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.2 t -82.59 135.15 35.14 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.189 0.519 . . . . 0.0 111.175 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.575 ' O ' HG22 ' A' ' 21' ' ' VAL . 45.0 m -143.09 58.83 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -32.88 128.54 0.37 Allowed Pre-proline 0 N--CA 1.463 0.191 0 O-C-N 124.673 1.233 . . . . 0.0 112.705 -177.295 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -93.31 25.56 22.38 Favored 'Cis proline' 0 N--CA 1.461 -0.409 0 C-N-CA 123.071 -1.637 . . . . 0.0 114.144 0.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.629 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.4 m -123.75 -174.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.068 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.6 m -126.11 146.85 49.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.485 HG22 ' HA ' ' A' ' 28' ' ' PRO . 18.4 p -127.57 166.33 18.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.15 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 43.3 ttp85 -151.18 119.15 6.22 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 57.15 41.25 27.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.506 0.669 . . . . 0.0 110.354 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.75 11.9 77.97 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.565 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.5 mt -121.57 127.58 26.01 Favored Pre-proline 0 C--N 1.325 -0.5 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.485 ' HA ' HG22 ' A' ' 23' ' ' THR . 17.4 Cg_exo -62.98 141.9 85.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.2 1.934 . . . . 0.0 112.416 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.439 HG13 ' HB2' ' A' ' 3' ' ' GLU . 39.8 t . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.448 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.648 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.6 tp10 . . . . . 0 C--O 1.239 0.526 0 CA-C-O 121.079 0.466 . . . . 0.0 110.372 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.4 p -107.71 151.42 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.485 179.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.521 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 14.8 t -116.92 40.86 2.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.108 0.48 . . . . 0.0 110.367 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.2 t -62.93 -40.58 89.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.377 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 13.1 62.58 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.778 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 22.2 74.78 Favored Glycine 0 C--N 1.319 -0.386 0 C-N-CA 121.593 -0.337 . . . . 0.0 112.804 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.08 147.49 27.15 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.384 0.274 . . . . 0.0 110.797 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.0 m -117.79 159.64 22.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.058 0.456 . . . . 0.0 110.224 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -82.26 -37.89 25.23 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.354 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.4 m -65.43 125.79 90.23 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.069 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.55 131.99 29.64 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 122.546 2.164 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.64 34.99 73.6 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.888 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.36 137.8 38.29 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.57 146.24 25.25 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -86.16 130.62 34.47 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 121.293 0.568 . . . . 0.0 111.706 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 75.1 m -137.52 62.1 1.59 Allowed 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.99 127.88 0.38 Allowed Pre-proline 0 N--CA 1.462 0.131 0 CA-C-N 114.619 -1.173 . . . . 0.0 112.581 -177.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -95.95 30.49 13.82 Favored 'Cis proline' 0 N--CA 1.46 -0.493 0 C-N-CA 123.493 -1.461 . . . . 0.0 114.112 0.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.553 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.1 m -126.92 177.06 5.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.521 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.3 m -119.98 141.42 49.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.164 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 14.4 p -132.41 141.66 48.96 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.89 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 44.1 ttt85 -131.1 127.71 38.69 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.4 t30 57.77 37.14 27.08 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.335 0.588 . . . . 0.0 110.54 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.52 18.2 76.9 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.778 -0.646 . . . . 0.0 113.001 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.452 HD13 ' HD2' ' A' ' 28' ' ' PRO . 37.6 tp -129.74 128.02 22.95 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.452 ' HD2' HD13 ' A' ' 27' ' ' LEU . 20.1 Cg_exo -61.5 141.01 90.4 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 121.988 1.792 . . . . 0.0 111.932 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.648 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.3 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.755 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.508 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 12.4 mm-40 . . . . . 0 CA--C 1.515 -0.403 0 CA-C-O 121.089 0.471 . . . . 0.0 111.189 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.7 p -113.11 148.21 35.75 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.743 178.291 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.519 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 11.2 t -118.03 40.0 3.25 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.057 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -64.37 -41.67 93.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.29 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.3 6.58 78.31 Favored Glycine 0 C--O 1.227 -0.283 0 CA-C-N 115.683 -0.689 . . . . 0.0 112.395 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.519 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 73.32 29.49 64.11 Favored Glycine 0 C--N 1.319 -0.399 0 CA-C-N 115.329 -0.436 . . . . 0.0 112.891 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.8 p -145.84 142.36 28.76 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 122.219 0.208 . . . . 0.0 111.073 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 20.9 m -122.13 169.05 11.26 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 178.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -94.02 -33.4 13.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.425 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 18.2 m -64.13 122.52 78.1 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.031 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.09 128.46 20.67 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.461 2.107 . . . . 0.0 111.753 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 37.23 84.48 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.437 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.45 143.86 27.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.999 0.428 . . . . 0.0 110.904 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.57 150.9 22.21 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.567 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.8 t -92.81 135.21 34.32 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.116 0.484 . . . . 0.0 111.368 -179.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.602 ' O ' HG21 ' A' ' 21' ' ' VAL . 64.7 m -141.67 62.47 1.45 Allowed 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.392 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.8 t90 -32.6 126.78 0.37 Allowed Pre-proline 0 N--CA 1.463 0.184 0 O-C-N 124.57 1.169 . . . . 0.0 112.374 -177.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 53.1 Cg_endo -97.62 32.78 10.37 Favored 'Cis proline' 0 N--CA 1.457 -0.621 0 C-N-CA 123.639 -1.4 . . . . 0.0 114.21 0.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.602 HG21 ' O ' ' A' ' 18' ' ' SER . 6.1 m -130.04 169.13 21.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.508 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 96.4 m -105.48 147.52 28.22 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.687 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.412 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 17.7 p -133.24 158.63 42.41 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.844 0.354 . . . . 0.0 110.535 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 28.6 ttt-85 -150.36 130.18 13.3 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 59.01 31.54 21.46 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 123.541 0.526 . . . . 0.0 110.884 -178.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.81 17.94 80.11 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.766 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.4 mt -126.45 131.41 23.92 Favored Pre-proline 0 C--N 1.326 -0.444 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 14.4 Cg_exo -65.26 140.83 66.17 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.275 1.983 . . . . 0.0 112.278 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.6 t . . . . . 0 C--N 1.316 -0.88 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.532 179.44 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.529 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 64.3 mm-40 . . . . . 0 CA--C 1.513 -0.459 0 CA-C-O 121.157 0.504 . . . . 0.0 111.266 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.621 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.9 p -115.33 150.38 36.38 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.733 178.243 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.5 t -120.4 38.14 4.07 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.243 0.544 . . . . 0.0 109.981 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.6 t -64.13 -41.75 93.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.075 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.62 6.21 83.86 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.49 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.35 20.43 77.08 Favored Glycine 0 C--N 1.318 -0.444 0 CA-C-N 115.331 -0.435 . . . . 0.0 112.971 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 20.7 p -147.05 141.76 26.72 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 122.1 0.16 . . . . 0.0 110.919 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.3 m -108.07 165.36 11.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.123 0.487 . . . . 0.0 110.445 179.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -83.12 -38.15 22.81 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.838 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.403 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -73.55 122.23 87.09 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.804 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.3 Cg_exo -64.96 133.55 36.34 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.744 2.296 . . . . 0.0 112.168 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 25.66 70.92 Favored Glycine 0 CA--C 1.519 0.284 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.036 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -92.17 147.38 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.659 0.266 . . . . 0.0 110.342 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -88.86 149.6 23.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.949 179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.6 t -91.55 136.56 33.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.167 0.508 . . . . 0.0 111.352 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 21' ' ' VAL . 50.1 m -144.9 61.78 1.31 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.453 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.2 127.14 0.35 Allowed Pre-proline 0 N--CA 1.465 0.277 0 O-C-N 124.608 1.193 . . . . 0.0 112.594 -177.407 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 44.4 Cg_endo -96.53 30.24 14.12 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.547 -1.439 . . . . 0.0 114.002 0.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.621 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.2 m -128.4 175.13 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 89.1 m -112.94 150.74 31.41 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.845 0.355 . . . . 0.0 111.204 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.412 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 13.0 p -131.67 160.61 34.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.633 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -150.54 127.96 11.42 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.7 m-20 58.99 33.72 23.19 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 123.655 0.597 . . . . 0.0 110.841 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.35 16.65 79.79 Favored Glycine 0 C--N 1.33 0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 112.863 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.426 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.7 mt -126.59 133.86 25.44 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 16.5 Cg_exo -63.26 141.18 81.07 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.313 2.009 . . . . 0.0 112.154 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.918 179.672 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.473 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 11.4 tp10 . . . . . 0 C--O 1.241 0.654 0 CA-C-O 121.301 0.572 . . . . 0.0 110.727 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.659 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -113.04 152.65 29.25 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.723 179.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.509 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 28.5 t -116.54 36.69 4.02 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.328 0.585 . . . . 0.0 110.222 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.7 t -65.03 -37.89 81.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.92 179.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.1 3.38 86.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.768 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.419 ' O ' HG23 ' A' ' 9' ' ' THR . . . 83.42 1.75 90.24 Favored Glycine 0 C--N 1.318 -0.444 0 C-N-CA 121.348 -0.454 . . . . 0.0 113.306 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 8' ' ' GLY . 16.7 p -147.3 141.69 26.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.697 0.248 . . . . 0.0 111.012 179.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.413 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.2 m -98.62 161.2 13.79 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.336 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -87.93 -35.83 17.45 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.509 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.463 ' O ' ' HB3' ' A' ' 15' ' ' ALA . 83.1 m -64.86 126.09 90.34 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -62.39 132.64 39.29 Favored 'Trans proline' 0 C--O 1.238 0.487 0 C-N-CA 122.785 2.323 . . . . 0.0 112.446 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.45 30.33 71.27 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.995 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.463 ' HB3' ' O ' ' A' ' 12' ' ' THR . . . -98.52 135.06 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.556 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.55 148.83 23.16 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.828 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -81.31 135.89 35.73 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.285 0.564 . . . . 0.0 111.381 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.583 ' O ' HG22 ' A' ' 21' ' ' VAL . 50.5 m -144.24 59.03 1.35 Allowed 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.322 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -32.97 128.75 0.37 Allowed Pre-proline 0 N--CA 1.462 0.169 0 O-C-N 124.63 1.206 . . . . 0.0 112.76 -177.256 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -92.7 24.91 23.6 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.066 -1.639 . . . . 0.0 114.209 0.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.659 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.5 m -124.97 -172.32 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 O-C-N 121.988 -0.445 . . . . 0.0 112.168 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.509 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.5 m -127.74 146.79 50.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.084 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.443 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.9 p -134.22 162.64 31.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.453 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.5 ttp180 -150.17 125.86 10.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.3 t30 60.03 33.4 21.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.418 0.628 . . . . 0.0 110.567 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.53 9.05 87.09 Favored Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.696 -0.684 . . . . 0.0 113.288 179.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 9.2 mp -118.78 129.79 25.19 Favored Pre-proline 0 C--N 1.327 -0.396 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.443 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.1 Cg_exo -64.97 140.81 67.81 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.247 1.965 . . . . 0.0 112.331 -179.612 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.473 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.4 t . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.107 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.663 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 2.6 mm-40 . . . . . 0 C--O 1.238 0.464 0 CA-C-O 121.124 0.488 . . . . 0.0 111.388 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.585 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 33.0 p -116.92 147.45 42.21 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.037 178.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.5 t -117.27 40.22 3.08 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.866 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 33.8 t -64.2 -42.35 95.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.385 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.78 7.83 76.84 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.395 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.515 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 72.04 31.03 64.65 Favored Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.405 -0.397 . . . . 0.0 112.774 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.3 p -144.92 142.89 30.25 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.646 -0.277 . . . . 0.0 110.89 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 17.6 m -124.94 165.22 18.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.985 0.421 . . . . 0.0 110.018 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -87.21 -33.98 19.15 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.766 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.49 HG23 ' HD2' ' A' ' 24' ' ' ARG . 19.7 m -70.29 125.84 92.13 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.176 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -65.94 129.97 23.32 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.456 2.104 . . . . 0.0 111.865 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.2 37.86 87.22 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.327 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -94.78 144.78 25.36 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.899 0.38 . . . . 0.0 110.713 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.26 148.96 23.3 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.508 178.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.8 t -93.64 134.14 36.26 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.238 0.542 . . . . 0.0 111.325 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.569 ' O ' HG21 ' A' ' 21' ' ' VAL . 50.6 m -140.03 61.77 1.52 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.272 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.0 t90 -32.16 126.36 0.35 Allowed Pre-proline 0 N--CA 1.463 0.185 0 O-C-N 124.504 1.128 . . . . 0.0 112.481 -177.462 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -98.36 33.81 9.16 Favored 'Cis proline' 0 N--CA 1.458 -0.595 0 C-N-CA 123.675 -1.385 . . . . 0.0 114.167 0.744 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.585 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 4.3 m -130.32 163.11 36.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.663 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 81.7 m -102.44 145.62 29.27 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.984 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 30.6 p -133.42 164.03 28.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.118 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.49 ' HD2' HG23 ' A' ' 12' ' ' THR . 30.5 ttt-85 -150.85 123.59 8.58 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.581 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.4 t30 58.84 34.65 23.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.426 0.631 . . . . 0.0 110.678 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.35 9.43 87.01 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.602 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.485 HD12 ' HA ' ' A' ' 27' ' ' LEU . 3.4 mm? -120.48 130.79 24.68 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.126 0.463 . . . . 0.0 109.917 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -63.76 141.71 79.93 Favored 'Trans proline' 0 N--CA 1.46 -0.462 0 C-N-CA 122.26 1.974 . . . . 0.0 112.253 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.482 ' CG1' ' HG3' ' A' ' 3' ' ' GLU . 37.2 t . . . . . 0 C--N 1.318 -0.786 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.857 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.625 ' OE2' ' HB3' ' A' ' 10' ' ' CYS . 48.2 tt0 . . . . . 0 C--O 1.235 0.339 0 CA-C-O 121.247 0.546 . . . . 0.0 111.05 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 24.4 p -108.69 152.63 24.55 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.607 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.2 t -119.19 41.34 3.1 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.156 0.503 . . . . 0.0 109.704 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.5 t -62.66 -39.64 85.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.687 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.76 11.61 59.08 Favored Glycine 0 N--CA 1.452 -0.241 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.726 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.74 19.28 73.09 Favored Glycine 0 C--N 1.319 -0.369 0 C-N-CA 121.532 -0.366 . . . . 0.0 112.558 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.25 26.18 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 122.559 0.343 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.625 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 39.3 m -106.83 172.11 7.0 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.028 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -96.8 -29.84 13.52 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.975 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.756 HG21 HH21 ' A' ' 24' ' ' ARG . 5.3 m -79.93 124.84 82.97 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.574 -179.651 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 36.2 Cg_exo -60.35 135.97 65.04 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.905 2.403 . . . . 0.0 112.913 -179.37 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.56 32.75 79.42 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.543 -0.753 . . . . 0.0 113.437 179.423 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.74 147.11 26.4 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.52 150.28 22.52 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -98.0 138.09 35.84 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.214 0.531 . . . . 0.0 111.04 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.8 m -144.2 62.92 1.34 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -33.01 127.26 0.39 Allowed Pre-proline 0 N--CA 1.465 0.296 0 O-C-N 124.563 1.164 . . . . 0.0 112.32 -177.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -97.08 33.11 10.13 Favored 'Cis proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.505 -1.456 . . . . 0.0 114.24 0.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.598 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.4 m -129.8 169.99 19.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.439 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 99.4 m -107.33 148.08 29.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.475 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.499 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 33.1 p -137.3 168.7 19.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.101 0.476 . . . . 0.0 110.664 -179.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.756 HH21 HG21 ' A' ' 12' ' ' THR . 56.9 ttm-85 -151.09 120.0 6.64 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.373 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 m120 57.85 36.64 26.54 Favored 'General case' 0 N--CA 1.467 0.417 0 O-C-N 123.41 0.444 . . . . 0.0 111.331 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.15 7.0 88.74 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 121.095 -0.574 . . . . 0.0 113.188 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.435 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 94.1 mt -113.34 126.17 28.57 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.462 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.499 ' HA ' ' CG2' ' A' ' 23' ' ' THR . 12.2 Cg_exo -67.5 140.94 53.88 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.395 2.064 . . . . 0.0 112.879 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.9 t . . . . . 0 C--N 1.318 -0.8 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.129 178.789 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.538 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 6.2 tp10 . . . . . 0 C--O 1.241 0.656 0 CA-C-O 121.224 0.535 . . . . 0.0 110.182 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 44.7 p -111.45 151.64 28.33 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.057 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 15.3 t -118.04 39.5 3.38 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.101 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.4 t -62.87 -40.6 89.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.475 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.57 4.81 85.19 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.76 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.21 13.56 82.72 Favored Glycine 0 C--N 1.317 -0.527 0 C-N-CA 121.433 -0.413 . . . . 0.0 113.03 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.4 p -147.82 142.04 26.16 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.155 0.182 . . . . 0.0 110.858 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 m -106.98 163.05 13.3 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 178.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 t30 -87.62 -35.73 17.89 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.719 0.771 . . . . 0.0 109.286 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.428 ' O ' ' HB2' ' A' ' 15' ' ' ALA . 32.2 m -65.85 126.01 90.97 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 114.76 -1.109 . . . . 0.0 111.213 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -64.45 133.77 38.76 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.519 2.146 . . . . 0.0 112.472 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.9 29.51 72.51 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.307 -0.86 . . . . 0.0 113.02 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.428 ' HB2' ' O ' ' A' ' 12' ' ' THR . . . -95.94 137.11 35.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.811 0.339 . . . . 0.0 110.621 179.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.3 149.43 23.05 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.585 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.5 t -86.61 136.2 33.14 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.352 0.596 . . . . 0.0 111.6 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.563 ' O ' HG22 ' A' ' 21' ' ' VAL . 43.5 m -143.48 59.44 1.39 Allowed 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.198 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -31.94 127.43 0.33 Allowed Pre-proline 0 N--CA 1.464 0.245 0 O-C-N 124.506 1.129 . . . . 0.0 112.543 -177.297 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -95.29 29.28 15.86 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.352 -1.52 . . . . 0.0 114.134 0.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.9 m -126.92 179.31 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.538 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 92.9 m -120.9 144.31 48.49 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.243 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.47 HG21 ' HA ' ' A' ' 28' ' ' PRO . 34.7 p -134.85 155.92 49.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.642 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -148.19 130.36 15.49 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.0 m120 59.74 30.99 20.58 Favored 'General case' 0 N--CA 1.465 0.3 0 O-C-N 123.589 0.556 . . . . 0.0 110.934 -178.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.19 17.58 80.2 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.753 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.405 HD13 ' HD2' ' A' ' 28' ' ' PRO . 36.4 tp -129.59 129.06 23.13 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' HG21 ' A' ' 23' ' ' THR . 20.5 Cg_exo -62.19 142.7 92.74 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.195 1.93 . . . . 0.0 111.854 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.519 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 46.0 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.702 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.23 0 CA-C-O 120.398 0.142 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.84 25.42 25.24 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.803 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.44 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 10.4 tp10 -73.02 121.97 21.0 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.627 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.3 p -110.77 153.54 25.19 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.108 0.48 . . . . 0.0 111.158 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.617 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 21.5 t -121.05 38.91 3.94 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.092 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.9 t -62.93 -40.48 89.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.404 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.1 5.41 83.07 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.849 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.0 11.56 84.34 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.93 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.2 p -148.08 142.42 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.243 0.217 . . . . 0.0 110.745 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.421 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.4 m -103.67 159.41 15.64 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.994 0.426 . . . . 0.0 110.153 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.7 m-80 -81.34 -38.64 26.37 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.463 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.451 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -70.43 125.01 91.87 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.207 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.1 Cg_exo -65.71 136.2 44.85 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.791 2.328 . . . . 0.0 112.013 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 23.88 74.51 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.709 -0.678 . . . . 0.0 113.05 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.04 137.63 36.56 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.3 148.21 23.68 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.4 t -83.8 137.05 33.9 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.43 0.633 . . . . 0.0 111.413 -179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' HG22 ' A' ' 21' ' ' VAL . 30.9 m -144.62 58.95 1.32 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.4 t90 -31.82 127.45 0.32 Allowed Pre-proline 0 N--CA 1.463 0.211 0 O-C-N 124.516 1.135 . . . . 0.0 112.628 -177.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -94.62 28.44 17.2 Favored 'Cis proline' 0 N--CA 1.46 -0.456 0 C-N-CA 123.278 -1.551 . . . . 0.0 114.142 0.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.627 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 12.6 m -126.3 -176.7 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.617 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.8 m -127.77 140.4 52.07 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.994 0.426 . . . . 0.0 111.091 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 40.1 p -132.25 157.26 44.83 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.728 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.412 ' HG2' ' OD1' ' A' ' 25' ' ' ASN . 54.9 ttp85 -147.02 127.8 14.35 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.412 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 7.7 m120 60.16 31.61 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 O-C-N 123.422 0.451 . . . . 0.0 110.768 -178.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.29 14.44 81.91 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.967 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.6 mt -127.41 135.95 28.2 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -60.36 141.53 95.91 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.069 1.846 . . . . 0.0 111.652 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.44 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 20.8 t . . . . . 0 C--N 1.317 -0.805 0 CA-C-O 121.483 0.659 . . . . 0.0 110.189 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.459 0 CA-C-O 120.682 0.277 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.19 -39.06 2.86 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.552 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 44.9 tt0 -80.24 108.4 13.81 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.548 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.2 p -101.87 152.21 21.18 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.944 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.0 t -117.58 40.92 2.96 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.841 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.5 t -62.32 -41.22 90.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.587 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.27 12.94 63.07 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.597 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.4 30.24 77.15 Favored Glycine 0 C--N 1.319 -0.392 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.36 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.66 149.24 29.59 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.892 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.422 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 60.2 m -123.56 171.76 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.343 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -88.46 -32.57 18.2 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.406 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.521 HG21 ' HD2' ' A' ' 13' ' ' PRO . 27.7 m -74.08 127.51 87.89 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.521 ' HD2' HG21 ' A' ' 12' ' ' THR . 41.3 Cg_endo -68.33 131.31 23.04 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.195 1.93 . . . . 0.0 111.644 179.299 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.73 29.39 69.53 Favored Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.627 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.48 146.76 24.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.758 0.313 . . . . 0.0 110.477 179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.66 144.88 26.0 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -96.53 130.86 43.62 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.262 0.553 . . . . 0.0 111.592 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.454 ' O ' HG21 ' A' ' 21' ' ' VAL . 59.6 m -131.98 63.13 1.62 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -33.87 127.94 0.44 Allowed Pre-proline 0 N--CA 1.462 0.158 0 O-C-N 124.382 1.051 . . . . 0.0 112.2 -177.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -96.96 33.73 9.54 Favored 'Cis proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.574 -1.428 . . . . 0.0 114.335 0.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.548 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.2 m -129.6 164.25 32.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.268 0.556 . . . . 0.0 112.205 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.552 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 92.2 m -97.06 150.89 20.31 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.872 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.409 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 3.1 p -138.56 141.51 39.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.632 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 33.3 mtm180 -125.77 119.34 27.64 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 57.55 41.62 25.53 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.773 0.671 . . . . 0.0 109.984 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.72 13.29 74.92 Favored Glycine 0 CA--C 1.52 0.395 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.202 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 43.8 tp -112.81 125.01 30.57 Favored Pre-proline 0 C--N 1.326 -0.433 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.409 ' HA ' ' CG2' ' A' ' 23' ' ' THR . 18.9 Cg_exo -63.5 142.31 84.11 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.344 2.03 . . . . 0.0 112.088 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.404 HG11 ' HB2' ' A' ' 3' ' ' GLU . 35.7 t . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.378 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.119 0 N-CA-C 112.227 0.454 . . . . 0.0 112.227 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.83 22.56 75.62 Favored Glycine 0 N--CA 1.453 -0.224 0 CA-C-N 115.483 -0.78 . . . . 0.0 113.33 179.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.8 tp10 -115.42 112.37 22.21 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 46.5 p -107.58 151.74 25.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.011 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.485 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.7 t -119.32 41.81 3.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.022 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.9 t -62.42 -39.63 85.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.694 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.36 12.87 61.54 Favored Glycine 0 N--CA 1.453 -0.222 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.891 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.41 21.87 74.52 Favored Glycine 0 C--N 1.321 -0.301 0 C-N-CA 121.453 -0.403 . . . . 0.0 112.614 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.86 147.66 27.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 110.614 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 15.7 m -114.74 167.01 11.14 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.14 0.495 . . . . 0.0 110.219 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -90.63 -34.71 15.35 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.788 178.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.444 HG22 ' HD2' ' A' ' 13' ' ' PRO . 23.3 m -67.88 126.06 92.15 Favored Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.398 -1.274 . . . . 0.0 111.326 -179.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD2' HG22 ' A' ' 12' ' ' THR . 34.4 Cg_endo -65.88 133.45 33.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.439 2.092 . . . . 0.0 112.137 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 31.63 74.37 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.714 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.96 139.21 34.95 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.615 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.48 149.02 23.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.559 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.4 t -88.88 135.6 33.45 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.27 0.557 . . . . 0.0 111.379 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.569 ' O ' HG23 ' A' ' 21' ' ' VAL . 43.6 m -141.03 59.71 1.52 Allowed 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.402 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.3 t90 -32.01 127.16 0.34 Allowed Pre-proline 0 N--CA 1.464 0.227 0 O-C-N 124.649 1.218 . . . . 0.0 112.496 -177.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.402 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.2 Cg_endo -96.02 31.08 12.91 Favored 'Cis proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.175 0.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.5 m -127.77 175.79 8.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.5 ' HB2' ' CG ' ' A' ' 3' ' ' GLU . 87.3 m -117.37 143.17 46.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.175 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 38.8 p -135.8 159.27 42.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.484 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -150.14 126.47 10.74 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.0 t30 60.03 34.8 21.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.518 0.675 . . . . 0.0 110.193 -178.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.59 14.07 79.87 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.995 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.5 mt -122.89 127.51 25.7 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 14.5 Cg_exo -65.82 142.1 68.15 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.415 2.076 . . . . 0.0 112.188 -179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.544 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.7 t . . . . . 0 C--N 1.317 -0.815 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.493 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.88 0.371 . . . . 0.0 111.837 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.63 -31.58 3.87 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.899 -0.591 . . . . 0.0 112.787 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.467 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 6.1 tp10 -72.1 109.97 6.25 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.149 0.499 . . . . 0.0 110.3 -179.617 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.9 p -107.88 153.0 23.67 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.983 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.408 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.4 t -120.7 40.49 3.51 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.049 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -61.94 -40.13 86.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.585 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.91 12.44 61.86 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.762 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.04 21.61 75.54 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 121.557 -0.354 . . . . 0.0 112.739 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.13 147.12 26.67 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 122.427 0.291 . . . . 0.0 110.939 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 18.5 m -112.07 167.36 10.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.038 0.447 . . . . 0.0 109.953 179.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -88.68 -35.64 16.65 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.472 ' O ' ' HB3' ' A' ' 15' ' ' ALA . 26.9 m -68.7 125.38 91.74 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 114.282 -1.326 . . . . 0.0 111.586 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 15.2 Cg_exo -66.17 133.37 32.79 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.554 2.169 . . . . 0.0 111.447 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.76 31.68 70.36 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.719 -0.673 . . . . 0.0 112.724 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.472 ' HB3' ' O ' ' A' ' 12' ' ' THR . . . -99.54 141.33 32.48 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.85 0.357 . . . . 0.0 110.468 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.1 m -89.45 149.1 23.09 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.656 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -90.81 136.32 33.15 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.279 0.562 . . . . 0.0 110.996 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.571 ' O ' HG22 ' A' ' 21' ' ' VAL . 56.9 m -142.66 60.42 1.43 Allowed 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -32.58 127.89 0.36 Allowed Pre-proline 0 N--CA 1.463 0.213 0 O-C-N 124.627 1.205 . . . . 0.0 112.45 -177.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -94.83 29.27 15.92 Favored 'Cis proline' 0 N--CA 1.46 -0.477 0 C-N-CA 123.238 -1.567 . . . . 0.0 114.22 0.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.0 m -126.88 179.88 3.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.985 0.422 . . . . 0.0 112.095 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.467 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 96.9 m -117.95 148.37 42.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.065 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 13.4 p -131.95 157.03 45.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 0.0 110.74 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.707 ' O ' ' HG ' ' A' ' 27' ' ' LEU . 53.7 ttp180 -150.31 130.56 13.67 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.6 t30 57.71 33.48 23.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 110.938 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.74 16.81 80.41 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.819 -0.628 . . . . 0.0 113.941 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.707 ' HG ' ' O ' ' A' ' 24' ' ' ARG . 3.9 pp -133.88 135.66 25.03 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.404 0.602 . . . . 0.0 109.871 178.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_exo -64.93 141.83 72.64 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.599 2.199 . . . . 0.0 112.722 -178.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 43.9 t . . . . . 0 C--N 1.317 -0.823 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.13 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.165 0 N-CA-C 112.126 0.417 . . . . 0.0 112.126 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.86 24.05 74.26 Favored Glycine 0 N--CA 1.452 -0.264 0 CA-C-N 115.459 -0.791 . . . . 0.0 113.613 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.602 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.9 tp10 -112.48 114.92 27.85 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.109 0.481 . . . . 0.0 110.363 179.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.581 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.1 p -108.44 152.04 25.23 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.863 179.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.6 t -119.0 40.81 3.21 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.098 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -62.23 -40.37 87.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 13.24 62.49 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.728 179.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.5 24.55 73.81 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 121.529 -0.367 . . . . 0.0 112.694 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 147.84 27.68 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 122.459 0.304 . . . . 0.0 110.927 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.5 m -118.28 164.11 15.69 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -88.76 -35.33 16.74 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.091 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.438 ' O ' ' HB1' ' A' ' 15' ' ' ALA . 24.6 m -67.9 125.49 91.45 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 114.574 -1.194 . . . . 0.0 111.361 -179.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.72 133.74 35.24 Favored 'Trans proline' 0 N--CA 1.46 -0.476 0 C-N-CA 122.694 2.263 . . . . 0.0 111.797 179.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.64 27.67 72.13 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.968 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.438 ' HB1' ' O ' ' A' ' 12' ' ' THR . . . -97.71 136.32 38.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.827 0.346 . . . . 0.0 110.31 179.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 149.94 22.82 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -86.16 136.61 33.13 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.299 0.571 . . . . 0.0 111.393 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.602 ' O ' HG23 ' A' ' 21' ' ' VAL . 40.9 m -142.89 59.56 1.42 Allowed 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.334 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.0 t90 -32.08 127.38 0.34 Allowed Pre-proline 0 N--CA 1.465 0.288 0 O-C-N 124.675 1.234 . . . . 0.0 112.598 -177.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -95.6 30.32 14.14 Favored 'Cis proline' 0 N--CA 1.459 -0.506 0 C-N-CA 123.432 -1.487 . . . . 0.0 114.132 0.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.602 HG23 ' O ' ' A' ' 18' ' ' SER . 10.5 m -127.27 176.73 6.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 97.0 m -119.29 140.54 50.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.383 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 39.5 p -130.68 131.93 45.12 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.277 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.4 ttp85 -98.67 106.64 18.93 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.8 t30 60.16 37.68 20.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.552 0.692 . . . . 0.0 109.399 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.26 -12.17 65.41 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.466 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -96.92 111.75 58.55 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 117.239 0.52 . . . . 0.0 110.396 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -49.14 138.47 28.4 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.943 2.428 . . . . 0.0 113.56 -179.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.602 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 44.6 t . . . . . 0 C--N 1.317 -0.834 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.541 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.178 0 CA-C-O 120.814 0.34 . . . . 0.0 111.447 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.82 -35.25 3.68 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.413 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.426 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 14.7 tp10 -71.74 109.38 5.59 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.3 p -108.22 152.41 24.63 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.134 0.492 . . . . 0.0 111.074 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.433 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.9 t -119.67 39.37 3.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.02 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.8 t -62.48 -40.42 88.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.443 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.05 3.84 84.73 Favored Glycine 0 C--O 1.227 -0.326 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.764 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.446 ' O ' HG23 ' A' ' 9' ' ' THR . . . 78.96 14.61 81.8 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.999 179.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.446 HG23 ' O ' ' A' ' 8' ' ' GLY . 18.6 p -148.35 141.86 25.39 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.148 0.179 . . . . 0.0 110.928 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.7 m -106.19 167.6 9.71 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -90.86 -33.9 15.47 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.645 0.736 . . . . 0.0 109.051 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.464 ' O ' ' HB3' ' A' ' 15' ' ' ALA . 34.9 m -63.88 126.99 91.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 114.834 -1.076 . . . . 0.0 111.018 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.39 128.83 23.54 Favored 'Trans proline' 0 C--O 1.237 0.446 0 C-N-CA 122.549 2.166 . . . . 0.0 112.4 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.38 31.77 79.89 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.186 -0.916 . . . . 0.0 112.781 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.464 ' HB3' ' O ' ' A' ' 12' ' ' THR . . . -89.82 143.34 26.88 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.871 0.367 . . . . 0.0 110.825 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.55 148.01 23.63 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.586 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -91.71 136.12 33.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.201 0.524 . . . . 0.0 110.883 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.8 m -142.34 59.96 1.45 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -32.56 127.91 0.36 Allowed Pre-proline 0 N--CA 1.463 0.186 0 O-C-N 124.625 1.203 . . . . 0.0 112.473 -177.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -94.47 27.76 18.22 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.293 -1.545 . . . . 0.0 114.178 0.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.9 m -124.78 -179.25 2.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.026 0.441 . . . . 0.0 111.959 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.9 m -119.79 150.34 40.58 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.299 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.463 HG21 ' HA ' ' A' ' 28' ' ' PRO . 7.6 p -130.26 154.13 47.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.631 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.445 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 14.7 tpt85 -142.14 124.22 15.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 24.3 t30 57.09 38.94 29.38 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.261 0.553 . . . . 0.0 110.793 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.62 16.97 76.18 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.342 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.1 mt -126.48 131.16 23.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.463 ' HA ' HG21 ' A' ' 23' ' ' THR . 16.7 Cg_exo -63.41 140.83 78.47 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.107 1.871 . . . . 0.0 112.214 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.426 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 33.9 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.814 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.094 0 CA-C-O 120.872 0.368 . . . . 0.0 111.835 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.44 -33.82 4.41 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.935 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.609 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 5.5 mm-40 -72.11 120.85 18.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.251 0.548 . . . . 0.0 111.827 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -115.01 147.93 39.48 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.546 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.438 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.2 t -117.71 39.8 3.25 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.222 0.534 . . . . 0.0 110.091 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 32.2 t -64.05 -40.7 89.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.008 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.25 12.68 68.5 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.595 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.438 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 65.8 31.04 78.51 Favored Glycine 0 C--N 1.319 -0.381 0 CA-C-N 115.467 -0.366 . . . . 0.0 112.786 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.79 148.54 28.63 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.602 -0.299 . . . . 0.0 110.971 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 23.5 m -125.2 167.87 14.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.081 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -90.3 -33.62 16.04 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.41 -0.813 . . . . 0.0 109.201 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.532 HG21 ' HD2' ' A' ' 24' ' ' ARG . 18.8 m -68.14 124.27 89.28 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.987 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -64.89 129.53 23.51 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.478 2.119 . . . . 0.0 111.87 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 37.33 86.03 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.488 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.434 ' HB1' ' HB ' ' A' ' 12' ' ' THR . . . -97.08 144.24 27.14 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.927 0.394 . . . . 0.0 110.915 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 150.65 22.49 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.696 178.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.5 t -93.94 135.43 35.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.21 0.529 . . . . 0.0 111.329 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.605 ' O ' HG23 ' A' ' 21' ' ' VAL . 66.9 m -141.63 61.92 1.46 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -32.56 126.99 0.37 Allowed Pre-proline 0 N--CA 1.462 0.159 0 O-C-N 124.554 1.159 . . . . 0.0 112.371 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.5 Cg_endo -97.18 32.77 10.51 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.585 -1.423 . . . . 0.0 114.171 0.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 18' ' ' SER . 8.7 m -130.34 169.95 20.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.609 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 88.7 m -106.51 148.3 28.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.459 HG23 ' HA ' ' A' ' 28' ' ' PRO . 15.7 p -133.44 157.29 45.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.357 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.532 ' HD2' HG21 ' A' ' 12' ' ' THR . 26.9 ttt-85 -150.35 130.54 13.61 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 58.68 31.43 21.13 Favored 'General case' 0 C--N 1.328 -0.354 0 O-C-N 123.509 0.505 . . . . 0.0 110.943 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.98 18.83 80.17 Favored Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.859 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.0 mt -129.41 132.04 24.01 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.459 ' HA ' HG23 ' A' ' 23' ' ' THR . 14.4 Cg_exo -64.83 140.85 68.92 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 122.18 1.92 . . . . 0.0 112.27 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.314 -0.943 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.455 179.391 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.14 0 CA-C-O 120.832 0.349 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.65 -29.39 4.52 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.133 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.479 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.7 tp10 -73.11 112.88 9.56 Favored 'General case' 0 C--O 1.241 0.636 0 CA-C-O 121.317 0.58 . . . . 0.0 110.71 -179.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.653 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.6 p -111.88 152.95 27.38 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.586 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.469 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 33.0 t -115.88 37.54 3.6 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.349 0.595 . . . . 0.0 110.28 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.2 t -64.91 -38.36 82.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.024 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.12 2.48 87.63 Favored Glycine 0 C--O 1.227 -0.321 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.894 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.52 3.01 90.01 Favored Glycine 0 C--N 1.317 -0.489 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.175 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.2 p -146.18 142.57 28.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.635 0.218 . . . . 0.0 110.839 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 m -101.06 160.25 14.54 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.14 0.495 . . . . 0.0 110.571 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -84.49 -37.75 20.93 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.34 178.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.456 ' O ' ' HB1' ' A' ' 15' ' ' ALA . 92.7 m -65.48 125.66 90.02 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.239 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -62.83 133.05 39.87 Favored 'Trans proline' 0 C--O 1.237 0.452 0 C-N-CA 122.787 2.325 . . . . 0.0 112.489 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.4 29.88 71.55 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.278 -0.874 . . . . 0.0 113.092 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.456 ' HB1' ' O ' ' A' ' 12' ' ' THR . . . -98.59 135.81 39.58 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.545 179.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 150.01 22.66 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.804 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.2 t -82.54 135.72 35.02 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.303 0.573 . . . . 0.0 111.444 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.2 m -143.57 59.03 1.39 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -32.88 128.57 0.37 Allowed Pre-proline 0 N--CA 1.462 0.167 0 O-C-N 124.605 1.19 . . . . 0.0 112.793 -177.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -93.05 25.66 22.16 Favored 'Cis proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.072 -1.637 . . . . 0.0 114.242 0.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.653 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.4 m -125.01 -173.79 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.469 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 96.0 m -126.25 144.72 50.68 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.346 -179.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.407 HG23 ' HA ' ' A' ' 28' ' ' PRO . 40.3 p -134.36 153.03 52.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.453 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttp180 -141.11 126.03 18.19 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.8 t30 58.75 36.21 24.73 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.612 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.91 14.23 80.29 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 113.003 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 45.1 tp -123.07 124.24 26.55 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.407 ' HA ' HG23 ' A' ' 23' ' ' THR . 16.9 Cg_exo -63.74 140.62 75.13 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.147 1.898 . . . . 0.0 112.334 -179.472 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.479 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 38.8 t . . . . . 0 C--N 1.314 -0.951 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.21 179.328 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.238 0 CA-C-O 120.778 0.323 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 72.58 37.08 58.29 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.894 -0.594 . . . . 0.0 112.947 179.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.58 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.6 tp10 -138.63 114.48 9.98 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.222 0.534 . . . . 0.0 109.95 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.7 p -110.85 151.23 28.09 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.237 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.467 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 12.0 t -118.01 39.26 3.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.979 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.5 t -62.2 -40.8 88.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.473 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.97 13.63 60.79 Favored Glycine 0 N--CA 1.452 -0.298 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.39 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.0 20.96 75.18 Favored Glycine 0 C--N 1.32 -0.324 0 CA-C-N 115.398 -0.401 . . . . 0.0 112.694 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.38 26.26 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.108 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 m -115.16 165.11 13.28 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -86.24 -36.89 19.13 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 28.0 m -61.11 125.54 84.04 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.959 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -63.38 130.93 30.01 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.729 2.286 . . . . 0.0 112.578 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 63.19 33.17 86.53 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.229 -0.896 . . . . 0.0 113.141 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.16 145.98 25.08 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.837 0.351 . . . . 0.0 110.503 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.15 147.55 24.13 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -92.31 135.99 33.56 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.289 0.566 . . . . 0.0 111.074 -179.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.432 ' O ' HG22 ' A' ' 21' ' ' VAL . 41.2 m -143.28 59.82 1.4 Allowed 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -32.14 127.5 0.34 Allowed Pre-proline 0 N--CA 1.463 0.224 0 O-C-N 124.587 1.179 . . . . 0.0 112.572 -177.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -95.18 28.71 16.78 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.402 -1.499 . . . . 0.0 114.157 0.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.584 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.7 m -125.15 177.89 4.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.969 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.58 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 95.3 m -118.67 149.05 42.06 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.216 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.479 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.2 p -132.75 166.06 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.338 0.589 . . . . 0.0 111.368 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -150.31 120.37 7.2 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.374 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.0 t30 57.14 38.48 29.02 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.275 0.56 . . . . 0.0 110.874 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.65 10.6 84.77 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-N 115.83 -0.623 . . . . 0.0 113.522 179.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.0 mt -121.55 131.95 24.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.479 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -62.87 141.66 85.46 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.222 1.948 . . . . 0.0 112.312 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.429 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 48.0 t . . . . . 0 C--N 1.319 -0.731 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.916 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.51 -36.96 3.57 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.602 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.556 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 25.3 tt0 -80.4 111.37 16.74 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.092 0.473 . . . . 0.0 110.311 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.564 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 47.8 p -103.21 151.98 22.01 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.6 t -117.92 40.12 3.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.215 0.531 . . . . 0.0 109.865 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -62.29 -40.99 89.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.541 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.65 13.31 60.95 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.557 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.81 23.57 74.13 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.559 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 146.84 26.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.624 -0.288 . . . . 0.0 111.058 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.4 m -111.51 167.54 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.831 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -83.73 -34.27 24.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.11 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.443 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.1 m -81.6 128.08 70.7 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.206 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 22.3 Cg_exo -63.43 137.67 61.43 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.714 2.276 . . . . 0.0 111.814 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.95 29.59 66.83 Favored Glycine 0 N--CA 1.453 -0.21 0 CA-C-N 115.868 -0.605 . . . . 0.0 112.714 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.599 ' HB1' HH11 ' A' ' 24' ' ' ARG . . . -93.91 144.97 24.97 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.845 0.355 . . . . 0.0 110.647 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.51 147.88 23.73 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -97.04 136.38 37.67 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.297 0.57 . . . . 0.0 111.208 -179.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.601 ' O ' HG23 ' A' ' 21' ' ' VAL . 49.8 m -142.79 60.64 1.43 Allowed 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.61 127.65 0.36 Allowed Pre-proline 0 N--CA 1.463 0.188 0 O-C-N 124.567 1.167 . . . . 0.0 112.475 -177.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -95.55 29.62 15.27 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.365 -1.514 . . . . 0.0 114.16 0.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 18' ' ' SER . 13.2 m -125.42 175.3 7.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 120.936 0.398 . . . . 0.0 112.007 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.556 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 68.0 m -113.5 148.17 36.53 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.202 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.6 p -128.55 156.88 42.62 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.828 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.599 HH11 ' HB1' ' A' ' 15' ' ' ALA . 7.4 ttp-105 -150.11 128.12 11.89 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 m120 58.75 32.69 22.45 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.668 0.605 . . . . 0.0 110.796 -178.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.68 20.46 79.8 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.849 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -129.37 133.04 24.67 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -64.79 141.09 70.33 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.23 1.953 . . . . 0.0 112.009 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 C--N 1.315 -0.899 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.126 179.909 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.068 0 CA-C-O 120.914 0.388 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -90.76 35.89 3.75 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.647 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.542 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.9 tp10 -160.15 123.74 3.58 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-O 121.378 0.608 . . . . 0.0 110.868 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 45.0 p -113.72 153.25 29.31 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.938 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.586 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 16.2 t -121.52 38.9 3.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.241 0.543 . . . . 0.0 110.349 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -63.29 -37.95 80.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.5 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.51 11.56 50.86 Favored Glycine 0 C--O 1.228 -0.232 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.066 179.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.23 2.06 82.41 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.857 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.78 145.43 25.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.576 0.227 . . . . 0.0 110.7 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.7 m -91.86 163.39 14.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.995 0.426 . . . . 0.0 109.869 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 t30 -85.94 -36.21 20.0 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.487 -0.779 . . . . 0.0 108.965 178.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 25.9 m -69.02 124.64 90.81 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.76 132.43 28.58 Favored 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.344 2.029 . . . . 0.0 111.992 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.49 34.44 50.03 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.747 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -110.93 143.11 42.1 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.686 0.279 . . . . 0.0 110.263 179.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.2 148.52 23.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.115 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.2 t -89.7 138.59 31.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.234 0.54 . . . . 0.0 111.509 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.511 ' O ' HG21 ' A' ' 21' ' ' VAL . 43.4 m -146.72 60.1 1.2 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.495 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.7 t90 -32.32 128.19 0.34 Allowed Pre-proline 0 N--CA 1.464 0.261 0 O-C-N 124.515 1.134 . . . . 0.0 112.618 -177.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -94.01 25.88 21.7 Favored 'Cis proline' 0 N--CA 1.46 -0.445 0 C-N-CA 123.196 -1.585 . . . . 0.0 113.957 0.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.8 m -124.49 -174.86 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 O-C-N 122.111 -0.368 . . . . 0.0 111.692 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.586 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 92.6 m -125.6 153.13 44.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.985 0.421 . . . . 0.0 111.277 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.487 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 20.9 p -134.69 162.39 32.48 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.916 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 59.3 ttt180 -150.42 126.03 10.27 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 59.76 31.37 20.78 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.843 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.67 13.25 83.37 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.857 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -117.94 130.52 24.66 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.487 ' HA ' ' CG2' ' A' ' 23' ' ' THR . 13.0 Cg_exo -65.86 139.91 58.94 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.247 1.965 . . . . 0.0 112.576 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.315 -0.901 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.267 179.262 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.204 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.64 -27.76 4.16 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.866 -0.607 . . . . 0.0 113.507 179.145 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.512 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.9 tp10 -70.73 113.22 7.6 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 121.315 0.579 . . . . 0.0 110.82 -179.19 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.664 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.8 p -113.1 153.67 27.82 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.824 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.537 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 27.4 t -119.1 37.37 4.15 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.285 0.564 . . . . 0.0 110.223 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.8 t -63.3 -38.34 81.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.216 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.65 10.88 60.81 Favored Glycine 0 N--CA 1.453 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.825 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.54 4.68 85.09 Favored Glycine 0 C--N 1.318 -0.442 0 C-N-CA 121.366 -0.445 . . . . 0.0 112.911 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.79 145.72 25.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.519 0.2 . . . . 0.0 110.744 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -94.26 159.85 14.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.207 0.527 . . . . 0.0 110.267 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -80.05 -39.98 28.65 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.231 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.436 HG22 ' NH2' ' A' ' 24' ' ' ARG . 36.0 m -80.42 121.69 81.79 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.812 179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.62 142.14 76.05 Favored 'Trans proline' 0 C--O 1.235 0.375 0 C-N-CA 122.839 2.36 . . . . 0.0 112.721 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.47 2.26 87.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 121.06 -0.591 . . . . 0.0 113.163 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.3 137.97 31.92 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.05 149.37 23.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.882 0.373 . . . . 0.0 110.002 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -80.51 136.84 36.37 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.29 0.567 . . . . 0.0 111.586 -179.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.492 ' O ' HG21 ' A' ' 21' ' ' VAL . 50.3 m -145.92 59.12 1.24 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -32.63 128.57 0.35 Allowed Pre-proline 0 N--CA 1.463 0.208 0 O-C-N 124.677 1.236 . . . . 0.0 112.657 -177.246 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -92.72 25.35 22.65 Favored 'Cis proline' 0 N--CA 1.461 -0.423 0 C-N-CA 123.108 -1.622 . . . . 0.0 114.231 0.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.664 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.6 m -125.19 -172.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 C-N-CA 120.495 -0.482 . . . . 0.0 112.259 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 76.2 m -128.1 143.63 51.07 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.413 HG23 ' HA ' ' A' ' 28' ' ' PRO . 67.6 p -134.13 145.14 49.01 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.587 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.436 ' NH2' HG22 ' A' ' 12' ' ' THR . 60.9 ttm-85 -111.73 109.49 19.37 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.58 35.84 22.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.34 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.53 -16.48 58.98 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.405 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.0 tp -89.42 119.07 69.6 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 117.112 0.456 . . . . 0.0 109.856 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.413 ' HA ' HG23 ' A' ' 23' ' ' THR . 23.3 Cg_exo -59.28 139.11 88.52 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 122.063 1.842 . . . . 0.0 112.547 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.512 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 41.9 t . . . . . 0 C--N 1.314 -0.936 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.063 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.138 0 CA-C-O 120.779 0.323 . . . . 0.0 111.566 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 86.83 -32.03 4.12 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.115 -0.564 . . . . 0.0 112.82 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.443 ' CG ' ' HB2' ' A' ' 22' ' ' CYS . 9.8 tp10 -72.88 113.65 10.15 Favored 'General case' 0 C--O 1.241 0.636 0 CA-C-O 121.157 0.504 . . . . 0.0 110.479 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.0 p -112.31 152.68 28.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.79 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.533 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 22.6 t -117.2 38.92 3.39 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.209 0.528 . . . . 0.0 110.332 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.28 -39.97 87.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.06 179.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.7 11.77 65.45 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.642 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.26 19.02 75.53 Favored Glycine 0 C--N 1.319 -0.371 0 C-N-CA 121.623 -0.322 . . . . 0.0 112.852 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.12 147.45 27.08 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 122.407 0.283 . . . . 0.0 110.83 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 m -115.4 158.81 21.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.997 0.427 . . . . 0.0 110.315 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -82.12 -38.16 25.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.479 178.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.425 ' O ' ' HB1' ' A' ' 15' ' ' ALA . 98.1 m -64.42 125.27 88.12 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.959 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -64.01 132.68 35.35 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.772 2.315 . . . . 0.0 112.016 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.33 28.36 71.45 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.546 -0.752 . . . . 0.0 112.818 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.425 ' HB1' ' O ' ' A' ' 12' ' ' THR . . . -94.18 136.61 34.29 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.031 0.443 . . . . 0.0 110.521 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -89.36 147.74 23.9 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.568 179.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.2 t -82.59 135.15 35.14 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.189 0.519 . . . . 0.0 111.175 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.575 ' O ' HG22 ' A' ' 21' ' ' VAL . 45.0 m -143.09 58.83 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -32.88 128.54 0.37 Allowed Pre-proline 0 N--CA 1.463 0.191 0 O-C-N 124.673 1.233 . . . . 0.0 112.705 -177.295 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -93.31 25.56 22.38 Favored 'Cis proline' 0 N--CA 1.461 -0.409 0 C-N-CA 123.071 -1.637 . . . . 0.0 114.144 0.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.629 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.4 m -123.75 -174.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.068 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.6 m -126.11 146.85 49.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.485 HG22 ' HA ' ' A' ' 28' ' ' PRO . 18.4 p -127.57 166.33 18.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.15 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 43.3 ttp85 -151.18 119.15 6.22 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 57.15 41.25 27.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.506 0.669 . . . . 0.0 110.354 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.75 11.9 77.97 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.565 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.5 mt -121.57 127.58 26.01 Favored Pre-proline 0 C--N 1.325 -0.5 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.485 ' HA ' HG22 ' A' ' 23' ' ' THR . 17.4 Cg_exo -62.98 141.9 85.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.2 1.934 . . . . 0.0 112.416 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.439 HG13 ' HB2' ' A' ' 3' ' ' GLU . 39.8 t . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.448 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.146 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 70.15 16.17 72.8 Favored Glycine 0 N--CA 1.453 -0.188 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.598 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.648 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.6 tp10 -107.06 110.32 22.41 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.079 0.466 . . . . 0.0 110.372 179.563 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.4 p -107.71 151.42 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.485 179.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.521 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 14.8 t -116.92 40.86 2.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.108 0.48 . . . . 0.0 110.367 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.2 t -62.93 -40.58 89.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.377 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 13.1 62.58 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.778 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 22.2 74.78 Favored Glycine 0 C--N 1.319 -0.386 0 C-N-CA 121.593 -0.337 . . . . 0.0 112.804 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.08 147.49 27.15 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.384 0.274 . . . . 0.0 110.797 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.0 m -117.79 159.64 22.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.058 0.456 . . . . 0.0 110.224 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -82.26 -37.89 25.23 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.354 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.4 m -65.43 125.79 90.23 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.069 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.55 131.99 29.64 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 122.546 2.164 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.64 34.99 73.6 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.888 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.36 137.8 38.29 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.57 146.24 25.25 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -86.16 130.62 34.47 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 121.293 0.568 . . . . 0.0 111.706 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 75.1 m -137.52 62.1 1.59 Allowed 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.99 127.88 0.38 Allowed Pre-proline 0 N--CA 1.462 0.131 0 CA-C-N 114.619 -1.173 . . . . 0.0 112.581 -177.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -95.95 30.49 13.82 Favored 'Cis proline' 0 N--CA 1.46 -0.493 0 C-N-CA 123.493 -1.461 . . . . 0.0 114.112 0.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.553 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.1 m -126.92 177.06 5.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.521 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.3 m -119.98 141.42 49.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.164 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 14.4 p -132.41 141.66 48.96 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.89 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 44.1 ttt85 -131.1 127.71 38.69 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.4 t30 57.77 37.14 27.08 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.335 0.588 . . . . 0.0 110.54 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.52 18.2 76.9 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.778 -0.646 . . . . 0.0 113.001 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.452 HD13 ' HD2' ' A' ' 28' ' ' PRO . 37.6 tp -129.74 128.02 22.95 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.452 ' HD2' HD13 ' A' ' 27' ' ' LEU . 20.1 Cg_exo -61.5 141.01 90.4 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 121.988 1.792 . . . . 0.0 111.932 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.648 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.3 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.755 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.161 0 CA-C-O 120.887 0.375 . . . . 0.0 111.619 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.24 -38.03 3.24 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.418 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.508 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 12.4 mm-40 -73.07 119.11 16.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.089 0.471 . . . . 0.0 111.189 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.7 p -113.11 148.21 35.75 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.743 178.291 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.519 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 11.2 t -118.03 40.0 3.25 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.057 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -64.37 -41.67 93.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.29 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.3 6.58 78.31 Favored Glycine 0 C--O 1.227 -0.283 0 CA-C-N 115.683 -0.689 . . . . 0.0 112.395 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.519 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 73.32 29.49 64.11 Favored Glycine 0 C--N 1.319 -0.399 0 CA-C-N 115.329 -0.436 . . . . 0.0 112.891 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.8 p -145.84 142.36 28.76 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 122.219 0.208 . . . . 0.0 111.073 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 20.9 m -122.13 169.05 11.26 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 178.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -94.02 -33.4 13.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.425 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 18.2 m -64.13 122.52 78.1 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.031 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.09 128.46 20.67 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.461 2.107 . . . . 0.0 111.753 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 37.23 84.48 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.437 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.45 143.86 27.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.999 0.428 . . . . 0.0 110.904 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.57 150.9 22.21 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.567 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.8 t -92.81 135.21 34.32 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.116 0.484 . . . . 0.0 111.368 -179.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.602 ' O ' HG21 ' A' ' 21' ' ' VAL . 64.7 m -141.67 62.47 1.45 Allowed 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.392 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.8 t90 -32.6 126.78 0.37 Allowed Pre-proline 0 N--CA 1.463 0.184 0 O-C-N 124.57 1.169 . . . . 0.0 112.374 -177.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 53.1 Cg_endo -97.62 32.78 10.37 Favored 'Cis proline' 0 N--CA 1.457 -0.621 0 C-N-CA 123.639 -1.4 . . . . 0.0 114.21 0.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.602 HG21 ' O ' ' A' ' 18' ' ' SER . 6.1 m -130.04 169.13 21.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.508 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 96.4 m -105.48 147.52 28.22 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.687 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.412 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 17.7 p -133.24 158.63 42.41 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.844 0.354 . . . . 0.0 110.535 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 28.6 ttt-85 -150.36 130.18 13.3 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 59.01 31.54 21.46 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 123.541 0.526 . . . . 0.0 110.884 -178.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.81 17.94 80.11 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.766 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.4 mt -126.45 131.41 23.92 Favored Pre-proline 0 C--N 1.326 -0.444 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 14.4 Cg_exo -65.26 140.83 66.17 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.275 1.983 . . . . 0.0 112.278 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.6 t . . . . . 0 C--N 1.316 -0.88 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.532 179.44 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.804 0.335 . . . . 0.0 111.356 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.51 -37.99 3.25 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.296 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.529 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 64.3 mm-40 -74.69 120.54 20.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.157 0.504 . . . . 0.0 111.266 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.621 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.9 p -115.33 150.38 36.38 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.733 178.243 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.5 t -120.4 38.14 4.07 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.243 0.544 . . . . 0.0 109.981 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.6 t -64.13 -41.75 93.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.075 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.62 6.21 83.86 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.49 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.35 20.43 77.08 Favored Glycine 0 C--N 1.318 -0.444 0 CA-C-N 115.331 -0.435 . . . . 0.0 112.971 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 20.7 p -147.05 141.76 26.72 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 122.1 0.16 . . . . 0.0 110.919 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.3 m -108.07 165.36 11.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.123 0.487 . . . . 0.0 110.445 179.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -83.12 -38.15 22.81 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.838 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.403 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -73.55 122.23 87.09 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.804 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.3 Cg_exo -64.96 133.55 36.34 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.744 2.296 . . . . 0.0 112.168 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 25.66 70.92 Favored Glycine 0 CA--C 1.519 0.284 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.036 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -92.17 147.38 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.659 0.266 . . . . 0.0 110.342 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -88.86 149.6 23.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.949 179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.6 t -91.55 136.56 33.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.167 0.508 . . . . 0.0 111.352 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 21' ' ' VAL . 50.1 m -144.9 61.78 1.31 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.453 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.2 127.14 0.35 Allowed Pre-proline 0 N--CA 1.465 0.277 0 O-C-N 124.608 1.193 . . . . 0.0 112.594 -177.407 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 44.4 Cg_endo -96.53 30.24 14.12 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.547 -1.439 . . . . 0.0 114.002 0.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.621 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.2 m -128.4 175.13 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 89.1 m -112.94 150.74 31.41 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.845 0.355 . . . . 0.0 111.204 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.412 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 13.0 p -131.67 160.61 34.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.633 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -150.54 127.96 11.42 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.7 m-20 58.99 33.72 23.19 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 123.655 0.597 . . . . 0.0 110.841 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.35 16.65 79.79 Favored Glycine 0 C--N 1.33 0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 112.863 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.426 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.7 mt -126.59 133.86 25.44 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 16.5 Cg_exo -63.26 141.18 81.07 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.313 2.009 . . . . 0.0 112.154 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.918 179.672 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.174 0 CA-C-O 120.92 0.391 . . . . 0.0 111.893 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 86.3 -30.99 4.24 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.128 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.473 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 11.4 tp10 -72.09 113.65 9.35 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.301 0.572 . . . . 0.0 110.727 -179.332 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.659 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -113.04 152.65 29.25 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.723 179.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.509 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 28.5 t -116.54 36.69 4.02 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.328 0.585 . . . . 0.0 110.222 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.7 t -65.03 -37.89 81.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.92 179.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.1 3.38 86.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.768 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.419 ' O ' HG23 ' A' ' 9' ' ' THR . . . 83.42 1.75 90.24 Favored Glycine 0 C--N 1.318 -0.444 0 C-N-CA 121.348 -0.454 . . . . 0.0 113.306 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 8' ' ' GLY . 16.7 p -147.3 141.69 26.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.697 0.248 . . . . 0.0 111.012 179.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.413 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.2 m -98.62 161.2 13.79 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.336 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -87.93 -35.83 17.45 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.509 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.463 ' O ' ' HB3' ' A' ' 15' ' ' ALA . 83.1 m -64.86 126.09 90.34 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -62.39 132.64 39.29 Favored 'Trans proline' 0 C--O 1.238 0.487 0 C-N-CA 122.785 2.323 . . . . 0.0 112.446 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.45 30.33 71.27 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.995 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.463 ' HB3' ' O ' ' A' ' 12' ' ' THR . . . -98.52 135.06 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.556 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.55 148.83 23.16 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.828 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -81.31 135.89 35.73 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.285 0.564 . . . . 0.0 111.381 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.583 ' O ' HG22 ' A' ' 21' ' ' VAL . 50.5 m -144.24 59.03 1.35 Allowed 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.322 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -32.97 128.75 0.37 Allowed Pre-proline 0 N--CA 1.462 0.169 0 O-C-N 124.63 1.206 . . . . 0.0 112.76 -177.256 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -92.7 24.91 23.6 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.066 -1.639 . . . . 0.0 114.209 0.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.659 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.5 m -124.97 -172.32 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 O-C-N 121.988 -0.445 . . . . 0.0 112.168 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.509 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.5 m -127.74 146.79 50.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.084 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.443 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.9 p -134.22 162.64 31.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.453 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.5 ttp180 -150.17 125.86 10.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.3 t30 60.03 33.4 21.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.418 0.628 . . . . 0.0 110.567 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.53 9.05 87.09 Favored Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.696 -0.684 . . . . 0.0 113.288 179.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 9.2 mp -118.78 129.79 25.19 Favored Pre-proline 0 C--N 1.327 -0.396 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.443 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.1 Cg_exo -64.97 140.81 67.81 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.247 1.965 . . . . 0.0 112.331 -179.612 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.473 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.4 t . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.107 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 120.848 0.356 . . . . 0.0 111.809 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 70.7 32.52 67.08 Favored Glycine 0 N--CA 1.451 -0.348 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.271 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.663 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 2.6 mm-40 -130.16 123.2 29.72 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 121.124 0.488 . . . . 0.0 111.388 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.585 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 33.0 p -116.92 147.45 42.21 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.037 178.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.5 t -117.27 40.22 3.08 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.866 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 33.8 t -64.2 -42.35 95.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.385 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.78 7.83 76.84 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.395 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.515 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 72.04 31.03 64.65 Favored Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.405 -0.397 . . . . 0.0 112.774 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.3 p -144.92 142.89 30.25 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.646 -0.277 . . . . 0.0 110.89 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 17.6 m -124.94 165.22 18.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.985 0.421 . . . . 0.0 110.018 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -87.21 -33.98 19.15 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.766 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.49 HG23 ' HD2' ' A' ' 24' ' ' ARG . 19.7 m -70.29 125.84 92.13 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.176 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -65.94 129.97 23.32 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.456 2.104 . . . . 0.0 111.865 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.2 37.86 87.22 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.327 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -94.78 144.78 25.36 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.899 0.38 . . . . 0.0 110.713 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.26 148.96 23.3 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.508 178.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.8 t -93.64 134.14 36.26 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.238 0.542 . . . . 0.0 111.325 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.569 ' O ' HG21 ' A' ' 21' ' ' VAL . 50.6 m -140.03 61.77 1.52 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.272 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.0 t90 -32.16 126.36 0.35 Allowed Pre-proline 0 N--CA 1.463 0.185 0 O-C-N 124.504 1.128 . . . . 0.0 112.481 -177.462 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -98.36 33.81 9.16 Favored 'Cis proline' 0 N--CA 1.458 -0.595 0 C-N-CA 123.675 -1.385 . . . . 0.0 114.167 0.744 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.585 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 4.3 m -130.32 163.11 36.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.663 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 81.7 m -102.44 145.62 29.27 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.984 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 30.6 p -133.42 164.03 28.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.118 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.49 ' HD2' HG23 ' A' ' 12' ' ' THR . 30.5 ttt-85 -150.85 123.59 8.58 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.581 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.4 t30 58.84 34.65 23.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.426 0.631 . . . . 0.0 110.678 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.35 9.43 87.01 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.602 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.485 HD12 ' HA ' ' A' ' 27' ' ' LEU . 3.4 mm? -120.48 130.79 24.68 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.126 0.463 . . . . 0.0 109.917 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -63.76 141.71 79.93 Favored 'Trans proline' 0 N--CA 1.46 -0.462 0 C-N-CA 122.26 1.974 . . . . 0.0 112.253 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.482 ' CG1' ' HG3' ' A' ' 3' ' ' GLU . 37.2 t . . . . . 0 C--N 1.318 -0.786 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.857 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 120.859 0.362 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.91 -35.9 4.46 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.431 179.299 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.625 ' OE2' ' HB3' ' A' ' 10' ' ' CYS . 48.2 tt0 -81.81 121.94 27.07 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.247 0.546 . . . . 0.0 111.05 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 24.4 p -108.69 152.63 24.55 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.607 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.2 t -119.19 41.34 3.1 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.156 0.503 . . . . 0.0 109.704 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.5 t -62.66 -39.64 85.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.687 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.76 11.61 59.08 Favored Glycine 0 N--CA 1.452 -0.241 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.726 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.74 19.28 73.09 Favored Glycine 0 C--N 1.319 -0.369 0 C-N-CA 121.532 -0.366 . . . . 0.0 112.558 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.25 26.18 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 122.559 0.343 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.625 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 39.3 m -106.83 172.11 7.0 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.028 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -96.8 -29.84 13.52 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.975 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.756 HG21 HH21 ' A' ' 24' ' ' ARG . 5.3 m -79.93 124.84 82.97 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.574 -179.651 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 36.2 Cg_exo -60.35 135.97 65.04 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.905 2.403 . . . . 0.0 112.913 -179.37 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.56 32.75 79.42 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.543 -0.753 . . . . 0.0 113.437 179.423 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.74 147.11 26.4 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.52 150.28 22.52 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -98.0 138.09 35.84 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.214 0.531 . . . . 0.0 111.04 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.8 m -144.2 62.92 1.34 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -33.01 127.26 0.39 Allowed Pre-proline 0 N--CA 1.465 0.296 0 O-C-N 124.563 1.164 . . . . 0.0 112.32 -177.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -97.08 33.11 10.13 Favored 'Cis proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.505 -1.456 . . . . 0.0 114.24 0.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.598 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.4 m -129.8 169.99 19.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.439 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 99.4 m -107.33 148.08 29.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.475 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.499 ' CG2' ' HA ' ' A' ' 28' ' ' PRO . 33.1 p -137.3 168.7 19.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.101 0.476 . . . . 0.0 110.664 -179.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.756 HH21 HG21 ' A' ' 12' ' ' THR . 56.9 ttm-85 -151.09 120.0 6.64 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.373 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 m120 57.85 36.64 26.54 Favored 'General case' 0 N--CA 1.467 0.417 0 O-C-N 123.41 0.444 . . . . 0.0 111.331 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.15 7.0 88.74 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 121.095 -0.574 . . . . 0.0 113.188 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.435 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 94.1 mt -113.34 126.17 28.57 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.462 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.499 ' HA ' ' CG2' ' A' ' 23' ' ' THR . 12.2 Cg_exo -67.5 140.94 53.88 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.395 2.064 . . . . 0.0 112.879 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.9 t . . . . . 0 C--N 1.318 -0.8 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.129 178.789 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.206 0 CA-C-O 120.922 0.391 . . . . 0.0 111.486 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.93 33.77 75.56 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.538 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 6.2 tp10 -129.43 114.08 15.71 Favored 'General case' 0 C--O 1.241 0.656 0 CA-C-O 121.224 0.535 . . . . 0.0 110.182 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 44.7 p -111.45 151.64 28.33 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.057 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 15.3 t -118.04 39.5 3.38 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.101 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.4 t -62.87 -40.6 89.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.475 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.57 4.81 85.19 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.76 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.21 13.56 82.72 Favored Glycine 0 C--N 1.317 -0.527 0 C-N-CA 121.433 -0.413 . . . . 0.0 113.03 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.4 p -147.82 142.04 26.16 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.155 0.182 . . . . 0.0 110.858 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 m -106.98 163.05 13.3 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 178.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 t30 -87.62 -35.73 17.89 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.719 0.771 . . . . 0.0 109.286 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.428 ' O ' ' HB2' ' A' ' 15' ' ' ALA . 32.2 m -65.85 126.01 90.97 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 114.76 -1.109 . . . . 0.0 111.213 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -64.45 133.77 38.76 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.519 2.146 . . . . 0.0 112.472 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.9 29.51 72.51 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.307 -0.86 . . . . 0.0 113.02 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.428 ' HB2' ' O ' ' A' ' 12' ' ' THR . . . -95.94 137.11 35.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.811 0.339 . . . . 0.0 110.621 179.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.3 149.43 23.05 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.585 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.5 t -86.61 136.2 33.14 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.352 0.596 . . . . 0.0 111.6 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.563 ' O ' HG22 ' A' ' 21' ' ' VAL . 43.5 m -143.48 59.44 1.39 Allowed 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.198 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -31.94 127.43 0.33 Allowed Pre-proline 0 N--CA 1.464 0.245 0 O-C-N 124.506 1.129 . . . . 0.0 112.543 -177.297 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -95.29 29.28 15.86 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.352 -1.52 . . . . 0.0 114.134 0.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.9 m -126.92 179.31 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.538 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 92.9 m -120.9 144.31 48.49 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.243 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.47 HG21 ' HA ' ' A' ' 28' ' ' PRO . 34.7 p -134.85 155.92 49.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.642 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -148.19 130.36 15.49 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.0 m120 59.74 30.99 20.58 Favored 'General case' 0 N--CA 1.465 0.3 0 O-C-N 123.589 0.556 . . . . 0.0 110.934 -178.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.19 17.58 80.2 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.753 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.405 HD13 ' HD2' ' A' ' 28' ' ' PRO . 36.4 tp -129.59 129.06 23.13 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' HG21 ' A' ' 23' ' ' THR . 20.5 Cg_exo -62.19 142.7 92.74 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.195 1.93 . . . . 0.0 111.854 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.519 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 46.0 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.702 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.468 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 10.4 tp10 . . . . . 0 C--O 1.238 0.496 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.646 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.3 p -110.77 153.54 25.19 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.108 0.48 . . . . 0.0 111.158 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.622 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 21.5 t -121.05 38.91 3.94 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.092 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.9 t -62.93 -40.48 89.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.404 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.1 5.41 83.07 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.849 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.0 11.56 84.34 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.93 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.2 p -148.08 142.42 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.243 0.217 . . . . 0.0 110.745 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.423 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.4 m -103.67 159.41 15.64 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.994 0.426 . . . . 0.0 110.153 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.7 m-80 -81.34 -38.64 26.37 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.463 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.475 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -70.43 125.01 91.87 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.207 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.1 Cg_exo -65.71 136.2 44.85 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.791 2.328 . . . . 0.0 112.013 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 23.88 74.51 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.709 -0.678 . . . . 0.0 113.05 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.04 137.63 36.56 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.3 148.21 23.68 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.4 t -83.8 137.05 33.9 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.43 0.633 . . . . 0.0 111.413 -179.232 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 30.9 m -144.62 58.95 1.32 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.4 t90 -31.82 127.45 0.32 Allowed Pre-proline 0 N--CA 1.463 0.211 0 O-C-N 124.516 1.135 . . . . 0.0 112.628 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -94.62 28.44 17.2 Favored 'Cis proline' 0 N--CA 1.46 -0.456 0 C-N-CA 123.278 -1.551 . . . . 0.0 114.142 0.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 12.6 m -126.3 -176.7 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.622 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.8 m -127.77 140.4 52.07 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.994 0.426 . . . . 0.0 111.091 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.506 HG22 ' HA ' ' A' ' 28' ' ' PRO . 40.1 p -132.25 157.26 44.83 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.728 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.43 ' HG2' ' OD1' ' A' ' 25' ' ' ASN . 54.9 ttp85 -147.02 127.8 14.35 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.43 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 7.7 m120 60.16 31.61 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 O-C-N 123.422 0.451 . . . . 0.0 110.768 -178.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.29 14.44 81.91 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.967 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.6 mt -127.41 135.95 28.2 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.506 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.7 Cg_exo -60.36 141.53 95.91 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.069 1.846 . . . . 0.0 111.652 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.468 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 20.8 t . . . . . 0 C--N 1.317 -0.805 0 CA-C-O 121.483 0.659 . . . . 0.0 110.189 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.559 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 44.9 tt0 . . . . . 0 N--CA 1.453 -0.295 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.547 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.2 p -101.87 152.21 21.18 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.944 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.0 t -117.58 40.92 2.96 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.841 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.5 t -62.32 -41.22 90.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.587 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.27 12.94 63.07 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.597 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.4 30.24 77.15 Favored Glycine 0 C--N 1.319 -0.392 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.36 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.66 149.24 29.59 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.892 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.441 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 60.2 m -123.56 171.76 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.343 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -88.46 -32.57 18.2 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.406 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.575 HG21 ' CD ' ' A' ' 24' ' ' ARG . 27.7 m -74.08 127.51 87.89 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.33 131.31 23.04 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.195 1.93 . . . . 0.0 111.644 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.73 29.39 69.53 Favored Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.627 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.474 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.48 146.76 24.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.758 0.313 . . . . 0.0 110.477 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.66 144.88 26.0 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -96.53 130.86 43.62 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.262 0.553 . . . . 0.0 111.592 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 59.6 m -131.98 63.13 1.62 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.7 t90 -33.87 127.94 0.44 Allowed Pre-proline 0 N--CA 1.462 0.158 0 O-C-N 124.382 1.051 . . . . 0.0 112.2 -177.469 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -96.96 33.73 9.54 Favored 'Cis proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.574 -1.428 . . . . 0.0 114.335 0.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.2 m -129.6 164.25 32.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.268 0.556 . . . . 0.0 112.205 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.559 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 92.2 m -97.06 150.89 20.31 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.872 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.728 HG22 ' HA ' ' A' ' 28' ' ' PRO . 3.1 p -138.56 141.51 39.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.632 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.575 ' CD ' HG21 ' A' ' 12' ' ' THR . 33.3 mtm180 -125.77 119.34 27.64 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 57.55 41.62 25.53 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.773 0.671 . . . . 0.0 109.984 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.72 13.29 74.92 Favored Glycine 0 CA--C 1.52 0.395 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.202 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 43.8 tp -112.81 125.01 30.57 Favored Pre-proline 0 C--N 1.326 -0.433 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.728 ' HA ' HG22 ' A' ' 23' ' ' THR . 18.9 Cg_exo -63.5 142.31 84.11 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.344 2.03 . . . . 0.0 112.088 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.7 t . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.378 -179.935 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.566 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.8 tp10 . . . . . 0 C--O 1.238 0.485 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 46.5 p -107.58 151.74 25.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.011 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.7 t -119.32 41.81 3.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.022 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.9 t -62.42 -39.63 85.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.694 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.36 12.87 61.54 Favored Glycine 0 N--CA 1.453 -0.222 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.891 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.41 21.87 74.52 Favored Glycine 0 C--N 1.321 -0.301 0 C-N-CA 121.453 -0.403 . . . . 0.0 112.614 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.86 147.66 27.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 110.614 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 15.7 m -114.74 167.01 11.14 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.14 0.495 . . . . 0.0 110.219 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -90.63 -34.71 15.35 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.788 178.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.3 m -67.88 126.06 92.15 Favored Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.398 -1.274 . . . . 0.0 111.326 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.88 133.45 33.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.439 2.092 . . . . 0.0 112.137 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 31.63 74.37 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.714 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.96 139.21 34.95 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.615 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.48 149.02 23.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.559 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.4 t -88.88 135.6 33.45 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.27 0.557 . . . . 0.0 111.379 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.6 m -141.03 59.71 1.52 Allowed 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.199 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.3 t90 -32.01 127.16 0.34 Allowed Pre-proline 0 N--CA 1.464 0.227 0 O-C-N 124.649 1.218 . . . . 0.0 112.496 -177.345 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.2 Cg_endo -96.02 31.08 12.91 Favored 'Cis proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.175 0.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.584 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.5 m -127.77 175.79 8.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.506 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 87.3 m -117.37 143.17 46.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.175 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.675 HG22 ' HA ' ' A' ' 28' ' ' PRO . 38.8 p -135.8 159.27 42.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.484 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -150.14 126.47 10.74 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.0 t30 60.03 34.8 21.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.518 0.675 . . . . 0.0 110.193 -178.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.59 14.07 79.87 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.995 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.431 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.5 mt -122.89 127.51 25.7 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.5 Cg_exo -65.82 142.1 68.15 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.415 2.076 . . . . 0.0 112.188 -179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.566 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.7 t . . . . . 0 C--N 1.317 -0.815 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.493 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.486 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 6.1 tp10 . . . . . 0 C--O 1.238 0.496 0 CA-C-O 121.149 0.499 . . . . 0.0 110.3 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.9 p -107.88 153.0 23.67 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.983 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.411 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.4 t -120.7 40.49 3.51 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.049 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -61.94 -40.13 86.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.585 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.91 12.44 61.86 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.762 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.04 21.61 75.54 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 121.557 -0.354 . . . . 0.0 112.739 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.13 147.12 26.67 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 122.427 0.291 . . . . 0.0 110.939 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 18.5 m -112.07 167.36 10.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.038 0.447 . . . . 0.0 109.953 179.29 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -88.68 -35.64 16.65 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 26.9 m -68.7 125.38 91.74 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 114.282 -1.326 . . . . 0.0 111.586 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 15.2 Cg_exo -66.17 133.37 32.79 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.554 2.169 . . . . 0.0 111.447 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.76 31.68 70.36 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.719 -0.673 . . . . 0.0 112.724 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -99.54 141.33 32.48 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.85 0.357 . . . . 0.0 110.468 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.1 m -89.45 149.1 23.09 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.656 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -90.81 136.32 33.15 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.279 0.562 . . . . 0.0 110.996 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 56.9 m -142.66 60.42 1.43 Allowed 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.58 127.89 0.36 Allowed Pre-proline 0 N--CA 1.463 0.213 0 O-C-N 124.627 1.205 . . . . 0.0 112.45 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.2 Cg_endo -94.83 29.27 15.92 Favored 'Cis proline' 0 N--CA 1.46 -0.477 0 C-N-CA 123.238 -1.567 . . . . 0.0 114.22 0.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.0 m -126.88 179.88 3.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.985 0.422 . . . . 0.0 112.095 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.483 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 96.9 m -117.95 148.37 42.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.065 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.631 HG22 ' HA ' ' A' ' 28' ' ' PRO . 13.4 p -131.95 157.03 45.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 0.0 110.74 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.719 ' O ' ' HG ' ' A' ' 27' ' ' LEU . 53.7 ttp180 -150.31 130.56 13.67 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.6 t30 57.71 33.48 23.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 110.938 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.74 16.81 80.41 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.819 -0.628 . . . . 0.0 113.941 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.719 ' HG ' ' O ' ' A' ' 24' ' ' ARG . 3.9 pp -133.88 135.66 25.03 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.404 0.602 . . . . 0.0 109.871 178.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.631 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.2 Cg_exo -64.93 141.83 72.64 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.599 2.199 . . . . 0.0 112.722 -178.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.486 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 43.9 t . . . . . 0 C--N 1.317 -0.823 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.13 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.624 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.9 tp10 . . . . . 0 C--O 1.239 0.516 0 CA-C-O 121.109 0.481 . . . . 0.0 110.363 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.1 p -108.44 152.04 25.23 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.863 179.527 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.6 t -119.0 40.81 3.21 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.098 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -62.23 -40.37 87.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 13.24 62.49 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.728 179.489 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.5 24.55 73.81 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 121.529 -0.367 . . . . 0.0 112.694 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 147.84 27.68 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 122.459 0.304 . . . . 0.0 110.927 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.5 m -118.28 164.11 15.69 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -88.76 -35.33 16.74 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.091 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.431 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 24.6 m -67.9 125.49 91.45 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 114.574 -1.194 . . . . 0.0 111.361 -179.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.72 133.74 35.24 Favored 'Trans proline' 0 N--CA 1.46 -0.476 0 C-N-CA 122.694 2.263 . . . . 0.0 111.797 179.583 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.64 27.67 72.13 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.968 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -97.71 136.32 38.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.827 0.346 . . . . 0.0 110.31 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 149.94 22.82 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -86.16 136.61 33.13 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.299 0.571 . . . . 0.0 111.393 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 40.9 m -142.89 59.56 1.42 Allowed 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.0 t90 -32.08 127.38 0.34 Allowed Pre-proline 0 N--CA 1.465 0.288 0 O-C-N 124.675 1.234 . . . . 0.0 112.598 -177.357 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.9 Cg_endo -95.6 30.32 14.14 Favored 'Cis proline' 0 N--CA 1.459 -0.506 0 C-N-CA 123.432 -1.487 . . . . 0.0 114.132 0.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 10.5 m -127.27 176.73 6.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 97.0 m -119.29 140.54 50.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.383 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.527 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.5 p -130.68 131.93 45.12 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.277 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.4 ttp85 -98.67 106.64 18.93 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.8 t30 60.16 37.68 20.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.552 0.692 . . . . 0.0 109.399 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.26 -12.17 65.41 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.466 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -96.92 111.75 58.55 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 117.239 0.52 . . . . 0.0 110.396 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.527 ' HA ' HG22 ' A' ' 23' ' ' THR . 0.9 OUTLIER -49.14 138.47 28.4 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.943 2.428 . . . . 0.0 113.56 -179.111 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.624 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 44.6 t . . . . . 0 C--N 1.317 -0.834 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.541 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.446 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 14.7 tp10 . . . . . 0 C--O 1.238 0.482 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.3 p -108.22 152.41 24.63 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.134 0.492 . . . . 0.0 111.074 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.437 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.9 t -119.67 39.37 3.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.02 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 25.8 t -62.48 -40.42 88.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.443 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.05 3.84 84.73 Favored Glycine 0 C--O 1.227 -0.326 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.764 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.96 14.61 81.8 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.999 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.6 p -148.35 141.86 25.39 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.148 0.179 . . . . 0.0 110.928 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.7 m -106.19 167.6 9.71 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -90.86 -33.9 15.47 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.645 0.736 . . . . 0.0 109.051 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 34.9 m -63.88 126.99 91.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 114.834 -1.076 . . . . 0.0 111.018 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.39 128.83 23.54 Favored 'Trans proline' 0 C--O 1.237 0.446 0 C-N-CA 122.549 2.166 . . . . 0.0 112.4 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.38 31.77 79.89 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.186 -0.916 . . . . 0.0 112.781 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.473 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.82 143.34 26.88 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.871 0.367 . . . . 0.0 110.825 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.55 148.01 23.63 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.586 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -91.71 136.12 33.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.201 0.524 . . . . 0.0 110.883 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.8 m -142.34 59.96 1.45 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.56 127.91 0.36 Allowed Pre-proline 0 N--CA 1.463 0.186 0 O-C-N 124.625 1.203 . . . . 0.0 112.473 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -94.47 27.76 18.22 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.293 -1.545 . . . . 0.0 114.178 0.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.59 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.9 m -124.78 -179.25 2.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.026 0.441 . . . . 0.0 111.959 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.437 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.9 m -119.79 150.34 40.58 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.299 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.708 HG22 ' HA ' ' A' ' 28' ' ' PRO . 7.6 p -130.26 154.13 47.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.631 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.465 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 14.7 tpt85 -142.14 124.22 15.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 24.3 t30 57.09 38.94 29.38 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.261 0.553 . . . . 0.0 110.793 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.62 16.97 76.18 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.342 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.1 mt -126.48 131.16 23.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.708 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.7 Cg_exo -63.41 140.83 78.47 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.107 1.871 . . . . 0.0 112.214 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.446 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 33.9 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.814 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.639 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 5.5 mm-40 . . . . . 0 CA--C 1.514 -0.441 0 CA-C-O 121.251 0.548 . . . . 0.0 111.827 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -115.01 147.93 39.48 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.546 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.436 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.2 t -117.71 39.8 3.25 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.222 0.534 . . . . 0.0 110.091 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 32.2 t -64.05 -40.7 89.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.008 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.25 12.68 68.5 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.595 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.436 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 65.8 31.04 78.51 Favored Glycine 0 C--N 1.319 -0.381 0 CA-C-N 115.467 -0.366 . . . . 0.0 112.786 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.79 148.54 28.63 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.602 -0.299 . . . . 0.0 110.971 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 23.5 m -125.2 167.87 14.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.081 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -90.3 -33.62 16.04 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.41 -0.813 . . . . 0.0 109.201 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.45 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 18.8 m -68.14 124.27 89.28 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.987 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -64.89 129.53 23.51 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.478 2.119 . . . . 0.0 111.87 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 37.33 86.03 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.488 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.45 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -97.08 144.24 27.14 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.927 0.394 . . . . 0.0 110.915 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 150.65 22.49 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.696 178.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.5 t -93.94 135.43 35.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.21 0.529 . . . . 0.0 111.329 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 66.9 m -141.63 61.92 1.46 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -32.56 126.99 0.37 Allowed Pre-proline 0 N--CA 1.462 0.159 0 O-C-N 124.554 1.159 . . . . 0.0 112.371 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.5 Cg_endo -97.18 32.77 10.51 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.585 -1.423 . . . . 0.0 114.171 0.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 8.7 m -130.34 169.95 20.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.639 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 88.7 m -106.51 148.3 28.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.748 HG22 ' HA ' ' A' ' 28' ' ' PRO . 15.7 p -133.44 157.29 45.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.357 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 26.9 ttt-85 -150.35 130.54 13.61 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 58.68 31.43 21.13 Favored 'General case' 0 C--N 1.328 -0.354 0 O-C-N 123.509 0.505 . . . . 0.0 110.943 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.98 18.83 80.17 Favored Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.859 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.454 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.0 mt -129.41 132.04 24.01 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.748 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.4 Cg_exo -64.83 140.85 68.92 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 122.18 1.92 . . . . 0.0 112.27 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.44 HG11 ' HG3' ' A' ' 3' ' ' GLU . 25.2 t . . . . . 0 C--N 1.314 -0.943 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.455 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.503 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.7 tp10 . . . . . 0 C--O 1.241 0.636 0 CA-C-O 121.317 0.58 . . . . 0.0 110.71 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.663 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.6 p -111.88 152.95 27.38 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.586 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.475 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 33.0 t -115.88 37.54 3.6 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.349 0.595 . . . . 0.0 110.28 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.436 HG23 ' HB ' ' A' ' 4' ' ' THR . 24.2 t -64.91 -38.36 82.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.024 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.12 2.48 87.63 Favored Glycine 0 C--O 1.227 -0.321 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.894 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.52 3.01 90.01 Favored Glycine 0 C--N 1.317 -0.489 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.175 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.2 p -146.18 142.57 28.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.635 0.218 . . . . 0.0 110.839 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.4 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.5 m -101.06 160.25 14.54 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.14 0.495 . . . . 0.0 110.571 179.507 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -84.49 -37.75 20.93 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.34 178.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.409 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 92.7 m -65.48 125.66 90.02 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.239 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.2 Cg_exo -62.83 133.05 39.87 Favored 'Trans proline' 0 C--O 1.237 0.452 0 C-N-CA 122.787 2.325 . . . . 0.0 112.489 -179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.4 29.88 71.55 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.278 -0.874 . . . . 0.0 113.092 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.59 135.81 39.58 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.545 179.37 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 150.01 22.66 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.804 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.2 t -82.54 135.72 35.02 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.303 0.573 . . . . 0.0 111.444 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.2 m -143.57 59.03 1.39 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.7 OUTLIER -32.88 128.57 0.37 Allowed Pre-proline 0 N--CA 1.462 0.167 0 O-C-N 124.605 1.19 . . . . 0.0 112.793 -177.295 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 49.6 Cg_endo -93.05 25.66 22.16 Favored 'Cis proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.072 -1.637 . . . . 0.0 114.242 0.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.663 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.4 m -125.01 -173.79 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.475 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 96.0 m -126.25 144.72 50.68 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.346 -179.598 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.758 HG22 ' HA ' ' A' ' 28' ' ' PRO . 40.3 p -134.36 153.03 52.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.453 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttp180 -141.11 126.03 18.19 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.8 t30 58.75 36.21 24.73 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.612 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.91 14.23 80.29 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 113.003 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 45.1 tp -123.07 124.24 26.55 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.758 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -63.74 140.62 75.13 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.147 1.898 . . . . 0.0 112.334 -179.472 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.503 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 38.8 t . . . . . 0 C--N 1.314 -0.951 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.21 179.328 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.596 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.6 tp10 . . . . . 0 C--O 1.24 0.555 0 CA-C-O 121.222 0.534 . . . . 0.0 109.95 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.7 p -110.85 151.23 28.09 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.237 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.47 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 12.0 t -118.01 39.26 3.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.979 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.5 t -62.2 -40.8 88.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.473 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.97 13.63 60.79 Favored Glycine 0 N--CA 1.452 -0.298 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.39 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.0 20.96 75.18 Favored Glycine 0 C--N 1.32 -0.324 0 CA-C-N 115.398 -0.401 . . . . 0.0 112.694 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.38 26.26 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.108 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 m -115.16 165.11 13.28 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -86.24 -36.89 19.13 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.334 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.401 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 28.0 m -61.11 125.54 84.04 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.959 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -63.38 130.93 30.01 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.729 2.286 . . . . 0.0 112.578 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 63.19 33.17 86.53 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.229 -0.896 . . . . 0.0 113.141 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.401 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.16 145.98 25.08 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.837 0.351 . . . . 0.0 110.503 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.15 147.55 24.13 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -92.31 135.99 33.56 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.289 0.566 . . . . 0.0 111.074 -179.386 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -143.28 59.82 1.4 Allowed 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.436 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.2 t90 -32.14 127.5 0.34 Allowed Pre-proline 0 N--CA 1.463 0.224 0 O-C-N 124.587 1.179 . . . . 0.0 112.572 -177.413 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.436 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.5 Cg_endo -95.18 28.71 16.78 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.402 -1.499 . . . . 0.0 114.157 0.791 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.7 m -125.15 177.89 4.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.969 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.596 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 95.3 m -118.67 149.05 42.06 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.216 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.72 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.2 p -132.75 166.06 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.338 0.589 . . . . 0.0 111.368 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -150.31 120.37 7.2 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.374 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.0 t30 57.14 38.48 29.02 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.275 0.56 . . . . 0.0 110.874 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.65 10.6 84.77 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-N 115.83 -0.623 . . . . 0.0 113.522 179.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.0 mt -121.55 131.95 24.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.72 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -62.87 141.66 85.46 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.222 1.948 . . . . 0.0 112.312 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.451 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 48.0 t . . . . . 0 C--N 1.319 -0.731 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.916 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.566 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 25.3 tt0 . . . . . 0 C--O 1.235 0.299 0 CA-C-O 121.092 0.473 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 47.8 p -103.21 151.98 22.01 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.6 t -117.92 40.12 3.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.215 0.531 . . . . 0.0 109.865 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -62.29 -40.99 89.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.541 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.65 13.31 60.95 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.557 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.81 23.57 74.13 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.559 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 146.84 26.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.624 -0.288 . . . . 0.0 111.058 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.4 m -111.51 167.54 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.831 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -83.73 -34.27 24.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.11 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.454 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.1 m -81.6 128.08 70.7 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.206 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 22.3 Cg_exo -63.43 137.67 61.43 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.714 2.276 . . . . 0.0 111.814 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.95 29.59 66.83 Favored Glycine 0 N--CA 1.453 -0.21 0 CA-C-N 115.868 -0.605 . . . . 0.0 112.714 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.91 144.97 24.97 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.845 0.355 . . . . 0.0 110.647 179.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.412 ' HB ' ' OG1' ' A' ' 23' ' ' THR . 1.0 OUTLIER -89.51 147.88 23.73 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.016 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -97.04 136.38 37.67 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.297 0.57 . . . . 0.0 111.208 -179.341 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 49.8 m -142.79 60.64 1.43 Allowed 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.524 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.61 127.65 0.36 Allowed Pre-proline 0 N--CA 1.463 0.188 0 O-C-N 124.567 1.167 . . . . 0.0 112.475 -177.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.524 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -95.55 29.62 15.27 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.365 -1.514 . . . . 0.0 114.16 0.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 13.2 m -125.42 175.3 7.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 120.936 0.398 . . . . 0.0 112.007 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.566 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 68.0 m -113.5 148.17 36.53 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.202 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.73 HG22 ' HA ' ' A' ' 28' ' ' PRO . 4.6 p -128.55 156.88 42.62 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.828 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.4 ttp-105 -150.11 128.12 11.89 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 58.75 32.69 22.45 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.668 0.605 . . . . 0.0 110.796 -178.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.68 20.46 79.8 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.849 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.409 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.4 mt -129.37 133.04 24.67 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.73 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.8 Cg_exo -64.79 141.09 70.33 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.23 1.953 . . . . 0.0 112.009 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 C--N 1.315 -0.899 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.126 179.909 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.559 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.9 tp10 . . . . . 0 C--O 1.24 0.563 0 CA-C-O 121.378 0.608 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.62 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 45.0 p -113.72 153.25 29.31 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.938 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.592 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 16.2 t -121.52 38.9 3.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.241 0.543 . . . . 0.0 110.349 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -63.29 -37.95 80.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.5 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.51 11.56 50.86 Favored Glycine 0 C--O 1.228 -0.232 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.066 179.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.23 2.06 82.41 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.857 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.78 145.43 25.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.576 0.227 . . . . 0.0 110.7 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.7 m -91.86 163.39 14.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.995 0.426 . . . . 0.0 109.869 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 t30 -85.94 -36.21 20.0 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.487 -0.779 . . . . 0.0 108.965 178.436 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 25.9 m -69.02 124.64 90.81 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.76 132.43 28.58 Favored 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.344 2.029 . . . . 0.0 111.992 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.49 34.44 50.03 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.747 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -110.93 143.11 42.1 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.686 0.279 . . . . 0.0 110.263 179.331 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.2 148.52 23.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.115 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.2 t -89.7 138.59 31.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.234 0.54 . . . . 0.0 111.509 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.4 m -146.72 60.1 1.2 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.427 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.7 t90 -32.32 128.19 0.34 Allowed Pre-proline 0 N--CA 1.464 0.261 0 O-C-N 124.515 1.134 . . . . 0.0 112.618 -177.494 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.427 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.1 Cg_endo -94.01 25.88 21.7 Favored 'Cis proline' 0 N--CA 1.46 -0.445 0 C-N-CA 123.196 -1.585 . . . . 0.0 113.957 0.753 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.8 m -124.49 -174.86 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 O-C-N 122.111 -0.368 . . . . 0.0 111.692 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 92.6 m -125.6 153.13 44.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.985 0.421 . . . . 0.0 111.277 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.961 HG22 ' HA ' ' A' ' 28' ' ' PRO . 20.9 p -134.69 162.39 32.48 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.916 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 59.3 ttt180 -150.42 126.03 10.27 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.305 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 59.76 31.37 20.78 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.843 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.67 13.25 83.37 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.857 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.42 HD13 ' HA ' ' A' ' 27' ' ' LEU . 3.5 mm? -117.94 130.52 24.66 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.15 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.961 ' HA ' HG22 ' A' ' 23' ' ' THR . 13.0 Cg_exo -65.86 139.91 58.94 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.247 1.965 . . . . 0.0 112.576 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.315 -0.901 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.267 179.262 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.537 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.9 tp10 . . . . . 0 C--O 1.242 0.658 0 CA-C-O 121.315 0.579 . . . . 0.0 110.82 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.68 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.8 p -113.1 153.67 27.82 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.824 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.542 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 27.4 t -119.1 37.37 4.15 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.285 0.564 . . . . 0.0 110.223 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.405 HG23 ' HB ' ' A' ' 4' ' ' THR . 23.8 t -63.3 -38.34 81.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.216 179.791 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.65 10.88 60.81 Favored Glycine 0 N--CA 1.453 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.825 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.54 4.68 85.09 Favored Glycine 0 C--N 1.318 -0.442 0 C-N-CA 121.366 -0.445 . . . . 0.0 112.911 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.79 145.72 25.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.519 0.2 . . . . 0.0 110.744 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -94.26 159.85 14.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.207 0.527 . . . . 0.0 110.267 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -80.05 -39.98 28.65 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.231 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 36.0 m -80.42 121.69 81.79 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.812 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.62 142.14 76.05 Favored 'Trans proline' 0 C--O 1.235 0.375 0 C-N-CA 122.839 2.36 . . . . 0.0 112.721 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.47 2.26 87.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 121.06 -0.591 . . . . 0.0 113.163 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.3 137.97 31.92 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.05 149.37 23.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.882 0.373 . . . . 0.0 110.002 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -80.51 136.84 36.37 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.29 0.567 . . . . 0.0 111.586 -179.124 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.3 m -145.92 59.12 1.24 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.9 OUTLIER -32.63 128.57 0.35 Allowed Pre-proline 0 N--CA 1.463 0.208 0 O-C-N 124.677 1.236 . . . . 0.0 112.657 -177.246 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.2 Cg_endo -92.72 25.35 22.65 Favored 'Cis proline' 0 N--CA 1.461 -0.423 0 C-N-CA 123.108 -1.622 . . . . 0.0 114.231 0.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.68 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.6 m -125.19 -172.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 C-N-CA 120.495 -0.482 . . . . 0.0 112.259 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.542 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 76.2 m -128.1 143.63 51.07 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.824 HG22 ' HA ' ' A' ' 28' ' ' PRO . 67.6 p -134.13 145.14 49.01 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.587 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.9 ttm-85 -111.73 109.49 19.37 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.547 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.58 35.84 22.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.34 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.53 -16.48 58.98 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.405 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.0 tp -89.42 119.07 69.6 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 117.112 0.456 . . . . 0.0 109.856 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.824 ' HA ' HG22 ' A' ' 23' ' ' THR . 23.3 Cg_exo -59.28 139.11 88.52 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 122.063 1.842 . . . . 0.0 112.547 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 41.9 t . . . . . 0 C--N 1.314 -0.936 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.063 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.448 ' CG ' ' HB2' ' A' ' 22' ' ' CYS . 9.8 tp10 . . . . . 0 C--O 1.241 0.636 0 CA-C-O 121.157 0.504 . . . . 0.0 110.479 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.636 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.0 p -112.31 152.68 28.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.79 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.538 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 22.6 t -117.2 38.92 3.39 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.209 0.528 . . . . 0.0 110.332 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.28 -39.97 87.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.06 179.732 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.7 11.77 65.45 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.642 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.26 19.02 75.53 Favored Glycine 0 C--N 1.319 -0.371 0 C-N-CA 121.623 -0.322 . . . . 0.0 112.852 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.12 147.45 27.08 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 122.407 0.283 . . . . 0.0 110.83 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 m -115.4 158.81 21.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.997 0.427 . . . . 0.0 110.315 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -82.12 -38.16 25.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.479 178.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.411 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 98.1 m -64.42 125.27 88.12 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.959 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 21.4 Cg_exo -64.01 132.68 35.35 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.772 2.315 . . . . 0.0 112.016 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.33 28.36 71.45 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.546 -0.752 . . . . 0.0 112.818 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -94.18 136.61 34.29 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.031 0.443 . . . . 0.0 110.521 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -89.36 147.74 23.9 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.568 179.089 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.2 t -82.59 135.15 35.14 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.189 0.519 . . . . 0.0 111.175 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 45.0 m -143.09 58.83 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -32.88 128.54 0.37 Allowed Pre-proline 0 N--CA 1.463 0.191 0 O-C-N 124.673 1.233 . . . . 0.0 112.705 -177.295 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -93.31 25.56 22.38 Favored 'Cis proline' 0 N--CA 1.461 -0.409 0 C-N-CA 123.071 -1.637 . . . . 0.0 114.144 0.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.636 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.4 m -123.75 -174.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.068 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.538 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.6 m -126.11 146.85 49.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.747 HG22 ' HA ' ' A' ' 28' ' ' PRO . 18.4 p -127.57 166.33 18.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.15 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 43.3 ttp85 -151.18 119.15 6.22 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 57.15 41.25 27.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.506 0.669 . . . . 0.0 110.354 -179.182 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.75 11.9 77.97 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.565 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.5 mt -121.57 127.58 26.01 Favored Pre-proline 0 C--N 1.325 -0.5 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.747 ' HA ' HG22 ' A' ' 23' ' ' THR . 17.4 Cg_exo -62.98 141.9 85.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.2 1.934 . . . . 0.0 112.416 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.442 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 39.8 t . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.448 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.672 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.6 tp10 . . . . . 0 C--O 1.239 0.526 0 CA-C-O 121.079 0.466 . . . . 0.0 110.372 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.4 p -107.71 151.42 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.485 179.443 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.524 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 14.8 t -116.92 40.86 2.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.108 0.48 . . . . 0.0 110.367 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.2 t -62.93 -40.58 89.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.377 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 13.1 62.58 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.778 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 22.2 74.78 Favored Glycine 0 C--N 1.319 -0.386 0 C-N-CA 121.593 -0.337 . . . . 0.0 112.804 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.08 147.49 27.15 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.384 0.274 . . . . 0.0 110.797 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.0 m -117.79 159.64 22.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.058 0.456 . . . . 0.0 110.224 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -82.26 -37.89 25.23 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.354 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.4 m -65.43 125.79 90.23 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.069 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.55 131.99 29.64 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 122.546 2.164 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.64 34.99 73.6 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.888 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.36 137.8 38.29 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.57 146.24 25.25 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -86.16 130.62 34.47 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 121.293 0.568 . . . . 0.0 111.706 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 75.1 m -137.52 62.1 1.59 Allowed 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.99 127.88 0.38 Allowed Pre-proline 0 N--CA 1.462 0.131 0 CA-C-N 114.619 -1.173 . . . . 0.0 112.581 -177.316 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -95.95 30.49 13.82 Favored 'Cis proline' 0 N--CA 1.46 -0.493 0 C-N-CA 123.493 -1.461 . . . . 0.0 114.112 0.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.1 m -126.92 177.06 5.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.524 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.3 m -119.98 141.42 49.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.164 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.557 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.4 p -132.41 141.66 48.96 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.89 -179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 44.1 ttt85 -131.1 127.71 38.69 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.263 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.4 t30 57.77 37.14 27.08 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.335 0.588 . . . . 0.0 110.54 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.52 18.2 76.9 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.778 -0.646 . . . . 0.0 113.001 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 37.6 tp -129.74 128.02 22.95 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.557 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.1 Cg_exo -61.5 141.01 90.4 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 121.988 1.792 . . . . 0.0 111.932 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.672 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.3 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.755 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.539 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 12.4 mm-40 . . . . . 0 CA--C 1.515 -0.403 0 CA-C-O 121.089 0.471 . . . . 0.0 111.189 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.7 p -113.11 148.21 35.75 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.743 178.291 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.521 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 11.2 t -118.03 40.0 3.25 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.057 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -64.37 -41.67 93.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.29 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.3 6.58 78.31 Favored Glycine 0 C--O 1.227 -0.283 0 CA-C-N 115.683 -0.689 . . . . 0.0 112.395 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.521 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 73.32 29.49 64.11 Favored Glycine 0 C--N 1.319 -0.399 0 CA-C-N 115.329 -0.436 . . . . 0.0 112.891 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.8 p -145.84 142.36 28.76 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 122.219 0.208 . . . . 0.0 111.073 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 20.9 m -122.13 169.05 11.26 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 178.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -94.02 -33.4 13.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.312 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.497 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 18.2 m -64.13 122.52 78.1 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.031 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.09 128.46 20.67 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.461 2.107 . . . . 0.0 111.753 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 37.23 84.48 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.437 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.497 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -96.45 143.86 27.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.999 0.428 . . . . 0.0 110.904 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.57 150.9 22.21 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.567 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.8 t -92.81 135.21 34.32 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.116 0.484 . . . . 0.0 111.368 -179.449 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 64.7 m -141.67 62.47 1.45 Allowed 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.392 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.8 t90 -32.6 126.78 0.37 Allowed Pre-proline 0 N--CA 1.463 0.184 0 O-C-N 124.57 1.169 . . . . 0.0 112.374 -177.585 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 53.1 Cg_endo -97.62 32.78 10.37 Favored 'Cis proline' 0 N--CA 1.457 -0.621 0 C-N-CA 123.639 -1.4 . . . . 0.0 114.21 0.812 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.586 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.1 m -130.04 169.13 21.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.539 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 96.4 m -105.48 147.52 28.22 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.687 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.839 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.7 p -133.24 158.63 42.41 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.844 0.354 . . . . 0.0 110.535 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 28.6 ttt-85 -150.36 130.18 13.3 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 59.01 31.54 21.46 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 123.541 0.526 . . . . 0.0 110.884 -178.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.81 17.94 80.11 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.766 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.455 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.4 mt -126.45 131.41 23.92 Favored Pre-proline 0 C--N 1.326 -0.444 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.839 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.4 Cg_exo -65.26 140.83 66.17 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.275 1.983 . . . . 0.0 112.278 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.493 HG11 ' HG3' ' A' ' 3' ' ' GLU . 29.6 t . . . . . 0 C--N 1.316 -0.88 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.532 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.557 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 64.3 mm-40 . . . . . 0 CA--C 1.513 -0.459 0 CA-C-O 121.157 0.504 . . . . 0.0 111.266 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.632 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.9 p -115.33 150.38 36.38 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.733 178.243 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.5 t -120.4 38.14 4.07 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.243 0.544 . . . . 0.0 109.981 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 23.6 t -64.13 -41.75 93.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.075 179.609 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.62 6.21 83.86 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.49 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.35 20.43 77.08 Favored Glycine 0 C--N 1.318 -0.444 0 CA-C-N 115.331 -0.435 . . . . 0.0 112.971 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 20.7 p -147.05 141.76 26.72 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 122.1 0.16 . . . . 0.0 110.919 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.3 m -108.07 165.36 11.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.123 0.487 . . . . 0.0 110.445 179.062 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -83.12 -38.15 22.81 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.838 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -73.55 122.23 87.09 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.804 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.3 Cg_exo -64.96 133.55 36.34 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.744 2.296 . . . . 0.0 112.168 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 25.66 70.92 Favored Glycine 0 CA--C 1.519 0.284 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.036 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -92.17 147.38 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.659 0.266 . . . . 0.0 110.342 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -88.86 149.6 23.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.949 179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.6 t -91.55 136.56 33.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.167 0.508 . . . . 0.0 111.352 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.1 m -144.9 61.78 1.31 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.2 127.14 0.35 Allowed Pre-proline 0 N--CA 1.465 0.277 0 O-C-N 124.608 1.193 . . . . 0.0 112.594 -177.407 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 44.4 Cg_endo -96.53 30.24 14.12 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.547 -1.439 . . . . 0.0 114.002 0.806 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.632 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.2 m -128.4 175.13 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.557 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 89.1 m -112.94 150.74 31.41 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.845 0.355 . . . . 0.0 111.204 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.827 HG22 ' HA ' ' A' ' 28' ' ' PRO . 13.0 p -131.67 160.61 34.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.633 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -150.54 127.96 11.42 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.7 m-20 58.99 33.72 23.19 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 123.655 0.597 . . . . 0.0 110.841 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.35 16.65 79.79 Favored Glycine 0 C--N 1.33 0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 112.863 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.442 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.7 mt -126.59 133.86 25.44 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.827 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.5 Cg_exo -63.26 141.18 81.07 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.313 2.009 . . . . 0.0 112.154 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 3' ' ' GLU . 39.7 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.918 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.498 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 11.4 tp10 . . . . . 0 C--O 1.241 0.654 0 CA-C-O 121.301 0.572 . . . . 0.0 110.727 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.678 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -113.04 152.65 29.25 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.723 179.501 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.515 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 28.5 t -116.54 36.69 4.02 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.328 0.585 . . . . 0.0 110.222 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.445 HG23 ' HB ' ' A' ' 4' ' ' THR . 22.7 t -65.03 -37.89 81.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.92 179.453 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.1 3.38 86.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.768 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.42 1.75 90.24 Favored Glycine 0 C--N 1.318 -0.444 0 C-N-CA 121.348 -0.454 . . . . 0.0 113.306 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.7 p -147.3 141.69 26.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.697 0.248 . . . . 0.0 111.012 179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.42 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.2 m -98.62 161.2 13.79 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.336 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.8 m-20 -87.93 -35.83 17.45 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.509 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 83.1 m -64.86 126.09 90.34 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.7 Cg_exo -62.39 132.64 39.29 Favored 'Trans proline' 0 C--O 1.238 0.487 0 C-N-CA 122.785 2.323 . . . . 0.0 112.446 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.45 30.33 71.27 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.995 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.52 135.06 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.556 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.55 148.83 23.16 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.828 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -81.31 135.89 35.73 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.285 0.564 . . . . 0.0 111.381 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.5 m -144.24 59.03 1.35 Allowed 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.322 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.7 OUTLIER -32.97 128.75 0.37 Allowed Pre-proline 0 N--CA 1.462 0.169 0 O-C-N 124.63 1.206 . . . . 0.0 112.76 -177.256 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.6 Cg_endo -92.7 24.91 23.6 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.066 -1.639 . . . . 0.0 114.209 0.897 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.678 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.5 m -124.97 -172.32 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 O-C-N 121.988 -0.445 . . . . 0.0 112.168 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.515 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.5 m -127.74 146.79 50.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.084 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.842 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.9 p -134.22 162.64 31.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.453 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.5 ttp180 -150.17 125.86 10.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.3 t30 60.03 33.4 21.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.418 0.628 . . . . 0.0 110.567 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.53 9.05 87.09 Favored Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.696 -0.684 . . . . 0.0 113.288 179.567 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.406 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 9.2 mp -118.78 129.79 25.19 Favored Pre-proline 0 C--N 1.327 -0.396 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.842 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.1 Cg_exo -64.97 140.81 67.81 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.247 1.965 . . . . 0.0 112.331 -179.612 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.4 t . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.107 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.696 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 2.6 mm-40 . . . . . 0 C--O 1.238 0.464 0 CA-C-O 121.124 0.488 . . . . 0.0 111.388 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.585 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 33.0 p -116.92 147.45 42.21 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.037 178.308 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.5 t -117.27 40.22 3.08 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.866 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.442 HG23 ' HB ' ' A' ' 4' ' ' THR . 33.8 t -64.2 -42.35 95.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.385 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.78 7.83 76.84 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.395 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.515 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 72.04 31.03 64.65 Favored Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.405 -0.397 . . . . 0.0 112.774 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.3 p -144.92 142.89 30.25 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.646 -0.277 . . . . 0.0 110.89 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 17.6 m -124.94 165.22 18.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.985 0.421 . . . . 0.0 110.018 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -87.21 -33.98 19.15 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.766 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.447 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 19.7 m -70.29 125.84 92.13 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.176 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -65.94 129.97 23.32 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.456 2.104 . . . . 0.0 111.865 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.2 37.86 87.22 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.327 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.447 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -94.78 144.78 25.36 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.899 0.38 . . . . 0.0 110.713 179.783 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.26 148.96 23.3 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.508 178.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.8 t -93.64 134.14 36.26 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.238 0.542 . . . . 0.0 111.325 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.6 m -140.03 61.77 1.52 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.0 t90 -32.16 126.36 0.35 Allowed Pre-proline 0 N--CA 1.463 0.185 0 O-C-N 124.504 1.128 . . . . 0.0 112.481 -177.462 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.489 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -98.36 33.81 9.16 Favored 'Cis proline' 0 N--CA 1.458 -0.595 0 C-N-CA 123.675 -1.385 . . . . 0.0 114.167 0.744 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.585 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 4.3 m -130.32 163.11 36.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.696 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 81.7 m -102.44 145.62 29.27 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.984 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.753 HG22 ' HA ' ' A' ' 28' ' ' PRO . 30.6 p -133.42 164.03 28.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.118 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 30.5 ttt-85 -150.85 123.59 8.58 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.4 t30 58.84 34.65 23.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.426 0.631 . . . . 0.0 110.678 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.35 9.43 87.01 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.602 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.419 ' HA ' HD13 ' A' ' 27' ' ' LEU . 3.4 mm? -120.48 130.79 24.68 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.126 0.463 . . . . 0.0 109.917 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.753 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.5 Cg_exo -63.76 141.71 79.93 Favored 'Trans proline' 0 N--CA 1.46 -0.462 0 C-N-CA 122.26 1.974 . . . . 0.0 112.253 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.491 ' CG1' ' HG3' ' A' ' 3' ' ' GLU . 37.2 t . . . . . 0 C--N 1.318 -0.786 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.857 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.641 ' OE2' ' HB3' ' A' ' 10' ' ' CYS . 48.2 tt0 . . . . . 0 C--O 1.235 0.339 0 CA-C-O 121.247 0.546 . . . . 0.0 111.05 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 24.4 p -108.69 152.63 24.55 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.607 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.2 t -119.19 41.34 3.1 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.156 0.503 . . . . 0.0 109.704 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.5 t -62.66 -39.64 85.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.687 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.76 11.61 59.08 Favored Glycine 0 N--CA 1.452 -0.241 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.726 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.74 19.28 73.09 Favored Glycine 0 C--N 1.319 -0.369 0 C-N-CA 121.532 -0.366 . . . . 0.0 112.558 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.25 26.18 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 122.559 0.343 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.641 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 39.3 m -106.83 172.11 7.0 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.028 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -96.8 -29.84 13.52 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.975 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.436 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.3 m -79.93 124.84 82.97 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.574 -179.651 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 36.2 Cg_exo -60.35 135.97 65.04 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.905 2.403 . . . . 0.0 112.913 -179.37 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.56 32.75 79.42 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.543 -0.753 . . . . 0.0 113.437 179.423 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.74 147.11 26.4 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.52 150.28 22.52 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -98.0 138.09 35.84 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.214 0.531 . . . . 0.0 111.04 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.8 m -144.2 62.92 1.34 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -33.01 127.26 0.39 Allowed Pre-proline 0 N--CA 1.465 0.296 0 O-C-N 124.563 1.164 . . . . 0.0 112.32 -177.551 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.3 Cg_endo -97.08 33.11 10.13 Favored 'Cis proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.505 -1.456 . . . . 0.0 114.24 0.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.4 m -129.8 169.99 19.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.436 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 99.4 m -107.33 148.08 29.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.475 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.955 HG22 ' HA ' ' A' ' 28' ' ' PRO . 33.1 p -137.3 168.7 19.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.101 0.476 . . . . 0.0 110.664 -179.494 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -151.09 120.0 6.64 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 57.85 36.64 26.54 Favored 'General case' 0 N--CA 1.467 0.417 0 O-C-N 123.41 0.444 . . . . 0.0 111.331 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.15 7.0 88.74 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 121.095 -0.574 . . . . 0.0 113.188 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.447 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 94.1 mt -113.34 126.17 28.57 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.462 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.955 ' HA ' HG22 ' A' ' 23' ' ' THR . 12.2 Cg_exo -67.5 140.94 53.88 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.395 2.064 . . . . 0.0 112.879 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.9 t . . . . . 0 C--N 1.318 -0.8 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.129 178.789 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.552 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 6.2 tp10 . . . . . 0 C--O 1.241 0.656 0 CA-C-O 121.224 0.535 . . . . 0.0 110.182 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 44.7 p -111.45 151.64 28.33 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.057 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.492 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 15.3 t -118.04 39.5 3.38 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.101 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.4 t -62.87 -40.6 89.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.475 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.57 4.81 85.19 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.76 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.21 13.56 82.72 Favored Glycine 0 C--N 1.317 -0.527 0 C-N-CA 121.433 -0.413 . . . . 0.0 113.03 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.4 p -147.82 142.04 26.16 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.155 0.182 . . . . 0.0 110.858 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 m -106.98 163.05 13.3 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 178.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 t30 -87.62 -35.73 17.89 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.719 0.771 . . . . 0.0 109.286 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 32.2 m -65.85 126.01 90.97 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 114.76 -1.109 . . . . 0.0 111.213 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -64.45 133.77 38.76 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.519 2.146 . . . . 0.0 112.472 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.9 29.51 72.51 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.307 -0.86 . . . . 0.0 113.02 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -95.94 137.11 35.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.811 0.339 . . . . 0.0 110.621 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.3 149.43 23.05 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.585 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.5 t -86.61 136.2 33.14 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.352 0.596 . . . . 0.0 111.6 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.5 m -143.48 59.44 1.39 Allowed 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.198 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -31.94 127.43 0.33 Allowed Pre-proline 0 N--CA 1.464 0.245 0 O-C-N 124.506 1.129 . . . . 0.0 112.543 -177.297 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 49.3 Cg_endo -95.29 29.28 15.86 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.352 -1.52 . . . . 0.0 114.134 0.783 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.597 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.9 m -126.92 179.31 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.552 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 92.9 m -120.9 144.31 48.49 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.243 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.676 HG22 ' HA ' ' A' ' 28' ' ' PRO . 34.7 p -134.85 155.92 49.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.642 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -148.19 130.36 15.49 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.0 m120 59.74 30.99 20.58 Favored 'General case' 0 N--CA 1.465 0.3 0 O-C-N 123.589 0.556 . . . . 0.0 110.934 -178.768 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.19 17.58 80.2 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.753 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 36.4 tp -129.59 129.06 23.13 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.676 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.5 Cg_exo -62.19 142.7 92.74 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.195 1.93 . . . . 0.0 111.854 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.539 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 46.0 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.702 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.23 0 CA-C-O 120.398 0.142 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.84 25.42 25.24 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.803 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.468 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 10.4 tp10 -73.02 121.97 21.0 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.646 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.3 p -110.77 153.54 25.19 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.108 0.48 . . . . 0.0 111.158 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.622 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 21.5 t -121.05 38.91 3.94 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.092 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.9 t -62.93 -40.48 89.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.404 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.1 5.41 83.07 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.849 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.0 11.56 84.34 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.93 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.2 p -148.08 142.42 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.243 0.217 . . . . 0.0 110.745 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.423 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.4 m -103.67 159.41 15.64 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.994 0.426 . . . . 0.0 110.153 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.7 m-80 -81.34 -38.64 26.37 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.463 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.475 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -70.43 125.01 91.87 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.207 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.1 Cg_exo -65.71 136.2 44.85 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.791 2.328 . . . . 0.0 112.013 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 23.88 74.51 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.709 -0.678 . . . . 0.0 113.05 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.04 137.63 36.56 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.3 148.21 23.68 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.4 t -83.8 137.05 33.9 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.43 0.633 . . . . 0.0 111.413 -179.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 30.9 m -144.62 58.95 1.32 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.4 t90 -31.82 127.45 0.32 Allowed Pre-proline 0 N--CA 1.463 0.211 0 O-C-N 124.516 1.135 . . . . 0.0 112.628 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -94.62 28.44 17.2 Favored 'Cis proline' 0 N--CA 1.46 -0.456 0 C-N-CA 123.278 -1.551 . . . . 0.0 114.142 0.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 12.6 m -126.3 -176.7 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.622 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.8 m -127.77 140.4 52.07 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.994 0.426 . . . . 0.0 111.091 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.506 HG22 ' HA ' ' A' ' 28' ' ' PRO . 40.1 p -132.25 157.26 44.83 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.728 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.43 ' HG2' ' OD1' ' A' ' 25' ' ' ASN . 54.9 ttp85 -147.02 127.8 14.35 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.43 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 7.7 m120 60.16 31.61 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 O-C-N 123.422 0.451 . . . . 0.0 110.768 -178.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.29 14.44 81.91 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.967 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.6 mt -127.41 135.95 28.2 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.506 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.7 Cg_exo -60.36 141.53 95.91 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.069 1.846 . . . . 0.0 111.652 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.468 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 20.8 t . . . . . 0 C--N 1.317 -0.805 0 CA-C-O 121.483 0.659 . . . . 0.0 110.189 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.459 0 CA-C-O 120.682 0.277 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.19 -39.06 2.86 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.559 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 44.9 tt0 -80.24 108.4 13.81 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.547 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.2 p -101.87 152.21 21.18 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.944 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.0 t -117.58 40.92 2.96 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.841 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.5 t -62.32 -41.22 90.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.587 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.27 12.94 63.07 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.597 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.4 30.24 77.15 Favored Glycine 0 C--N 1.319 -0.392 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.36 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.66 149.24 29.59 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.892 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.441 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 60.2 m -123.56 171.76 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.343 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -88.46 -32.57 18.2 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.406 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.575 HG21 ' CD ' ' A' ' 24' ' ' ARG . 27.7 m -74.08 127.51 87.89 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.33 131.31 23.04 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.195 1.93 . . . . 0.0 111.644 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.73 29.39 69.53 Favored Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.627 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.474 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.48 146.76 24.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.758 0.313 . . . . 0.0 110.477 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.66 144.88 26.0 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -96.53 130.86 43.62 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.262 0.553 . . . . 0.0 111.592 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 59.6 m -131.98 63.13 1.62 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.7 t90 -33.87 127.94 0.44 Allowed Pre-proline 0 N--CA 1.462 0.158 0 O-C-N 124.382 1.051 . . . . 0.0 112.2 -177.469 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -96.96 33.73 9.54 Favored 'Cis proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.574 -1.428 . . . . 0.0 114.335 0.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.2 m -129.6 164.25 32.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.268 0.556 . . . . 0.0 112.205 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.559 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 92.2 m -97.06 150.89 20.31 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.872 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.728 HG22 ' HA ' ' A' ' 28' ' ' PRO . 3.1 p -138.56 141.51 39.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.632 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.575 ' CD ' HG21 ' A' ' 12' ' ' THR . 33.3 mtm180 -125.77 119.34 27.64 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 57.55 41.62 25.53 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.773 0.671 . . . . 0.0 109.984 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.72 13.29 74.92 Favored Glycine 0 CA--C 1.52 0.395 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.202 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 43.8 tp -112.81 125.01 30.57 Favored Pre-proline 0 C--N 1.326 -0.433 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.728 ' HA ' HG22 ' A' ' 23' ' ' THR . 18.9 Cg_exo -63.5 142.31 84.11 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.344 2.03 . . . . 0.0 112.088 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.7 t . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.378 -179.935 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.119 0 N-CA-C 112.227 0.454 . . . . 0.0 112.227 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.83 22.56 75.62 Favored Glycine 0 N--CA 1.453 -0.224 0 CA-C-N 115.483 -0.78 . . . . 0.0 113.33 179.223 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.566 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.8 tp10 -115.42 112.37 22.21 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 46.5 p -107.58 151.74 25.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.011 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.7 t -119.32 41.81 3.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.022 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.9 t -62.42 -39.63 85.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.694 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.36 12.87 61.54 Favored Glycine 0 N--CA 1.453 -0.222 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.891 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.41 21.87 74.52 Favored Glycine 0 C--N 1.321 -0.301 0 C-N-CA 121.453 -0.403 . . . . 0.0 112.614 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.86 147.66 27.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 110.614 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 15.7 m -114.74 167.01 11.14 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.14 0.495 . . . . 0.0 110.219 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -90.63 -34.71 15.35 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.788 178.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.3 m -67.88 126.06 92.15 Favored Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.398 -1.274 . . . . 0.0 111.326 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.88 133.45 33.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.439 2.092 . . . . 0.0 112.137 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 31.63 74.37 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.714 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.96 139.21 34.95 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.615 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.48 149.02 23.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.559 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.4 t -88.88 135.6 33.45 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.27 0.557 . . . . 0.0 111.379 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.6 m -141.03 59.71 1.52 Allowed 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.199 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.3 t90 -32.01 127.16 0.34 Allowed Pre-proline 0 N--CA 1.464 0.227 0 O-C-N 124.649 1.218 . . . . 0.0 112.496 -177.345 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.2 Cg_endo -96.02 31.08 12.91 Favored 'Cis proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.175 0.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.584 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.5 m -127.77 175.79 8.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.506 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 87.3 m -117.37 143.17 46.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.175 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.675 HG22 ' HA ' ' A' ' 28' ' ' PRO . 38.8 p -135.8 159.27 42.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.484 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -150.14 126.47 10.74 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.0 t30 60.03 34.8 21.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.518 0.675 . . . . 0.0 110.193 -178.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.59 14.07 79.87 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.995 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.431 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.5 mt -122.89 127.51 25.7 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.5 Cg_exo -65.82 142.1 68.15 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.415 2.076 . . . . 0.0 112.188 -179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.566 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.7 t . . . . . 0 C--N 1.317 -0.815 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.493 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.88 0.371 . . . . 0.0 111.837 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.63 -31.58 3.87 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.899 -0.591 . . . . 0.0 112.787 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.486 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 6.1 tp10 -72.1 109.97 6.25 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.149 0.499 . . . . 0.0 110.3 -179.617 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.9 p -107.88 153.0 23.67 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.983 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.411 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.4 t -120.7 40.49 3.51 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.049 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -61.94 -40.13 86.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.585 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.91 12.44 61.86 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.762 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.04 21.61 75.54 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 121.557 -0.354 . . . . 0.0 112.739 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.13 147.12 26.67 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 122.427 0.291 . . . . 0.0 110.939 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 18.5 m -112.07 167.36 10.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.038 0.447 . . . . 0.0 109.953 179.29 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -88.68 -35.64 16.65 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 26.9 m -68.7 125.38 91.74 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 114.282 -1.326 . . . . 0.0 111.586 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 15.2 Cg_exo -66.17 133.37 32.79 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.554 2.169 . . . . 0.0 111.447 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.76 31.68 70.36 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.719 -0.673 . . . . 0.0 112.724 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -99.54 141.33 32.48 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.85 0.357 . . . . 0.0 110.468 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.1 m -89.45 149.1 23.09 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.656 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -90.81 136.32 33.15 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.279 0.562 . . . . 0.0 110.996 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 56.9 m -142.66 60.42 1.43 Allowed 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.58 127.89 0.36 Allowed Pre-proline 0 N--CA 1.463 0.213 0 O-C-N 124.627 1.205 . . . . 0.0 112.45 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.2 Cg_endo -94.83 29.27 15.92 Favored 'Cis proline' 0 N--CA 1.46 -0.477 0 C-N-CA 123.238 -1.567 . . . . 0.0 114.22 0.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.0 m -126.88 179.88 3.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.985 0.422 . . . . 0.0 112.095 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.483 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 96.9 m -117.95 148.37 42.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.065 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.631 HG22 ' HA ' ' A' ' 28' ' ' PRO . 13.4 p -131.95 157.03 45.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 0.0 110.74 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.719 ' O ' ' HG ' ' A' ' 27' ' ' LEU . 53.7 ttp180 -150.31 130.56 13.67 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.6 t30 57.71 33.48 23.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 110.938 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.74 16.81 80.41 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.819 -0.628 . . . . 0.0 113.941 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.719 ' HG ' ' O ' ' A' ' 24' ' ' ARG . 3.9 pp -133.88 135.66 25.03 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.404 0.602 . . . . 0.0 109.871 178.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.631 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.2 Cg_exo -64.93 141.83 72.64 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.599 2.199 . . . . 0.0 112.722 -178.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.486 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 43.9 t . . . . . 0 C--N 1.317 -0.823 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.13 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.165 0 N-CA-C 112.126 0.417 . . . . 0.0 112.126 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.86 24.05 74.26 Favored Glycine 0 N--CA 1.452 -0.264 0 CA-C-N 115.459 -0.791 . . . . 0.0 113.613 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.624 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.9 tp10 -112.48 114.92 27.85 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.109 0.481 . . . . 0.0 110.363 179.47 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.1 p -108.44 152.04 25.23 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.863 179.527 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.6 t -119.0 40.81 3.21 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.098 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -62.23 -40.37 87.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 13.24 62.49 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.728 179.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.5 24.55 73.81 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 121.529 -0.367 . . . . 0.0 112.694 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 147.84 27.68 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 122.459 0.304 . . . . 0.0 110.927 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.5 m -118.28 164.11 15.69 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -88.76 -35.33 16.74 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.091 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.431 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 24.6 m -67.9 125.49 91.45 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 114.574 -1.194 . . . . 0.0 111.361 -179.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.72 133.74 35.24 Favored 'Trans proline' 0 N--CA 1.46 -0.476 0 C-N-CA 122.694 2.263 . . . . 0.0 111.797 179.583 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.64 27.67 72.13 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.968 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -97.71 136.32 38.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.827 0.346 . . . . 0.0 110.31 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 149.94 22.82 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -86.16 136.61 33.13 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.299 0.571 . . . . 0.0 111.393 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 40.9 m -142.89 59.56 1.42 Allowed 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.0 t90 -32.08 127.38 0.34 Allowed Pre-proline 0 N--CA 1.465 0.288 0 O-C-N 124.675 1.234 . . . . 0.0 112.598 -177.357 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.9 Cg_endo -95.6 30.32 14.14 Favored 'Cis proline' 0 N--CA 1.459 -0.506 0 C-N-CA 123.432 -1.487 . . . . 0.0 114.132 0.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 10.5 m -127.27 176.73 6.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 97.0 m -119.29 140.54 50.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.383 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.527 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.5 p -130.68 131.93 45.12 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.277 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.4 ttp85 -98.67 106.64 18.93 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.8 t30 60.16 37.68 20.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.552 0.692 . . . . 0.0 109.399 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.26 -12.17 65.41 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.466 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -96.92 111.75 58.55 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 117.239 0.52 . . . . 0.0 110.396 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.527 ' HA ' HG22 ' A' ' 23' ' ' THR . 0.9 OUTLIER -49.14 138.47 28.4 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.943 2.428 . . . . 0.0 113.56 -179.111 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.624 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 44.6 t . . . . . 0 C--N 1.317 -0.834 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.541 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.178 0 CA-C-O 120.814 0.34 . . . . 0.0 111.447 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.82 -35.25 3.68 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.413 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.446 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 14.7 tp10 -71.74 109.38 5.59 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.3 p -108.22 152.41 24.63 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.134 0.492 . . . . 0.0 111.074 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.437 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.9 t -119.67 39.37 3.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.02 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 25.8 t -62.48 -40.42 88.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.443 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.05 3.84 84.73 Favored Glycine 0 C--O 1.227 -0.326 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.764 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.96 14.61 81.8 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.999 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.6 p -148.35 141.86 25.39 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.148 0.179 . . . . 0.0 110.928 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.7 m -106.19 167.6 9.71 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -90.86 -33.9 15.47 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.645 0.736 . . . . 0.0 109.051 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 34.9 m -63.88 126.99 91.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 114.834 -1.076 . . . . 0.0 111.018 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.39 128.83 23.54 Favored 'Trans proline' 0 C--O 1.237 0.446 0 C-N-CA 122.549 2.166 . . . . 0.0 112.4 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.38 31.77 79.89 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.186 -0.916 . . . . 0.0 112.781 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.473 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.82 143.34 26.88 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.871 0.367 . . . . 0.0 110.825 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.55 148.01 23.63 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.586 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -91.71 136.12 33.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.201 0.524 . . . . 0.0 110.883 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.8 m -142.34 59.96 1.45 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.56 127.91 0.36 Allowed Pre-proline 0 N--CA 1.463 0.186 0 O-C-N 124.625 1.203 . . . . 0.0 112.473 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -94.47 27.76 18.22 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.293 -1.545 . . . . 0.0 114.178 0.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.59 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.9 m -124.78 -179.25 2.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.026 0.441 . . . . 0.0 111.959 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.437 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.9 m -119.79 150.34 40.58 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.299 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.708 HG22 ' HA ' ' A' ' 28' ' ' PRO . 7.6 p -130.26 154.13 47.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.631 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.465 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 14.7 tpt85 -142.14 124.22 15.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 24.3 t30 57.09 38.94 29.38 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.261 0.553 . . . . 0.0 110.793 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.62 16.97 76.18 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.342 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.1 mt -126.48 131.16 23.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.708 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.7 Cg_exo -63.41 140.83 78.47 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.107 1.871 . . . . 0.0 112.214 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.446 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 33.9 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.814 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.094 0 CA-C-O 120.872 0.368 . . . . 0.0 111.835 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.44 -33.82 4.41 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.935 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.639 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 5.5 mm-40 -72.11 120.85 18.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.251 0.548 . . . . 0.0 111.827 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -115.01 147.93 39.48 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.546 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.436 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.2 t -117.71 39.8 3.25 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.222 0.534 . . . . 0.0 110.091 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 32.2 t -64.05 -40.7 89.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.008 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.25 12.68 68.5 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.595 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.436 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 65.8 31.04 78.51 Favored Glycine 0 C--N 1.319 -0.381 0 CA-C-N 115.467 -0.366 . . . . 0.0 112.786 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.79 148.54 28.63 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.602 -0.299 . . . . 0.0 110.971 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 23.5 m -125.2 167.87 14.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.081 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -90.3 -33.62 16.04 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.41 -0.813 . . . . 0.0 109.201 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.45 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 18.8 m -68.14 124.27 89.28 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.987 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -64.89 129.53 23.51 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.478 2.119 . . . . 0.0 111.87 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 37.33 86.03 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.488 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.45 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -97.08 144.24 27.14 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.927 0.394 . . . . 0.0 110.915 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 150.65 22.49 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.696 178.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.5 t -93.94 135.43 35.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.21 0.529 . . . . 0.0 111.329 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 66.9 m -141.63 61.92 1.46 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -32.56 126.99 0.37 Allowed Pre-proline 0 N--CA 1.462 0.159 0 O-C-N 124.554 1.159 . . . . 0.0 112.371 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.5 Cg_endo -97.18 32.77 10.51 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.585 -1.423 . . . . 0.0 114.171 0.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 8.7 m -130.34 169.95 20.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.639 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 88.7 m -106.51 148.3 28.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.748 HG22 ' HA ' ' A' ' 28' ' ' PRO . 15.7 p -133.44 157.29 45.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.357 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 26.9 ttt-85 -150.35 130.54 13.61 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 58.68 31.43 21.13 Favored 'General case' 0 C--N 1.328 -0.354 0 O-C-N 123.509 0.505 . . . . 0.0 110.943 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.98 18.83 80.17 Favored Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.859 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.454 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.0 mt -129.41 132.04 24.01 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.748 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.4 Cg_exo -64.83 140.85 68.92 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 122.18 1.92 . . . . 0.0 112.27 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.44 HG11 ' HG3' ' A' ' 3' ' ' GLU . 25.2 t . . . . . 0 C--N 1.314 -0.943 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.455 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.14 0 CA-C-O 120.832 0.349 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.65 -29.39 4.52 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.133 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.503 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.7 tp10 -73.11 112.88 9.56 Favored 'General case' 0 C--O 1.241 0.636 0 CA-C-O 121.317 0.58 . . . . 0.0 110.71 -179.366 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.663 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.6 p -111.88 152.95 27.38 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.586 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.475 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 33.0 t -115.88 37.54 3.6 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.349 0.595 . . . . 0.0 110.28 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.436 HG23 ' HB ' ' A' ' 4' ' ' THR . 24.2 t -64.91 -38.36 82.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.024 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.12 2.48 87.63 Favored Glycine 0 C--O 1.227 -0.321 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.894 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.52 3.01 90.01 Favored Glycine 0 C--N 1.317 -0.489 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.175 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.2 p -146.18 142.57 28.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.635 0.218 . . . . 0.0 110.839 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.4 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.5 m -101.06 160.25 14.54 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.14 0.495 . . . . 0.0 110.571 179.507 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -84.49 -37.75 20.93 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.34 178.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.409 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 92.7 m -65.48 125.66 90.02 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.239 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.2 Cg_exo -62.83 133.05 39.87 Favored 'Trans proline' 0 C--O 1.237 0.452 0 C-N-CA 122.787 2.325 . . . . 0.0 112.489 -179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.4 29.88 71.55 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.278 -0.874 . . . . 0.0 113.092 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.59 135.81 39.58 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.545 179.37 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 150.01 22.66 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.804 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.2 t -82.54 135.72 35.02 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.303 0.573 . . . . 0.0 111.444 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.2 m -143.57 59.03 1.39 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.7 OUTLIER -32.88 128.57 0.37 Allowed Pre-proline 0 N--CA 1.462 0.167 0 O-C-N 124.605 1.19 . . . . 0.0 112.793 -177.295 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 49.6 Cg_endo -93.05 25.66 22.16 Favored 'Cis proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.072 -1.637 . . . . 0.0 114.242 0.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.663 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.4 m -125.01 -173.79 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.475 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 96.0 m -126.25 144.72 50.68 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.346 -179.598 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.758 HG22 ' HA ' ' A' ' 28' ' ' PRO . 40.3 p -134.36 153.03 52.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.453 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttp180 -141.11 126.03 18.19 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.8 t30 58.75 36.21 24.73 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.612 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.91 14.23 80.29 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 113.003 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 45.1 tp -123.07 124.24 26.55 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.758 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -63.74 140.62 75.13 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.147 1.898 . . . . 0.0 112.334 -179.472 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.503 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 38.8 t . . . . . 0 C--N 1.314 -0.951 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.21 179.328 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.238 0 CA-C-O 120.778 0.323 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 72.58 37.08 58.29 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.894 -0.594 . . . . 0.0 112.947 179.672 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.596 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.6 tp10 -138.63 114.48 9.98 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.222 0.534 . . . . 0.0 109.95 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.7 p -110.85 151.23 28.09 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.237 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.47 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 12.0 t -118.01 39.26 3.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.979 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.5 t -62.2 -40.8 88.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.473 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.97 13.63 60.79 Favored Glycine 0 N--CA 1.452 -0.298 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.39 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.0 20.96 75.18 Favored Glycine 0 C--N 1.32 -0.324 0 CA-C-N 115.398 -0.401 . . . . 0.0 112.694 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.38 26.26 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.108 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 m -115.16 165.11 13.28 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -86.24 -36.89 19.13 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.334 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.401 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 28.0 m -61.11 125.54 84.04 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.959 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -63.38 130.93 30.01 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.729 2.286 . . . . 0.0 112.578 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 63.19 33.17 86.53 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.229 -0.896 . . . . 0.0 113.141 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.401 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.16 145.98 25.08 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.837 0.351 . . . . 0.0 110.503 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.15 147.55 24.13 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -92.31 135.99 33.56 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.289 0.566 . . . . 0.0 111.074 -179.386 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -143.28 59.82 1.4 Allowed 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.436 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.2 t90 -32.14 127.5 0.34 Allowed Pre-proline 0 N--CA 1.463 0.224 0 O-C-N 124.587 1.179 . . . . 0.0 112.572 -177.413 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.436 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.5 Cg_endo -95.18 28.71 16.78 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.402 -1.499 . . . . 0.0 114.157 0.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.7 m -125.15 177.89 4.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.969 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.596 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 95.3 m -118.67 149.05 42.06 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.216 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.72 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.2 p -132.75 166.06 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.338 0.589 . . . . 0.0 111.368 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -150.31 120.37 7.2 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.374 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.0 t30 57.14 38.48 29.02 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.275 0.56 . . . . 0.0 110.874 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.65 10.6 84.77 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-N 115.83 -0.623 . . . . 0.0 113.522 179.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.0 mt -121.55 131.95 24.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.72 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -62.87 141.66 85.46 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.222 1.948 . . . . 0.0 112.312 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.451 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 48.0 t . . . . . 0 C--N 1.319 -0.731 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.916 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.51 -36.96 3.57 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.602 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.566 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 25.3 tt0 -80.4 111.37 16.74 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.092 0.473 . . . . 0.0 110.311 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 47.8 p -103.21 151.98 22.01 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.6 t -117.92 40.12 3.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.215 0.531 . . . . 0.0 109.865 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -62.29 -40.99 89.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.541 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.65 13.31 60.95 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.557 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.81 23.57 74.13 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.559 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 146.84 26.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.624 -0.288 . . . . 0.0 111.058 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.4 m -111.51 167.54 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.831 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -83.73 -34.27 24.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.11 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.454 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.1 m -81.6 128.08 70.7 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.206 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 22.3 Cg_exo -63.43 137.67 61.43 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.714 2.276 . . . . 0.0 111.814 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.95 29.59 66.83 Favored Glycine 0 N--CA 1.453 -0.21 0 CA-C-N 115.868 -0.605 . . . . 0.0 112.714 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.91 144.97 24.97 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.845 0.355 . . . . 0.0 110.647 179.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.412 ' HB ' ' OG1' ' A' ' 23' ' ' THR . 1.0 OUTLIER -89.51 147.88 23.73 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.016 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -97.04 136.38 37.67 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.297 0.57 . . . . 0.0 111.208 -179.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 49.8 m -142.79 60.64 1.43 Allowed 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.524 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.61 127.65 0.36 Allowed Pre-proline 0 N--CA 1.463 0.188 0 O-C-N 124.567 1.167 . . . . 0.0 112.475 -177.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.524 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -95.55 29.62 15.27 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.365 -1.514 . . . . 0.0 114.16 0.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 13.2 m -125.42 175.3 7.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 120.936 0.398 . . . . 0.0 112.007 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.566 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 68.0 m -113.5 148.17 36.53 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.202 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.73 HG22 ' HA ' ' A' ' 28' ' ' PRO . 4.6 p -128.55 156.88 42.62 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.828 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.4 ttp-105 -150.11 128.12 11.89 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 58.75 32.69 22.45 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.668 0.605 . . . . 0.0 110.796 -178.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.68 20.46 79.8 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.849 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.409 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.4 mt -129.37 133.04 24.67 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.73 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.8 Cg_exo -64.79 141.09 70.33 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.23 1.953 . . . . 0.0 112.009 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 C--N 1.315 -0.899 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.126 179.909 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.068 0 CA-C-O 120.914 0.388 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -90.76 35.89 3.75 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.647 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.559 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.9 tp10 -160.15 123.74 3.58 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-O 121.378 0.608 . . . . 0.0 110.868 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.62 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 45.0 p -113.72 153.25 29.31 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.938 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.592 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 16.2 t -121.52 38.9 3.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.241 0.543 . . . . 0.0 110.349 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -63.29 -37.95 80.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.5 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.51 11.56 50.86 Favored Glycine 0 C--O 1.228 -0.232 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.066 179.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.23 2.06 82.41 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.857 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.78 145.43 25.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.576 0.227 . . . . 0.0 110.7 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.7 m -91.86 163.39 14.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.995 0.426 . . . . 0.0 109.869 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 t30 -85.94 -36.21 20.0 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.487 -0.779 . . . . 0.0 108.965 178.436 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 25.9 m -69.02 124.64 90.81 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.76 132.43 28.58 Favored 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.344 2.029 . . . . 0.0 111.992 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.49 34.44 50.03 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.747 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -110.93 143.11 42.1 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.686 0.279 . . . . 0.0 110.263 179.331 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.2 148.52 23.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.115 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.2 t -89.7 138.59 31.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.234 0.54 . . . . 0.0 111.509 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.4 m -146.72 60.1 1.2 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.427 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.7 t90 -32.32 128.19 0.34 Allowed Pre-proline 0 N--CA 1.464 0.261 0 O-C-N 124.515 1.134 . . . . 0.0 112.618 -177.494 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.427 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.1 Cg_endo -94.01 25.88 21.7 Favored 'Cis proline' 0 N--CA 1.46 -0.445 0 C-N-CA 123.196 -1.585 . . . . 0.0 113.957 0.753 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.8 m -124.49 -174.86 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 O-C-N 122.111 -0.368 . . . . 0.0 111.692 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 92.6 m -125.6 153.13 44.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.985 0.421 . . . . 0.0 111.277 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.961 HG22 ' HA ' ' A' ' 28' ' ' PRO . 20.9 p -134.69 162.39 32.48 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.916 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 59.3 ttt180 -150.42 126.03 10.27 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.305 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 59.76 31.37 20.78 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.843 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.67 13.25 83.37 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.857 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.42 HD13 ' HA ' ' A' ' 27' ' ' LEU . 3.5 mm? -117.94 130.52 24.66 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.15 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.961 ' HA ' HG22 ' A' ' 23' ' ' THR . 13.0 Cg_exo -65.86 139.91 58.94 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.247 1.965 . . . . 0.0 112.576 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.315 -0.901 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.267 179.262 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.204 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.64 -27.76 4.16 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.866 -0.607 . . . . 0.0 113.507 179.145 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.537 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.9 tp10 -70.73 113.22 7.6 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 121.315 0.579 . . . . 0.0 110.82 -179.19 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.68 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.8 p -113.1 153.67 27.82 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.824 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.542 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 27.4 t -119.1 37.37 4.15 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.285 0.564 . . . . 0.0 110.223 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.405 HG23 ' HB ' ' A' ' 4' ' ' THR . 23.8 t -63.3 -38.34 81.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.216 179.791 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.65 10.88 60.81 Favored Glycine 0 N--CA 1.453 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.825 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.54 4.68 85.09 Favored Glycine 0 C--N 1.318 -0.442 0 C-N-CA 121.366 -0.445 . . . . 0.0 112.911 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.79 145.72 25.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.519 0.2 . . . . 0.0 110.744 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -94.26 159.85 14.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.207 0.527 . . . . 0.0 110.267 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -80.05 -39.98 28.65 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.231 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 36.0 m -80.42 121.69 81.79 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.812 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.62 142.14 76.05 Favored 'Trans proline' 0 C--O 1.235 0.375 0 C-N-CA 122.839 2.36 . . . . 0.0 112.721 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.47 2.26 87.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 121.06 -0.591 . . . . 0.0 113.163 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.3 137.97 31.92 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.05 149.37 23.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.882 0.373 . . . . 0.0 110.002 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -80.51 136.84 36.37 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.29 0.567 . . . . 0.0 111.586 -179.124 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.3 m -145.92 59.12 1.24 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.9 OUTLIER -32.63 128.57 0.35 Allowed Pre-proline 0 N--CA 1.463 0.208 0 O-C-N 124.677 1.236 . . . . 0.0 112.657 -177.246 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.2 Cg_endo -92.72 25.35 22.65 Favored 'Cis proline' 0 N--CA 1.461 -0.423 0 C-N-CA 123.108 -1.622 . . . . 0.0 114.231 0.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.68 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.6 m -125.19 -172.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 C-N-CA 120.495 -0.482 . . . . 0.0 112.259 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.542 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 76.2 m -128.1 143.63 51.07 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.824 HG22 ' HA ' ' A' ' 28' ' ' PRO . 67.6 p -134.13 145.14 49.01 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.587 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.9 ttm-85 -111.73 109.49 19.37 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.547 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.58 35.84 22.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.34 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.53 -16.48 58.98 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.405 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.0 tp -89.42 119.07 69.6 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 117.112 0.456 . . . . 0.0 109.856 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.824 ' HA ' HG22 ' A' ' 23' ' ' THR . 23.3 Cg_exo -59.28 139.11 88.52 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 122.063 1.842 . . . . 0.0 112.547 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 41.9 t . . . . . 0 C--N 1.314 -0.936 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.063 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.138 0 CA-C-O 120.779 0.323 . . . . 0.0 111.566 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 86.83 -32.03 4.12 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.115 -0.564 . . . . 0.0 112.82 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.448 ' CG ' ' HB2' ' A' ' 22' ' ' CYS . 9.8 tp10 -72.88 113.65 10.15 Favored 'General case' 0 C--O 1.241 0.636 0 CA-C-O 121.157 0.504 . . . . 0.0 110.479 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.636 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.0 p -112.31 152.68 28.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.79 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.538 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 22.6 t -117.2 38.92 3.39 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.209 0.528 . . . . 0.0 110.332 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.28 -39.97 87.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.06 179.732 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.7 11.77 65.45 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.642 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.26 19.02 75.53 Favored Glycine 0 C--N 1.319 -0.371 0 C-N-CA 121.623 -0.322 . . . . 0.0 112.852 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.12 147.45 27.08 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 122.407 0.283 . . . . 0.0 110.83 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 m -115.4 158.81 21.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.997 0.427 . . . . 0.0 110.315 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -82.12 -38.16 25.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.479 178.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.411 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 98.1 m -64.42 125.27 88.12 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.959 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 21.4 Cg_exo -64.01 132.68 35.35 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.772 2.315 . . . . 0.0 112.016 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.33 28.36 71.45 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.546 -0.752 . . . . 0.0 112.818 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -94.18 136.61 34.29 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.031 0.443 . . . . 0.0 110.521 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -89.36 147.74 23.9 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.568 179.089 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.2 t -82.59 135.15 35.14 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.189 0.519 . . . . 0.0 111.175 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 45.0 m -143.09 58.83 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -32.88 128.54 0.37 Allowed Pre-proline 0 N--CA 1.463 0.191 0 O-C-N 124.673 1.233 . . . . 0.0 112.705 -177.295 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -93.31 25.56 22.38 Favored 'Cis proline' 0 N--CA 1.461 -0.409 0 C-N-CA 123.071 -1.637 . . . . 0.0 114.144 0.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.636 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.4 m -123.75 -174.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.068 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.538 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.6 m -126.11 146.85 49.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.747 HG22 ' HA ' ' A' ' 28' ' ' PRO . 18.4 p -127.57 166.33 18.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.15 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 43.3 ttp85 -151.18 119.15 6.22 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 57.15 41.25 27.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.506 0.669 . . . . 0.0 110.354 -179.182 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.75 11.9 77.97 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.565 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.5 mt -121.57 127.58 26.01 Favored Pre-proline 0 C--N 1.325 -0.5 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.747 ' HA ' HG22 ' A' ' 23' ' ' THR . 17.4 Cg_exo -62.98 141.9 85.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.2 1.934 . . . . 0.0 112.416 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.442 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 39.8 t . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.448 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.146 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 70.15 16.17 72.8 Favored Glycine 0 N--CA 1.453 -0.188 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.598 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.672 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.6 tp10 -107.06 110.32 22.41 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.079 0.466 . . . . 0.0 110.372 179.563 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.4 p -107.71 151.42 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.485 179.443 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.524 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 14.8 t -116.92 40.86 2.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.108 0.48 . . . . 0.0 110.367 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.2 t -62.93 -40.58 89.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.377 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 13.1 62.58 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.778 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 22.2 74.78 Favored Glycine 0 C--N 1.319 -0.386 0 C-N-CA 121.593 -0.337 . . . . 0.0 112.804 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.08 147.49 27.15 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.384 0.274 . . . . 0.0 110.797 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.0 m -117.79 159.64 22.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.058 0.456 . . . . 0.0 110.224 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -82.26 -37.89 25.23 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.354 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.4 m -65.43 125.79 90.23 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.069 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.55 131.99 29.64 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 122.546 2.164 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.64 34.99 73.6 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.888 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.36 137.8 38.29 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.57 146.24 25.25 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -86.16 130.62 34.47 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 121.293 0.568 . . . . 0.0 111.706 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 75.1 m -137.52 62.1 1.59 Allowed 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.99 127.88 0.38 Allowed Pre-proline 0 N--CA 1.462 0.131 0 CA-C-N 114.619 -1.173 . . . . 0.0 112.581 -177.316 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -95.95 30.49 13.82 Favored 'Cis proline' 0 N--CA 1.46 -0.493 0 C-N-CA 123.493 -1.461 . . . . 0.0 114.112 0.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.1 m -126.92 177.06 5.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.524 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.3 m -119.98 141.42 49.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.164 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.557 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.4 p -132.41 141.66 48.96 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.89 -179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 44.1 ttt85 -131.1 127.71 38.69 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.263 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.4 t30 57.77 37.14 27.08 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.335 0.588 . . . . 0.0 110.54 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.52 18.2 76.9 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.778 -0.646 . . . . 0.0 113.001 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 37.6 tp -129.74 128.02 22.95 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.557 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.1 Cg_exo -61.5 141.01 90.4 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 121.988 1.792 . . . . 0.0 111.932 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.672 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.3 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.755 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.161 0 CA-C-O 120.887 0.375 . . . . 0.0 111.619 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.24 -38.03 3.24 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.418 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.539 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 12.4 mm-40 -73.07 119.11 16.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.089 0.471 . . . . 0.0 111.189 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.7 p -113.11 148.21 35.75 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.743 178.291 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.521 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 11.2 t -118.03 40.0 3.25 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.057 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -64.37 -41.67 93.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.29 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.3 6.58 78.31 Favored Glycine 0 C--O 1.227 -0.283 0 CA-C-N 115.683 -0.689 . . . . 0.0 112.395 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.521 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 73.32 29.49 64.11 Favored Glycine 0 C--N 1.319 -0.399 0 CA-C-N 115.329 -0.436 . . . . 0.0 112.891 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.8 p -145.84 142.36 28.76 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 122.219 0.208 . . . . 0.0 111.073 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 20.9 m -122.13 169.05 11.26 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 178.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -94.02 -33.4 13.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.312 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.497 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 18.2 m -64.13 122.52 78.1 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.031 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.09 128.46 20.67 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.461 2.107 . . . . 0.0 111.753 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 37.23 84.48 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.437 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.497 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -96.45 143.86 27.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.999 0.428 . . . . 0.0 110.904 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.57 150.9 22.21 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.567 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.8 t -92.81 135.21 34.32 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.116 0.484 . . . . 0.0 111.368 -179.449 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 64.7 m -141.67 62.47 1.45 Allowed 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.8 t90 -32.6 126.78 0.37 Allowed Pre-proline 0 N--CA 1.463 0.184 0 O-C-N 124.57 1.169 . . . . 0.0 112.374 -177.585 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 53.1 Cg_endo -97.62 32.78 10.37 Favored 'Cis proline' 0 N--CA 1.457 -0.621 0 C-N-CA 123.639 -1.4 . . . . 0.0 114.21 0.812 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.586 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.1 m -130.04 169.13 21.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.539 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 96.4 m -105.48 147.52 28.22 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.687 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.839 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.7 p -133.24 158.63 42.41 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.844 0.354 . . . . 0.0 110.535 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 28.6 ttt-85 -150.36 130.18 13.3 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 59.01 31.54 21.46 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 123.541 0.526 . . . . 0.0 110.884 -178.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.81 17.94 80.11 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.766 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.455 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.4 mt -126.45 131.41 23.92 Favored Pre-proline 0 C--N 1.326 -0.444 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.839 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.4 Cg_exo -65.26 140.83 66.17 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.275 1.983 . . . . 0.0 112.278 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.493 HG11 ' HG3' ' A' ' 3' ' ' GLU . 29.6 t . . . . . 0 C--N 1.316 -0.88 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.532 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.804 0.335 . . . . 0.0 111.356 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.51 -37.99 3.25 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.296 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.557 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 64.3 mm-40 -74.69 120.54 20.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.157 0.504 . . . . 0.0 111.266 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.632 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.9 p -115.33 150.38 36.38 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.733 178.243 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.5 t -120.4 38.14 4.07 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.243 0.544 . . . . 0.0 109.981 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 23.6 t -64.13 -41.75 93.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.075 179.609 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.62 6.21 83.86 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.49 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.35 20.43 77.08 Favored Glycine 0 C--N 1.318 -0.444 0 CA-C-N 115.331 -0.435 . . . . 0.0 112.971 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 20.7 p -147.05 141.76 26.72 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 122.1 0.16 . . . . 0.0 110.919 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.3 m -108.07 165.36 11.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.123 0.487 . . . . 0.0 110.445 179.062 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -83.12 -38.15 22.81 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.838 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -73.55 122.23 87.09 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.804 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.3 Cg_exo -64.96 133.55 36.34 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.744 2.296 . . . . 0.0 112.168 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 25.66 70.92 Favored Glycine 0 CA--C 1.519 0.284 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.036 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -92.17 147.38 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.659 0.266 . . . . 0.0 110.342 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -88.86 149.6 23.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.949 179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.6 t -91.55 136.56 33.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.167 0.508 . . . . 0.0 111.352 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.1 m -144.9 61.78 1.31 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.2 127.14 0.35 Allowed Pre-proline 0 N--CA 1.465 0.277 0 O-C-N 124.608 1.193 . . . . 0.0 112.594 -177.407 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 44.4 Cg_endo -96.53 30.24 14.12 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.547 -1.439 . . . . 0.0 114.002 0.806 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.632 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.2 m -128.4 175.13 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.557 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 89.1 m -112.94 150.74 31.41 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.845 0.355 . . . . 0.0 111.204 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.827 HG22 ' HA ' ' A' ' 28' ' ' PRO . 13.0 p -131.67 160.61 34.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.633 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -150.54 127.96 11.42 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.7 m-20 58.99 33.72 23.19 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 123.655 0.597 . . . . 0.0 110.841 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.35 16.65 79.79 Favored Glycine 0 C--N 1.33 0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 112.863 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.442 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.7 mt -126.59 133.86 25.44 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.827 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.5 Cg_exo -63.26 141.18 81.07 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.313 2.009 . . . . 0.0 112.154 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 3' ' ' GLU . 39.7 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.918 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.174 0 CA-C-O 120.92 0.391 . . . . 0.0 111.893 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 86.3 -30.99 4.24 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.128 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.498 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 11.4 tp10 -72.09 113.65 9.35 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.301 0.572 . . . . 0.0 110.727 -179.332 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.678 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -113.04 152.65 29.25 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.723 179.501 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.515 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 28.5 t -116.54 36.69 4.02 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.328 0.585 . . . . 0.0 110.222 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.445 HG23 ' HB ' ' A' ' 4' ' ' THR . 22.7 t -65.03 -37.89 81.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.92 179.453 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.1 3.38 86.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.768 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.42 1.75 90.24 Favored Glycine 0 C--N 1.318 -0.444 0 C-N-CA 121.348 -0.454 . . . . 0.0 113.306 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.7 p -147.3 141.69 26.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.697 0.248 . . . . 0.0 111.012 179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.42 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.2 m -98.62 161.2 13.79 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.336 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.8 m-20 -87.93 -35.83 17.45 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.509 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 83.1 m -64.86 126.09 90.34 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.7 Cg_exo -62.39 132.64 39.29 Favored 'Trans proline' 0 C--O 1.238 0.487 0 C-N-CA 122.785 2.323 . . . . 0.0 112.446 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.45 30.33 71.27 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.995 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.52 135.06 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.556 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.55 148.83 23.16 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.828 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -81.31 135.89 35.73 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.285 0.564 . . . . 0.0 111.381 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.5 m -144.24 59.03 1.35 Allowed 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.322 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.7 OUTLIER -32.97 128.75 0.37 Allowed Pre-proline 0 N--CA 1.462 0.169 0 O-C-N 124.63 1.206 . . . . 0.0 112.76 -177.256 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.6 Cg_endo -92.7 24.91 23.6 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.066 -1.639 . . . . 0.0 114.209 0.897 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.678 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.5 m -124.97 -172.32 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 O-C-N 121.988 -0.445 . . . . 0.0 112.168 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.515 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.5 m -127.74 146.79 50.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.084 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.842 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.9 p -134.22 162.64 31.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.453 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.5 ttp180 -150.17 125.86 10.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.3 t30 60.03 33.4 21.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.418 0.628 . . . . 0.0 110.567 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.53 9.05 87.09 Favored Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.696 -0.684 . . . . 0.0 113.288 179.567 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.406 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 9.2 mp -118.78 129.79 25.19 Favored Pre-proline 0 C--N 1.327 -0.396 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.842 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.1 Cg_exo -64.97 140.81 67.81 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.247 1.965 . . . . 0.0 112.331 -179.612 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.4 t . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.107 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 120.848 0.356 . . . . 0.0 111.809 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 70.7 32.52 67.08 Favored Glycine 0 N--CA 1.451 -0.348 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.271 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.696 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 2.6 mm-40 -130.16 123.2 29.72 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 121.124 0.488 . . . . 0.0 111.388 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.585 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 33.0 p -116.92 147.45 42.21 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.037 178.308 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.5 t -117.27 40.22 3.08 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.866 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.442 HG23 ' HB ' ' A' ' 4' ' ' THR . 33.8 t -64.2 -42.35 95.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.385 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.78 7.83 76.84 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.395 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.515 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 72.04 31.03 64.65 Favored Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.405 -0.397 . . . . 0.0 112.774 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.3 p -144.92 142.89 30.25 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.646 -0.277 . . . . 0.0 110.89 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 17.6 m -124.94 165.22 18.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.985 0.421 . . . . 0.0 110.018 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -87.21 -33.98 19.15 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.766 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.447 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 19.7 m -70.29 125.84 92.13 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.176 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -65.94 129.97 23.32 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.456 2.104 . . . . 0.0 111.865 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.2 37.86 87.22 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.327 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.447 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -94.78 144.78 25.36 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.899 0.38 . . . . 0.0 110.713 179.783 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.26 148.96 23.3 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.508 178.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.8 t -93.64 134.14 36.26 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.238 0.542 . . . . 0.0 111.325 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.6 m -140.03 61.77 1.52 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.0 t90 -32.16 126.36 0.35 Allowed Pre-proline 0 N--CA 1.463 0.185 0 O-C-N 124.504 1.128 . . . . 0.0 112.481 -177.462 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.489 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -98.36 33.81 9.16 Favored 'Cis proline' 0 N--CA 1.458 -0.595 0 C-N-CA 123.675 -1.385 . . . . 0.0 114.167 0.744 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.585 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 4.3 m -130.32 163.11 36.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.696 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 81.7 m -102.44 145.62 29.27 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.984 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.753 HG22 ' HA ' ' A' ' 28' ' ' PRO . 30.6 p -133.42 164.03 28.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.118 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 30.5 ttt-85 -150.85 123.59 8.58 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.4 t30 58.84 34.65 23.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.426 0.631 . . . . 0.0 110.678 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.35 9.43 87.01 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.602 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.419 ' HA ' HD13 ' A' ' 27' ' ' LEU . 3.4 mm? -120.48 130.79 24.68 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.126 0.463 . . . . 0.0 109.917 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.753 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.5 Cg_exo -63.76 141.71 79.93 Favored 'Trans proline' 0 N--CA 1.46 -0.462 0 C-N-CA 122.26 1.974 . . . . 0.0 112.253 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.491 ' CG1' ' HG3' ' A' ' 3' ' ' GLU . 37.2 t . . . . . 0 C--N 1.318 -0.786 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.857 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 120.859 0.362 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.91 -35.9 4.46 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.431 179.299 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.641 ' OE2' ' HB3' ' A' ' 10' ' ' CYS . 48.2 tt0 -81.81 121.94 27.07 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.247 0.546 . . . . 0.0 111.05 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 24.4 p -108.69 152.63 24.55 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.607 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.2 t -119.19 41.34 3.1 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.156 0.503 . . . . 0.0 109.704 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.5 t -62.66 -39.64 85.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.687 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.76 11.61 59.08 Favored Glycine 0 N--CA 1.452 -0.241 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.726 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.74 19.28 73.09 Favored Glycine 0 C--N 1.319 -0.369 0 C-N-CA 121.532 -0.366 . . . . 0.0 112.558 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.25 26.18 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 122.559 0.343 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.641 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 39.3 m -106.83 172.11 7.0 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.028 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -96.8 -29.84 13.52 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.975 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.436 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.3 m -79.93 124.84 82.97 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.574 -179.651 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 36.2 Cg_exo -60.35 135.97 65.04 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.905 2.403 . . . . 0.0 112.913 -179.37 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.56 32.75 79.42 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.543 -0.753 . . . . 0.0 113.437 179.423 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.74 147.11 26.4 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.52 150.28 22.52 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -98.0 138.09 35.84 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.214 0.531 . . . . 0.0 111.04 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.8 m -144.2 62.92 1.34 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -33.01 127.26 0.39 Allowed Pre-proline 0 N--CA 1.465 0.296 0 O-C-N 124.563 1.164 . . . . 0.0 112.32 -177.551 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.3 Cg_endo -97.08 33.11 10.13 Favored 'Cis proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.505 -1.456 . . . . 0.0 114.24 0.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.4 m -129.8 169.99 19.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.436 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 99.4 m -107.33 148.08 29.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.475 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.955 HG22 ' HA ' ' A' ' 28' ' ' PRO . 33.1 p -137.3 168.7 19.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.101 0.476 . . . . 0.0 110.664 -179.494 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -151.09 120.0 6.64 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 57.85 36.64 26.54 Favored 'General case' 0 N--CA 1.467 0.417 0 O-C-N 123.41 0.444 . . . . 0.0 111.331 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.15 7.0 88.74 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 121.095 -0.574 . . . . 0.0 113.188 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.447 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 94.1 mt -113.34 126.17 28.57 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.462 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.955 ' HA ' HG22 ' A' ' 23' ' ' THR . 12.2 Cg_exo -67.5 140.94 53.88 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.395 2.064 . . . . 0.0 112.879 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.9 t . . . . . 0 C--N 1.318 -0.8 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.129 178.789 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.206 0 CA-C-O 120.922 0.391 . . . . 0.0 111.486 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.93 33.77 75.56 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.552 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 6.2 tp10 -129.43 114.08 15.71 Favored 'General case' 0 C--O 1.241 0.656 0 CA-C-O 121.224 0.535 . . . . 0.0 110.182 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 44.7 p -111.45 151.64 28.33 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.057 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.492 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 15.3 t -118.04 39.5 3.38 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.101 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.4 t -62.87 -40.6 89.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.475 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.57 4.81 85.19 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.76 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.21 13.56 82.72 Favored Glycine 0 C--N 1.317 -0.527 0 C-N-CA 121.433 -0.413 . . . . 0.0 113.03 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.4 p -147.82 142.04 26.16 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.155 0.182 . . . . 0.0 110.858 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 m -106.98 163.05 13.3 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 178.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 t30 -87.62 -35.73 17.89 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.719 0.771 . . . . 0.0 109.286 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 32.2 m -65.85 126.01 90.97 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 114.76 -1.109 . . . . 0.0 111.213 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -64.45 133.77 38.76 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.519 2.146 . . . . 0.0 112.472 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.9 29.51 72.51 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.307 -0.86 . . . . 0.0 113.02 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -95.94 137.11 35.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.811 0.339 . . . . 0.0 110.621 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.3 149.43 23.05 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.585 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.5 t -86.61 136.2 33.14 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.352 0.596 . . . . 0.0 111.6 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.5 m -143.48 59.44 1.39 Allowed 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.198 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -31.94 127.43 0.33 Allowed Pre-proline 0 N--CA 1.464 0.245 0 O-C-N 124.506 1.129 . . . . 0.0 112.543 -177.297 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 49.3 Cg_endo -95.29 29.28 15.86 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.352 -1.52 . . . . 0.0 114.134 0.783 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.597 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.9 m -126.92 179.31 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.552 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 92.9 m -120.9 144.31 48.49 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.243 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.676 HG22 ' HA ' ' A' ' 28' ' ' PRO . 34.7 p -134.85 155.92 49.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.642 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -148.19 130.36 15.49 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.0 m120 59.74 30.99 20.58 Favored 'General case' 0 N--CA 1.465 0.3 0 O-C-N 123.589 0.556 . . . . 0.0 110.934 -178.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.19 17.58 80.2 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.753 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 36.4 tp -129.59 129.06 23.13 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.676 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.5 Cg_exo -62.19 142.7 92.74 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.195 1.93 . . . . 0.0 111.854 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.539 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 46.0 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.702 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.468 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 10.4 tp10 . . . . . 0 C--O 1.238 0.496 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.646 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.3 p -110.77 153.54 25.19 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.108 0.48 . . . . 0.0 111.158 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.622 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 21.5 t -121.05 38.91 3.94 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.092 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.9 t -62.93 -40.48 89.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.404 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.1 5.41 83.07 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.849 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.0 11.56 84.34 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.93 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.2 p -148.08 142.42 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.243 0.217 . . . . 0.0 110.745 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.423 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.4 m -103.67 159.41 15.64 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.994 0.426 . . . . 0.0 110.153 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.7 m-80 -81.34 -38.64 26.37 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.463 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.475 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -70.43 125.01 91.87 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.207 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.1 Cg_exo -65.71 136.2 44.85 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.791 2.328 . . . . 0.0 112.013 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 23.88 74.51 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.709 -0.678 . . . . 0.0 113.05 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.04 137.63 36.56 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.3 148.21 23.68 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.4 t -83.8 137.05 33.9 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.43 0.633 . . . . 0.0 111.413 -179.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 30.9 m -144.62 58.95 1.32 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.4 t90 -31.82 127.45 0.32 Allowed Pre-proline 0 N--CA 1.463 0.211 0 O-C-N 124.516 1.135 . . . . 0.0 112.628 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -94.62 28.44 17.2 Favored 'Cis proline' 0 N--CA 1.46 -0.456 0 C-N-CA 123.278 -1.551 . . . . 0.0 114.142 0.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 12.6 m -126.3 -176.7 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.622 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.8 m -127.77 140.4 52.07 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.994 0.426 . . . . 0.0 111.091 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.506 HG22 ' HA ' ' A' ' 28' ' ' PRO . 40.1 p -132.25 157.26 44.83 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.728 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.43 ' HG2' ' OD1' ' A' ' 25' ' ' ASN . 54.9 ttp85 -147.02 127.8 14.35 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.43 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 7.7 m120 60.16 31.61 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 O-C-N 123.422 0.451 . . . . 0.0 110.768 -178.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.29 14.44 81.91 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.967 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.6 mt -127.41 135.95 28.2 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.506 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.7 Cg_exo -60.36 141.53 95.91 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.069 1.846 . . . . 0.0 111.652 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.468 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 20.8 t . . . . . 0 C--N 1.317 -0.805 0 CA-C-O 121.483 0.659 . . . . 0.0 110.189 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.559 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 44.9 tt0 . . . . . 0 N--CA 1.453 -0.295 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.547 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.2 p -101.87 152.21 21.18 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.944 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.0 t -117.58 40.92 2.96 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.841 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.5 t -62.32 -41.22 90.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.587 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.27 12.94 63.07 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.597 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.4 30.24 77.15 Favored Glycine 0 C--N 1.319 -0.392 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.36 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.66 149.24 29.59 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.892 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.441 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 60.2 m -123.56 171.76 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.343 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -88.46 -32.57 18.2 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.406 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.575 HG21 ' CD ' ' A' ' 24' ' ' ARG . 27.7 m -74.08 127.51 87.89 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.33 131.31 23.04 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.195 1.93 . . . . 0.0 111.644 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.73 29.39 69.53 Favored Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.627 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.474 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.48 146.76 24.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.758 0.313 . . . . 0.0 110.477 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.66 144.88 26.0 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -96.53 130.86 43.62 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.262 0.553 . . . . 0.0 111.592 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 59.6 m -131.98 63.13 1.62 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.7 t90 -33.87 127.94 0.44 Allowed Pre-proline 0 N--CA 1.462 0.158 0 O-C-N 124.382 1.051 . . . . 0.0 112.2 -177.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -96.96 33.73 9.54 Favored 'Cis proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.574 -1.428 . . . . 0.0 114.335 0.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.2 m -129.6 164.25 32.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.268 0.556 . . . . 0.0 112.205 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.559 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 92.2 m -97.06 150.89 20.31 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.872 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.728 HG22 ' HA ' ' A' ' 28' ' ' PRO . 3.1 p -138.56 141.51 39.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.632 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.575 ' CD ' HG21 ' A' ' 12' ' ' THR . 33.3 mtm180 -125.77 119.34 27.64 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 57.55 41.62 25.53 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.773 0.671 . . . . 0.0 109.984 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.72 13.29 74.92 Favored Glycine 0 CA--C 1.52 0.395 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.202 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 43.8 tp -112.81 125.01 30.57 Favored Pre-proline 0 C--N 1.326 -0.433 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.728 ' HA ' HG22 ' A' ' 23' ' ' THR . 18.9 Cg_exo -63.5 142.31 84.11 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.344 2.03 . . . . 0.0 112.088 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.7 t . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.378 -179.935 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.566 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.8 tp10 . . . . . 0 C--O 1.238 0.485 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 46.5 p -107.58 151.74 25.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.011 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.7 t -119.32 41.81 3.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.022 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.9 t -62.42 -39.63 85.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.694 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.36 12.87 61.54 Favored Glycine 0 N--CA 1.453 -0.222 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.891 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.41 21.87 74.52 Favored Glycine 0 C--N 1.321 -0.301 0 C-N-CA 121.453 -0.403 . . . . 0.0 112.614 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.86 147.66 27.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 110.614 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 15.7 m -114.74 167.01 11.14 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.14 0.495 . . . . 0.0 110.219 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -90.63 -34.71 15.35 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.788 178.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.3 m -67.88 126.06 92.15 Favored Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.398 -1.274 . . . . 0.0 111.326 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.88 133.45 33.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.439 2.092 . . . . 0.0 112.137 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 31.63 74.37 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.714 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.96 139.21 34.95 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.615 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.48 149.02 23.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.559 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.4 t -88.88 135.6 33.45 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.27 0.557 . . . . 0.0 111.379 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.6 m -141.03 59.71 1.52 Allowed 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.3 t90 -32.01 127.16 0.34 Allowed Pre-proline 0 N--CA 1.464 0.227 0 O-C-N 124.649 1.218 . . . . 0.0 112.496 -177.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.2 Cg_endo -96.02 31.08 12.91 Favored 'Cis proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.175 0.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.584 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.5 m -127.77 175.79 8.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.506 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 87.3 m -117.37 143.17 46.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.175 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.675 HG22 ' HA ' ' A' ' 28' ' ' PRO . 38.8 p -135.8 159.27 42.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.484 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -150.14 126.47 10.74 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.0 t30 60.03 34.8 21.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.518 0.675 . . . . 0.0 110.193 -178.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.59 14.07 79.87 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.995 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.431 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.5 mt -122.89 127.51 25.7 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.5 Cg_exo -65.82 142.1 68.15 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.415 2.076 . . . . 0.0 112.188 -179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.566 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.7 t . . . . . 0 C--N 1.317 -0.815 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.493 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.486 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 6.1 tp10 . . . . . 0 C--O 1.238 0.496 0 CA-C-O 121.149 0.499 . . . . 0.0 110.3 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.9 p -107.88 153.0 23.67 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.983 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.411 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.4 t -120.7 40.49 3.51 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.049 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -61.94 -40.13 86.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.585 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.91 12.44 61.86 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.762 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.04 21.61 75.54 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 121.557 -0.354 . . . . 0.0 112.739 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.13 147.12 26.67 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 122.427 0.291 . . . . 0.0 110.939 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 18.5 m -112.07 167.36 10.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.038 0.447 . . . . 0.0 109.953 179.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -88.68 -35.64 16.65 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 26.9 m -68.7 125.38 91.74 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 114.282 -1.326 . . . . 0.0 111.586 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 15.2 Cg_exo -66.17 133.37 32.79 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.554 2.169 . . . . 0.0 111.447 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.76 31.68 70.36 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.719 -0.673 . . . . 0.0 112.724 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -99.54 141.33 32.48 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.85 0.357 . . . . 0.0 110.468 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.1 m -89.45 149.1 23.09 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.656 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -90.81 136.32 33.15 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.279 0.562 . . . . 0.0 110.996 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 56.9 m -142.66 60.42 1.43 Allowed 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.58 127.89 0.36 Allowed Pre-proline 0 N--CA 1.463 0.213 0 O-C-N 124.627 1.205 . . . . 0.0 112.45 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.2 Cg_endo -94.83 29.27 15.92 Favored 'Cis proline' 0 N--CA 1.46 -0.477 0 C-N-CA 123.238 -1.567 . . . . 0.0 114.22 0.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.0 m -126.88 179.88 3.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.985 0.422 . . . . 0.0 112.095 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.483 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 96.9 m -117.95 148.37 42.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.065 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.631 HG22 ' HA ' ' A' ' 28' ' ' PRO . 13.4 p -131.95 157.03 45.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 0.0 110.74 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.719 ' O ' ' HG ' ' A' ' 27' ' ' LEU . 53.7 ttp180 -150.31 130.56 13.67 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.6 t30 57.71 33.48 23.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 110.938 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.74 16.81 80.41 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.819 -0.628 . . . . 0.0 113.941 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.719 ' HG ' ' O ' ' A' ' 24' ' ' ARG . 3.9 pp -133.88 135.66 25.03 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.404 0.602 . . . . 0.0 109.871 178.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.631 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.2 Cg_exo -64.93 141.83 72.64 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.599 2.199 . . . . 0.0 112.722 -178.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.486 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 43.9 t . . . . . 0 C--N 1.317 -0.823 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.13 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.624 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.9 tp10 . . . . . 0 C--O 1.239 0.516 0 CA-C-O 121.109 0.481 . . . . 0.0 110.363 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.1 p -108.44 152.04 25.23 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.863 179.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.6 t -119.0 40.81 3.21 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.098 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -62.23 -40.37 87.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 13.24 62.49 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.728 179.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.5 24.55 73.81 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 121.529 -0.367 . . . . 0.0 112.694 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 147.84 27.68 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 122.459 0.304 . . . . 0.0 110.927 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.5 m -118.28 164.11 15.69 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -88.76 -35.33 16.74 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.091 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.431 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 24.6 m -67.9 125.49 91.45 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 114.574 -1.194 . . . . 0.0 111.361 -179.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.72 133.74 35.24 Favored 'Trans proline' 0 N--CA 1.46 -0.476 0 C-N-CA 122.694 2.263 . . . . 0.0 111.797 179.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.64 27.67 72.13 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.968 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -97.71 136.32 38.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.827 0.346 . . . . 0.0 110.31 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 149.94 22.82 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -86.16 136.61 33.13 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.299 0.571 . . . . 0.0 111.393 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 40.9 m -142.89 59.56 1.42 Allowed 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.0 t90 -32.08 127.38 0.34 Allowed Pre-proline 0 N--CA 1.465 0.288 0 O-C-N 124.675 1.234 . . . . 0.0 112.598 -177.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.9 Cg_endo -95.6 30.32 14.14 Favored 'Cis proline' 0 N--CA 1.459 -0.506 0 C-N-CA 123.432 -1.487 . . . . 0.0 114.132 0.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 10.5 m -127.27 176.73 6.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 97.0 m -119.29 140.54 50.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.383 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.527 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.5 p -130.68 131.93 45.12 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.277 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.4 ttp85 -98.67 106.64 18.93 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.8 t30 60.16 37.68 20.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.552 0.692 . . . . 0.0 109.399 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.26 -12.17 65.41 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.466 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -96.92 111.75 58.55 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 117.239 0.52 . . . . 0.0 110.396 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.527 ' HA ' HG22 ' A' ' 23' ' ' THR . 0.9 OUTLIER -49.14 138.47 28.4 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.943 2.428 . . . . 0.0 113.56 -179.111 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.624 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 44.6 t . . . . . 0 C--N 1.317 -0.834 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.541 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.446 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 14.7 tp10 . . . . . 0 C--O 1.238 0.482 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.3 p -108.22 152.41 24.63 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.134 0.492 . . . . 0.0 111.074 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.437 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.9 t -119.67 39.37 3.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.02 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 25.8 t -62.48 -40.42 88.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.443 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.05 3.84 84.73 Favored Glycine 0 C--O 1.227 -0.326 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.764 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.96 14.61 81.8 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.999 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.6 p -148.35 141.86 25.39 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.148 0.179 . . . . 0.0 110.928 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.7 m -106.19 167.6 9.71 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -90.86 -33.9 15.47 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.645 0.736 . . . . 0.0 109.051 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 34.9 m -63.88 126.99 91.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 114.834 -1.076 . . . . 0.0 111.018 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.39 128.83 23.54 Favored 'Trans proline' 0 C--O 1.237 0.446 0 C-N-CA 122.549 2.166 . . . . 0.0 112.4 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.38 31.77 79.89 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.186 -0.916 . . . . 0.0 112.781 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.473 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.82 143.34 26.88 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.871 0.367 . . . . 0.0 110.825 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.55 148.01 23.63 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.586 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -91.71 136.12 33.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.201 0.524 . . . . 0.0 110.883 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.8 m -142.34 59.96 1.45 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.56 127.91 0.36 Allowed Pre-proline 0 N--CA 1.463 0.186 0 O-C-N 124.625 1.203 . . . . 0.0 112.473 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -94.47 27.76 18.22 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.293 -1.545 . . . . 0.0 114.178 0.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.59 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.9 m -124.78 -179.25 2.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.026 0.441 . . . . 0.0 111.959 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.437 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.9 m -119.79 150.34 40.58 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.299 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.708 HG22 ' HA ' ' A' ' 28' ' ' PRO . 7.6 p -130.26 154.13 47.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.631 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.465 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 14.7 tpt85 -142.14 124.22 15.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 24.3 t30 57.09 38.94 29.38 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.261 0.553 . . . . 0.0 110.793 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.62 16.97 76.18 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.342 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.1 mt -126.48 131.16 23.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.708 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.7 Cg_exo -63.41 140.83 78.47 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.107 1.871 . . . . 0.0 112.214 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.446 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 33.9 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.814 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.639 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 5.5 mm-40 . . . . . 0 CA--C 1.514 -0.441 0 CA-C-O 121.251 0.548 . . . . 0.0 111.827 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -115.01 147.93 39.48 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.546 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.436 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.2 t -117.71 39.8 3.25 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.222 0.534 . . . . 0.0 110.091 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 32.2 t -64.05 -40.7 89.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.008 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.25 12.68 68.5 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.595 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.436 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 65.8 31.04 78.51 Favored Glycine 0 C--N 1.319 -0.381 0 CA-C-N 115.467 -0.366 . . . . 0.0 112.786 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.79 148.54 28.63 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.602 -0.299 . . . . 0.0 110.971 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 23.5 m -125.2 167.87 14.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.081 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -90.3 -33.62 16.04 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.41 -0.813 . . . . 0.0 109.201 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.45 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 18.8 m -68.14 124.27 89.28 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.987 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -64.89 129.53 23.51 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.478 2.119 . . . . 0.0 111.87 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 37.33 86.03 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.488 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.45 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -97.08 144.24 27.14 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.927 0.394 . . . . 0.0 110.915 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 150.65 22.49 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.696 178.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.5 t -93.94 135.43 35.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.21 0.529 . . . . 0.0 111.329 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 66.9 m -141.63 61.92 1.46 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -32.56 126.99 0.37 Allowed Pre-proline 0 N--CA 1.462 0.159 0 O-C-N 124.554 1.159 . . . . 0.0 112.371 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.5 Cg_endo -97.18 32.77 10.51 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.585 -1.423 . . . . 0.0 114.171 0.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 8.7 m -130.34 169.95 20.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.639 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 88.7 m -106.51 148.3 28.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.748 HG22 ' HA ' ' A' ' 28' ' ' PRO . 15.7 p -133.44 157.29 45.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.357 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 26.9 ttt-85 -150.35 130.54 13.61 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 58.68 31.43 21.13 Favored 'General case' 0 C--N 1.328 -0.354 0 O-C-N 123.509 0.505 . . . . 0.0 110.943 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.98 18.83 80.17 Favored Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.859 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.454 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.0 mt -129.41 132.04 24.01 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.748 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.4 Cg_exo -64.83 140.85 68.92 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 122.18 1.92 . . . . 0.0 112.27 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.44 HG11 ' HG3' ' A' ' 3' ' ' GLU . 25.2 t . . . . . 0 C--N 1.314 -0.943 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.455 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.503 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.7 tp10 . . . . . 0 C--O 1.241 0.636 0 CA-C-O 121.317 0.58 . . . . 0.0 110.71 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.663 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.6 p -111.88 152.95 27.38 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.586 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.475 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 33.0 t -115.88 37.54 3.6 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.349 0.595 . . . . 0.0 110.28 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.436 HG23 ' HB ' ' A' ' 4' ' ' THR . 24.2 t -64.91 -38.36 82.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.024 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.12 2.48 87.63 Favored Glycine 0 C--O 1.227 -0.321 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.894 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.52 3.01 90.01 Favored Glycine 0 C--N 1.317 -0.489 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.175 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.2 p -146.18 142.57 28.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.635 0.218 . . . . 0.0 110.839 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.4 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.5 m -101.06 160.25 14.54 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.14 0.495 . . . . 0.0 110.571 179.507 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -84.49 -37.75 20.93 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.34 178.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.409 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 92.7 m -65.48 125.66 90.02 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.239 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.2 Cg_exo -62.83 133.05 39.87 Favored 'Trans proline' 0 C--O 1.237 0.452 0 C-N-CA 122.787 2.325 . . . . 0.0 112.489 -179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.4 29.88 71.55 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.278 -0.874 . . . . 0.0 113.092 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.59 135.81 39.58 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.545 179.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 150.01 22.66 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.804 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.2 t -82.54 135.72 35.02 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.303 0.573 . . . . 0.0 111.444 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.2 m -143.57 59.03 1.39 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.7 OUTLIER -32.88 128.57 0.37 Allowed Pre-proline 0 N--CA 1.462 0.167 0 O-C-N 124.605 1.19 . . . . 0.0 112.793 -177.295 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 49.6 Cg_endo -93.05 25.66 22.16 Favored 'Cis proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.072 -1.637 . . . . 0.0 114.242 0.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.663 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.4 m -125.01 -173.79 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.475 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 96.0 m -126.25 144.72 50.68 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.346 -179.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.758 HG22 ' HA ' ' A' ' 28' ' ' PRO . 40.3 p -134.36 153.03 52.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.453 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttp180 -141.11 126.03 18.19 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.8 t30 58.75 36.21 24.73 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.612 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.91 14.23 80.29 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 113.003 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 45.1 tp -123.07 124.24 26.55 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.758 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -63.74 140.62 75.13 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.147 1.898 . . . . 0.0 112.334 -179.472 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.503 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 38.8 t . . . . . 0 C--N 1.314 -0.951 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.21 179.328 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.596 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.6 tp10 . . . . . 0 C--O 1.24 0.555 0 CA-C-O 121.222 0.534 . . . . 0.0 109.95 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.7 p -110.85 151.23 28.09 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.237 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.47 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 12.0 t -118.01 39.26 3.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.979 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.5 t -62.2 -40.8 88.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.473 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.97 13.63 60.79 Favored Glycine 0 N--CA 1.452 -0.298 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.39 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.0 20.96 75.18 Favored Glycine 0 C--N 1.32 -0.324 0 CA-C-N 115.398 -0.401 . . . . 0.0 112.694 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.38 26.26 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.108 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 m -115.16 165.11 13.28 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -86.24 -36.89 19.13 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.401 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 28.0 m -61.11 125.54 84.04 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.959 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -63.38 130.93 30.01 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.729 2.286 . . . . 0.0 112.578 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 63.19 33.17 86.53 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.229 -0.896 . . . . 0.0 113.141 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.401 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.16 145.98 25.08 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.837 0.351 . . . . 0.0 110.503 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.15 147.55 24.13 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -92.31 135.99 33.56 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.289 0.566 . . . . 0.0 111.074 -179.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -143.28 59.82 1.4 Allowed 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.436 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.2 t90 -32.14 127.5 0.34 Allowed Pre-proline 0 N--CA 1.463 0.224 0 O-C-N 124.587 1.179 . . . . 0.0 112.572 -177.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.436 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.5 Cg_endo -95.18 28.71 16.78 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.402 -1.499 . . . . 0.0 114.157 0.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.7 m -125.15 177.89 4.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.969 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.596 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 95.3 m -118.67 149.05 42.06 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.216 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.72 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.2 p -132.75 166.06 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.338 0.589 . . . . 0.0 111.368 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -150.31 120.37 7.2 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.374 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.0 t30 57.14 38.48 29.02 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.275 0.56 . . . . 0.0 110.874 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.65 10.6 84.77 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-N 115.83 -0.623 . . . . 0.0 113.522 179.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.0 mt -121.55 131.95 24.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.72 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -62.87 141.66 85.46 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.222 1.948 . . . . 0.0 112.312 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.451 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 48.0 t . . . . . 0 C--N 1.319 -0.731 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.916 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.566 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 25.3 tt0 . . . . . 0 C--O 1.235 0.299 0 CA-C-O 121.092 0.473 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 47.8 p -103.21 151.98 22.01 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.6 t -117.92 40.12 3.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.215 0.531 . . . . 0.0 109.865 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -62.29 -40.99 89.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.541 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.65 13.31 60.95 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.557 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.81 23.57 74.13 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.559 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 146.84 26.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.624 -0.288 . . . . 0.0 111.058 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.4 m -111.51 167.54 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.831 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -83.73 -34.27 24.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.11 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.454 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.1 m -81.6 128.08 70.7 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.206 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 22.3 Cg_exo -63.43 137.67 61.43 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.714 2.276 . . . . 0.0 111.814 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.95 29.59 66.83 Favored Glycine 0 N--CA 1.453 -0.21 0 CA-C-N 115.868 -0.605 . . . . 0.0 112.714 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.91 144.97 24.97 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.845 0.355 . . . . 0.0 110.647 179.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.412 ' HB ' ' OG1' ' A' ' 23' ' ' THR . 1.0 OUTLIER -89.51 147.88 23.73 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.016 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -97.04 136.38 37.67 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.297 0.57 . . . . 0.0 111.208 -179.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 49.8 m -142.79 60.64 1.43 Allowed 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.524 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.61 127.65 0.36 Allowed Pre-proline 0 N--CA 1.463 0.188 0 O-C-N 124.567 1.167 . . . . 0.0 112.475 -177.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.524 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -95.55 29.62 15.27 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.365 -1.514 . . . . 0.0 114.16 0.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 13.2 m -125.42 175.3 7.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 120.936 0.398 . . . . 0.0 112.007 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.566 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 68.0 m -113.5 148.17 36.53 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.202 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.73 HG22 ' HA ' ' A' ' 28' ' ' PRO . 4.6 p -128.55 156.88 42.62 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.828 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.4 ttp-105 -150.11 128.12 11.89 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 m120 58.75 32.69 22.45 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.668 0.605 . . . . 0.0 110.796 -178.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.68 20.46 79.8 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.849 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.409 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.4 mt -129.37 133.04 24.67 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.73 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.8 Cg_exo -64.79 141.09 70.33 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.23 1.953 . . . . 0.0 112.009 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 C--N 1.315 -0.899 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.126 179.909 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.559 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.9 tp10 . . . . . 0 C--O 1.24 0.563 0 CA-C-O 121.378 0.608 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.62 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 45.0 p -113.72 153.25 29.31 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.938 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.592 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 16.2 t -121.52 38.9 3.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.241 0.543 . . . . 0.0 110.349 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -63.29 -37.95 80.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.5 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.51 11.56 50.86 Favored Glycine 0 C--O 1.228 -0.232 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.066 179.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.23 2.06 82.41 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.857 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.78 145.43 25.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.576 0.227 . . . . 0.0 110.7 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.7 m -91.86 163.39 14.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.995 0.426 . . . . 0.0 109.869 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 t30 -85.94 -36.21 20.0 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.487 -0.779 . . . . 0.0 108.965 178.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 25.9 m -69.02 124.64 90.81 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.76 132.43 28.58 Favored 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.344 2.029 . . . . 0.0 111.992 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.49 34.44 50.03 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.747 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -110.93 143.11 42.1 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.686 0.279 . . . . 0.0 110.263 179.331 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.2 148.52 23.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.115 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.2 t -89.7 138.59 31.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.234 0.54 . . . . 0.0 111.509 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.4 m -146.72 60.1 1.2 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.427 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.7 t90 -32.32 128.19 0.34 Allowed Pre-proline 0 N--CA 1.464 0.261 0 O-C-N 124.515 1.134 . . . . 0.0 112.618 -177.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.427 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.1 Cg_endo -94.01 25.88 21.7 Favored 'Cis proline' 0 N--CA 1.46 -0.445 0 C-N-CA 123.196 -1.585 . . . . 0.0 113.957 0.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.8 m -124.49 -174.86 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 O-C-N 122.111 -0.368 . . . . 0.0 111.692 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 92.6 m -125.6 153.13 44.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.985 0.421 . . . . 0.0 111.277 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.961 HG22 ' HA ' ' A' ' 28' ' ' PRO . 20.9 p -134.69 162.39 32.48 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.916 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 59.3 ttt180 -150.42 126.03 10.27 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 59.76 31.37 20.78 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.843 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.67 13.25 83.37 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.857 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.42 HD13 ' HA ' ' A' ' 27' ' ' LEU . 3.5 mm? -117.94 130.52 24.66 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.15 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.961 ' HA ' HG22 ' A' ' 23' ' ' THR . 13.0 Cg_exo -65.86 139.91 58.94 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.247 1.965 . . . . 0.0 112.576 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.315 -0.901 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.267 179.262 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.537 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.9 tp10 . . . . . 0 C--O 1.242 0.658 0 CA-C-O 121.315 0.579 . . . . 0.0 110.82 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.68 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.8 p -113.1 153.67 27.82 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.824 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.542 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 27.4 t -119.1 37.37 4.15 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.285 0.564 . . . . 0.0 110.223 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.405 HG23 ' HB ' ' A' ' 4' ' ' THR . 23.8 t -63.3 -38.34 81.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.216 179.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.65 10.88 60.81 Favored Glycine 0 N--CA 1.453 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.825 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.54 4.68 85.09 Favored Glycine 0 C--N 1.318 -0.442 0 C-N-CA 121.366 -0.445 . . . . 0.0 112.911 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.79 145.72 25.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.519 0.2 . . . . 0.0 110.744 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -94.26 159.85 14.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.207 0.527 . . . . 0.0 110.267 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -80.05 -39.98 28.65 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.231 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 36.0 m -80.42 121.69 81.79 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.812 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.62 142.14 76.05 Favored 'Trans proline' 0 C--O 1.235 0.375 0 C-N-CA 122.839 2.36 . . . . 0.0 112.721 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.47 2.26 87.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 121.06 -0.591 . . . . 0.0 113.163 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.3 137.97 31.92 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.05 149.37 23.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.882 0.373 . . . . 0.0 110.002 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -80.51 136.84 36.37 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.29 0.567 . . . . 0.0 111.586 -179.124 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.3 m -145.92 59.12 1.24 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.9 OUTLIER -32.63 128.57 0.35 Allowed Pre-proline 0 N--CA 1.463 0.208 0 O-C-N 124.677 1.236 . . . . 0.0 112.657 -177.246 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.2 Cg_endo -92.72 25.35 22.65 Favored 'Cis proline' 0 N--CA 1.461 -0.423 0 C-N-CA 123.108 -1.622 . . . . 0.0 114.231 0.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.68 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.6 m -125.19 -172.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 C-N-CA 120.495 -0.482 . . . . 0.0 112.259 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.542 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 76.2 m -128.1 143.63 51.07 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.824 HG22 ' HA ' ' A' ' 28' ' ' PRO . 67.6 p -134.13 145.14 49.01 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.587 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.9 ttm-85 -111.73 109.49 19.37 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.58 35.84 22.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.34 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.53 -16.48 58.98 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.405 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.0 tp -89.42 119.07 69.6 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 117.112 0.456 . . . . 0.0 109.856 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.824 ' HA ' HG22 ' A' ' 23' ' ' THR . 23.3 Cg_exo -59.28 139.11 88.52 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 122.063 1.842 . . . . 0.0 112.547 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 41.9 t . . . . . 0 C--N 1.314 -0.936 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.063 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.448 ' CG ' ' HB2' ' A' ' 22' ' ' CYS . 9.8 tp10 . . . . . 0 C--O 1.241 0.636 0 CA-C-O 121.157 0.504 . . . . 0.0 110.479 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.636 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.0 p -112.31 152.68 28.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.79 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.538 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 22.6 t -117.2 38.92 3.39 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.209 0.528 . . . . 0.0 110.332 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.28 -39.97 87.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.06 179.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.7 11.77 65.45 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.642 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.26 19.02 75.53 Favored Glycine 0 C--N 1.319 -0.371 0 C-N-CA 121.623 -0.322 . . . . 0.0 112.852 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.12 147.45 27.08 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 122.407 0.283 . . . . 0.0 110.83 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 m -115.4 158.81 21.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.997 0.427 . . . . 0.0 110.315 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -82.12 -38.16 25.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.479 178.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.411 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 98.1 m -64.42 125.27 88.12 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.959 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 21.4 Cg_exo -64.01 132.68 35.35 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.772 2.315 . . . . 0.0 112.016 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.33 28.36 71.45 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.546 -0.752 . . . . 0.0 112.818 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -94.18 136.61 34.29 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.031 0.443 . . . . 0.0 110.521 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -89.36 147.74 23.9 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.568 179.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.2 t -82.59 135.15 35.14 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.189 0.519 . . . . 0.0 111.175 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 45.0 m -143.09 58.83 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -32.88 128.54 0.37 Allowed Pre-proline 0 N--CA 1.463 0.191 0 O-C-N 124.673 1.233 . . . . 0.0 112.705 -177.295 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -93.31 25.56 22.38 Favored 'Cis proline' 0 N--CA 1.461 -0.409 0 C-N-CA 123.071 -1.637 . . . . 0.0 114.144 0.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.636 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.4 m -123.75 -174.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.068 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.538 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.6 m -126.11 146.85 49.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.747 HG22 ' HA ' ' A' ' 28' ' ' PRO . 18.4 p -127.57 166.33 18.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.15 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 43.3 ttp85 -151.18 119.15 6.22 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 57.15 41.25 27.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.506 0.669 . . . . 0.0 110.354 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.75 11.9 77.97 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.565 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.5 mt -121.57 127.58 26.01 Favored Pre-proline 0 C--N 1.325 -0.5 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.747 ' HA ' HG22 ' A' ' 23' ' ' THR . 17.4 Cg_exo -62.98 141.9 85.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.2 1.934 . . . . 0.0 112.416 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.442 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 39.8 t . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.448 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.672 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.6 tp10 . . . . . 0 C--O 1.239 0.526 0 CA-C-O 121.079 0.466 . . . . 0.0 110.372 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.4 p -107.71 151.42 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.485 179.443 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.524 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 14.8 t -116.92 40.86 2.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.108 0.48 . . . . 0.0 110.367 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.2 t -62.93 -40.58 89.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.377 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 13.1 62.58 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.778 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 22.2 74.78 Favored Glycine 0 C--N 1.319 -0.386 0 C-N-CA 121.593 -0.337 . . . . 0.0 112.804 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.08 147.49 27.15 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.384 0.274 . . . . 0.0 110.797 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.0 m -117.79 159.64 22.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.058 0.456 . . . . 0.0 110.224 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -82.26 -37.89 25.23 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.354 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.4 m -65.43 125.79 90.23 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.069 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.55 131.99 29.64 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 122.546 2.164 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.64 34.99 73.6 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.888 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.36 137.8 38.29 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.57 146.24 25.25 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -86.16 130.62 34.47 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 121.293 0.568 . . . . 0.0 111.706 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 75.1 m -137.52 62.1 1.59 Allowed 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.99 127.88 0.38 Allowed Pre-proline 0 N--CA 1.462 0.131 0 CA-C-N 114.619 -1.173 . . . . 0.0 112.581 -177.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -95.95 30.49 13.82 Favored 'Cis proline' 0 N--CA 1.46 -0.493 0 C-N-CA 123.493 -1.461 . . . . 0.0 114.112 0.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.1 m -126.92 177.06 5.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.524 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.3 m -119.98 141.42 49.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.164 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.557 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.4 p -132.41 141.66 48.96 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.89 -179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 44.1 ttt85 -131.1 127.71 38.69 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.4 t30 57.77 37.14 27.08 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.335 0.588 . . . . 0.0 110.54 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.52 18.2 76.9 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.778 -0.646 . . . . 0.0 113.001 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 37.6 tp -129.74 128.02 22.95 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.557 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.1 Cg_exo -61.5 141.01 90.4 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 121.988 1.792 . . . . 0.0 111.932 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.672 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.3 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.755 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.539 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 12.4 mm-40 . . . . . 0 CA--C 1.515 -0.403 0 CA-C-O 121.089 0.471 . . . . 0.0 111.189 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.7 p -113.11 148.21 35.75 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.743 178.291 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.521 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 11.2 t -118.03 40.0 3.25 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.057 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -64.37 -41.67 93.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.29 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.3 6.58 78.31 Favored Glycine 0 C--O 1.227 -0.283 0 CA-C-N 115.683 -0.689 . . . . 0.0 112.395 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.521 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 73.32 29.49 64.11 Favored Glycine 0 C--N 1.319 -0.399 0 CA-C-N 115.329 -0.436 . . . . 0.0 112.891 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.8 p -145.84 142.36 28.76 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 122.219 0.208 . . . . 0.0 111.073 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 20.9 m -122.13 169.05 11.26 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 178.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -94.02 -33.4 13.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.497 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 18.2 m -64.13 122.52 78.1 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.031 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.09 128.46 20.67 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.461 2.107 . . . . 0.0 111.753 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 37.23 84.48 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.437 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.497 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -96.45 143.86 27.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.999 0.428 . . . . 0.0 110.904 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.57 150.9 22.21 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.567 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.8 t -92.81 135.21 34.32 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.116 0.484 . . . . 0.0 111.368 -179.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 64.7 m -141.67 62.47 1.45 Allowed 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.8 t90 -32.6 126.78 0.37 Allowed Pre-proline 0 N--CA 1.463 0.184 0 O-C-N 124.57 1.169 . . . . 0.0 112.374 -177.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 53.1 Cg_endo -97.62 32.78 10.37 Favored 'Cis proline' 0 N--CA 1.457 -0.621 0 C-N-CA 123.639 -1.4 . . . . 0.0 114.21 0.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.586 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.1 m -130.04 169.13 21.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.539 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 96.4 m -105.48 147.52 28.22 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.687 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.839 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.7 p -133.24 158.63 42.41 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.844 0.354 . . . . 0.0 110.535 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 28.6 ttt-85 -150.36 130.18 13.3 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 59.01 31.54 21.46 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 123.541 0.526 . . . . 0.0 110.884 -178.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.81 17.94 80.11 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.766 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.455 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.4 mt -126.45 131.41 23.92 Favored Pre-proline 0 C--N 1.326 -0.444 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.839 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.4 Cg_exo -65.26 140.83 66.17 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.275 1.983 . . . . 0.0 112.278 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.493 HG11 ' HG3' ' A' ' 3' ' ' GLU . 29.6 t . . . . . 0 C--N 1.316 -0.88 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.532 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.557 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 64.3 mm-40 . . . . . 0 CA--C 1.513 -0.459 0 CA-C-O 121.157 0.504 . . . . 0.0 111.266 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.632 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.9 p -115.33 150.38 36.38 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.733 178.243 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.5 t -120.4 38.14 4.07 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.243 0.544 . . . . 0.0 109.981 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 23.6 t -64.13 -41.75 93.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.075 179.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.62 6.21 83.86 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.49 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.35 20.43 77.08 Favored Glycine 0 C--N 1.318 -0.444 0 CA-C-N 115.331 -0.435 . . . . 0.0 112.971 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 20.7 p -147.05 141.76 26.72 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 122.1 0.16 . . . . 0.0 110.919 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.3 m -108.07 165.36 11.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.123 0.487 . . . . 0.0 110.445 179.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -83.12 -38.15 22.81 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.838 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -73.55 122.23 87.09 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.804 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.3 Cg_exo -64.96 133.55 36.34 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.744 2.296 . . . . 0.0 112.168 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 25.66 70.92 Favored Glycine 0 CA--C 1.519 0.284 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.036 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -92.17 147.38 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.659 0.266 . . . . 0.0 110.342 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -88.86 149.6 23.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.949 179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.6 t -91.55 136.56 33.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.167 0.508 . . . . 0.0 111.352 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.1 m -144.9 61.78 1.31 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.2 127.14 0.35 Allowed Pre-proline 0 N--CA 1.465 0.277 0 O-C-N 124.608 1.193 . . . . 0.0 112.594 -177.407 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 44.4 Cg_endo -96.53 30.24 14.12 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.547 -1.439 . . . . 0.0 114.002 0.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.632 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.2 m -128.4 175.13 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.557 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 89.1 m -112.94 150.74 31.41 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.845 0.355 . . . . 0.0 111.204 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.827 HG22 ' HA ' ' A' ' 28' ' ' PRO . 13.0 p -131.67 160.61 34.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.633 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -150.54 127.96 11.42 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.7 m-20 58.99 33.72 23.19 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 123.655 0.597 . . . . 0.0 110.841 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.35 16.65 79.79 Favored Glycine 0 C--N 1.33 0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 112.863 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.442 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.7 mt -126.59 133.86 25.44 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.827 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.5 Cg_exo -63.26 141.18 81.07 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.313 2.009 . . . . 0.0 112.154 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 3' ' ' GLU . 39.7 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.918 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.498 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 11.4 tp10 . . . . . 0 C--O 1.241 0.654 0 CA-C-O 121.301 0.572 . . . . 0.0 110.727 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.678 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -113.04 152.65 29.25 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.723 179.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.515 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 28.5 t -116.54 36.69 4.02 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.328 0.585 . . . . 0.0 110.222 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.445 HG23 ' HB ' ' A' ' 4' ' ' THR . 22.7 t -65.03 -37.89 81.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.92 179.453 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.1 3.38 86.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.768 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.42 1.75 90.24 Favored Glycine 0 C--N 1.318 -0.444 0 C-N-CA 121.348 -0.454 . . . . 0.0 113.306 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.7 p -147.3 141.69 26.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.697 0.248 . . . . 0.0 111.012 179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.42 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.2 m -98.62 161.2 13.79 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.336 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -87.93 -35.83 17.45 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.509 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 83.1 m -64.86 126.09 90.34 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.7 Cg_exo -62.39 132.64 39.29 Favored 'Trans proline' 0 C--O 1.238 0.487 0 C-N-CA 122.785 2.323 . . . . 0.0 112.446 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.45 30.33 71.27 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.995 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.52 135.06 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.556 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.55 148.83 23.16 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.828 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -81.31 135.89 35.73 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.285 0.564 . . . . 0.0 111.381 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.5 m -144.24 59.03 1.35 Allowed 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.7 OUTLIER -32.97 128.75 0.37 Allowed Pre-proline 0 N--CA 1.462 0.169 0 O-C-N 124.63 1.206 . . . . 0.0 112.76 -177.256 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.6 Cg_endo -92.7 24.91 23.6 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.066 -1.639 . . . . 0.0 114.209 0.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.678 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.5 m -124.97 -172.32 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 O-C-N 121.988 -0.445 . . . . 0.0 112.168 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.515 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.5 m -127.74 146.79 50.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.084 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.842 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.9 p -134.22 162.64 31.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.453 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.5 ttp180 -150.17 125.86 10.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.3 t30 60.03 33.4 21.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.418 0.628 . . . . 0.0 110.567 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.53 9.05 87.09 Favored Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.696 -0.684 . . . . 0.0 113.288 179.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.406 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 9.2 mp -118.78 129.79 25.19 Favored Pre-proline 0 C--N 1.327 -0.396 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.842 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.1 Cg_exo -64.97 140.81 67.81 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.247 1.965 . . . . 0.0 112.331 -179.612 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.4 t . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.107 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.696 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 2.6 mm-40 . . . . . 0 C--O 1.238 0.464 0 CA-C-O 121.124 0.488 . . . . 0.0 111.388 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.585 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 33.0 p -116.92 147.45 42.21 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.037 178.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.5 t -117.27 40.22 3.08 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.866 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.442 HG23 ' HB ' ' A' ' 4' ' ' THR . 33.8 t -64.2 -42.35 95.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.385 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.78 7.83 76.84 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.395 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.515 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 72.04 31.03 64.65 Favored Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.405 -0.397 . . . . 0.0 112.774 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.3 p -144.92 142.89 30.25 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.646 -0.277 . . . . 0.0 110.89 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 17.6 m -124.94 165.22 18.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.985 0.421 . . . . 0.0 110.018 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -87.21 -33.98 19.15 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.766 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.447 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 19.7 m -70.29 125.84 92.13 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.176 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -65.94 129.97 23.32 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.456 2.104 . . . . 0.0 111.865 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.2 37.86 87.22 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.327 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.447 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -94.78 144.78 25.36 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.899 0.38 . . . . 0.0 110.713 179.783 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.26 148.96 23.3 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.508 178.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.8 t -93.64 134.14 36.26 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.238 0.542 . . . . 0.0 111.325 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.6 m -140.03 61.77 1.52 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.0 t90 -32.16 126.36 0.35 Allowed Pre-proline 0 N--CA 1.463 0.185 0 O-C-N 124.504 1.128 . . . . 0.0 112.481 -177.462 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.489 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -98.36 33.81 9.16 Favored 'Cis proline' 0 N--CA 1.458 -0.595 0 C-N-CA 123.675 -1.385 . . . . 0.0 114.167 0.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.585 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 4.3 m -130.32 163.11 36.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.696 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 81.7 m -102.44 145.62 29.27 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.984 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.753 HG22 ' HA ' ' A' ' 28' ' ' PRO . 30.6 p -133.42 164.03 28.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.118 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 30.5 ttt-85 -150.85 123.59 8.58 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.4 t30 58.84 34.65 23.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.426 0.631 . . . . 0.0 110.678 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.35 9.43 87.01 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.602 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.419 ' HA ' HD13 ' A' ' 27' ' ' LEU . 3.4 mm? -120.48 130.79 24.68 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.126 0.463 . . . . 0.0 109.917 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.753 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.5 Cg_exo -63.76 141.71 79.93 Favored 'Trans proline' 0 N--CA 1.46 -0.462 0 C-N-CA 122.26 1.974 . . . . 0.0 112.253 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.491 ' CG1' ' HG3' ' A' ' 3' ' ' GLU . 37.2 t . . . . . 0 C--N 1.318 -0.786 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.857 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.641 ' OE2' ' HB3' ' A' ' 10' ' ' CYS . 48.2 tt0 . . . . . 0 C--O 1.235 0.339 0 CA-C-O 121.247 0.546 . . . . 0.0 111.05 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 24.4 p -108.69 152.63 24.55 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.607 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.2 t -119.19 41.34 3.1 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.156 0.503 . . . . 0.0 109.704 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.5 t -62.66 -39.64 85.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.687 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.76 11.61 59.08 Favored Glycine 0 N--CA 1.452 -0.241 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.726 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.74 19.28 73.09 Favored Glycine 0 C--N 1.319 -0.369 0 C-N-CA 121.532 -0.366 . . . . 0.0 112.558 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.25 26.18 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 122.559 0.343 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.641 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 39.3 m -106.83 172.11 7.0 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.028 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -96.8 -29.84 13.52 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.975 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.436 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.3 m -79.93 124.84 82.97 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.574 -179.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 36.2 Cg_exo -60.35 135.97 65.04 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.905 2.403 . . . . 0.0 112.913 -179.37 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.56 32.75 79.42 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.543 -0.753 . . . . 0.0 113.437 179.423 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.74 147.11 26.4 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.52 150.28 22.52 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -98.0 138.09 35.84 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.214 0.531 . . . . 0.0 111.04 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.8 m -144.2 62.92 1.34 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -33.01 127.26 0.39 Allowed Pre-proline 0 N--CA 1.465 0.296 0 O-C-N 124.563 1.164 . . . . 0.0 112.32 -177.551 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.3 Cg_endo -97.08 33.11 10.13 Favored 'Cis proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.505 -1.456 . . . . 0.0 114.24 0.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.4 m -129.8 169.99 19.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.436 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 99.4 m -107.33 148.08 29.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.475 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.955 HG22 ' HA ' ' A' ' 28' ' ' PRO . 33.1 p -137.3 168.7 19.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.101 0.476 . . . . 0.0 110.664 -179.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -151.09 120.0 6.64 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 m120 57.85 36.64 26.54 Favored 'General case' 0 N--CA 1.467 0.417 0 O-C-N 123.41 0.444 . . . . 0.0 111.331 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.15 7.0 88.74 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 121.095 -0.574 . . . . 0.0 113.188 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.447 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 94.1 mt -113.34 126.17 28.57 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.462 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.955 ' HA ' HG22 ' A' ' 23' ' ' THR . 12.2 Cg_exo -67.5 140.94 53.88 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.395 2.064 . . . . 0.0 112.879 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.9 t . . . . . 0 C--N 1.318 -0.8 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.129 178.789 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.552 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 6.2 tp10 . . . . . 0 C--O 1.241 0.656 0 CA-C-O 121.224 0.535 . . . . 0.0 110.182 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 44.7 p -111.45 151.64 28.33 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.057 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.492 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 15.3 t -118.04 39.5 3.38 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.101 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.4 t -62.87 -40.6 89.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.475 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.57 4.81 85.19 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.76 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.21 13.56 82.72 Favored Glycine 0 C--N 1.317 -0.527 0 C-N-CA 121.433 -0.413 . . . . 0.0 113.03 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.4 p -147.82 142.04 26.16 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.155 0.182 . . . . 0.0 110.858 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 m -106.98 163.05 13.3 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 178.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 t30 -87.62 -35.73 17.89 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.719 0.771 . . . . 0.0 109.286 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 32.2 m -65.85 126.01 90.97 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 114.76 -1.109 . . . . 0.0 111.213 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -64.45 133.77 38.76 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.519 2.146 . . . . 0.0 112.472 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.9 29.51 72.51 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.307 -0.86 . . . . 0.0 113.02 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -95.94 137.11 35.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.811 0.339 . . . . 0.0 110.621 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.3 149.43 23.05 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.585 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.5 t -86.61 136.2 33.14 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.352 0.596 . . . . 0.0 111.6 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.5 m -143.48 59.44 1.39 Allowed 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -31.94 127.43 0.33 Allowed Pre-proline 0 N--CA 1.464 0.245 0 O-C-N 124.506 1.129 . . . . 0.0 112.543 -177.297 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 49.3 Cg_endo -95.29 29.28 15.86 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.352 -1.52 . . . . 0.0 114.134 0.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.597 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.9 m -126.92 179.31 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.552 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 92.9 m -120.9 144.31 48.49 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.243 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.676 HG22 ' HA ' ' A' ' 28' ' ' PRO . 34.7 p -134.85 155.92 49.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.642 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -148.19 130.36 15.49 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.0 m120 59.74 30.99 20.58 Favored 'General case' 0 N--CA 1.465 0.3 0 O-C-N 123.589 0.556 . . . . 0.0 110.934 -178.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.19 17.58 80.2 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.753 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 36.4 tp -129.59 129.06 23.13 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.676 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.5 Cg_exo -62.19 142.7 92.74 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.195 1.93 . . . . 0.0 111.854 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.539 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 46.0 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.702 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.23 0 CA-C-O 120.398 0.142 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.84 25.42 25.24 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.803 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.468 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 10.4 tp10 -73.02 121.97 21.0 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.646 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.3 p -110.77 153.54 25.19 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.108 0.48 . . . . 0.0 111.158 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.622 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 21.5 t -121.05 38.91 3.94 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.092 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 23.9 t -62.93 -40.48 89.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.404 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.1 5.41 83.07 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.849 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.0 11.56 84.34 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.93 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.2 p -148.08 142.42 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.243 0.217 . . . . 0.0 110.745 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.423 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.4 m -103.67 159.41 15.64 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.994 0.426 . . . . 0.0 110.153 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.7 m-80 -81.34 -38.64 26.37 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.463 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.475 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -70.43 125.01 91.87 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.207 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.1 Cg_exo -65.71 136.2 44.85 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.791 2.328 . . . . 0.0 112.013 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 23.88 74.51 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.709 -0.678 . . . . 0.0 113.05 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.04 137.63 36.56 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.3 148.21 23.68 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.4 t -83.8 137.05 33.9 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.43 0.633 . . . . 0.0 111.413 -179.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 30.9 m -144.62 58.95 1.32 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.4 t90 -31.82 127.45 0.32 Allowed Pre-proline 0 N--CA 1.463 0.211 0 O-C-N 124.516 1.135 . . . . 0.0 112.628 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -94.62 28.44 17.2 Favored 'Cis proline' 0 N--CA 1.46 -0.456 0 C-N-CA 123.278 -1.551 . . . . 0.0 114.142 0.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 12.6 m -126.3 -176.7 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.622 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.8 m -127.77 140.4 52.07 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.994 0.426 . . . . 0.0 111.091 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.506 HG22 ' HA ' ' A' ' 28' ' ' PRO . 40.1 p -132.25 157.26 44.83 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.728 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.43 ' HG2' ' OD1' ' A' ' 25' ' ' ASN . 54.9 ttp85 -147.02 127.8 14.35 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.43 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 7.7 m120 60.16 31.61 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 O-C-N 123.422 0.451 . . . . 0.0 110.768 -178.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.29 14.44 81.91 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.967 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.6 mt -127.41 135.95 28.2 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.506 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.7 Cg_exo -60.36 141.53 95.91 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.069 1.846 . . . . 0.0 111.652 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.468 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 20.8 t . . . . . 0 C--N 1.317 -0.805 0 CA-C-O 121.483 0.659 . . . . 0.0 110.189 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.459 0 CA-C-O 120.682 0.277 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.19 -39.06 2.86 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.559 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 44.9 tt0 -80.24 108.4 13.81 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.547 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.2 p -101.87 152.21 21.18 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.944 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.0 t -117.58 40.92 2.96 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.841 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.5 t -62.32 -41.22 90.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.587 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.27 12.94 63.07 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.597 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.4 30.24 77.15 Favored Glycine 0 C--N 1.319 -0.392 0 C-N-CA 121.466 -0.397 . . . . 0.0 112.36 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.66 149.24 29.59 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.892 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.441 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 60.2 m -123.56 171.76 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.343 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -88.46 -32.57 18.2 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.406 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.575 HG21 ' CD ' ' A' ' 24' ' ' ARG . 27.7 m -74.08 127.51 87.89 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.33 131.31 23.04 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.195 1.93 . . . . 0.0 111.644 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.73 29.39 69.53 Favored Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.627 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.474 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.48 146.76 24.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.758 0.313 . . . . 0.0 110.477 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.66 144.88 26.0 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -96.53 130.86 43.62 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.262 0.553 . . . . 0.0 111.592 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 59.6 m -131.98 63.13 1.62 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.7 t90 -33.87 127.94 0.44 Allowed Pre-proline 0 N--CA 1.462 0.158 0 O-C-N 124.382 1.051 . . . . 0.0 112.2 -177.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -96.96 33.73 9.54 Favored 'Cis proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.574 -1.428 . . . . 0.0 114.335 0.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.2 m -129.6 164.25 32.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.268 0.556 . . . . 0.0 112.205 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.559 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 92.2 m -97.06 150.89 20.31 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.872 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.728 HG22 ' HA ' ' A' ' 28' ' ' PRO . 3.1 p -138.56 141.51 39.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.632 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.575 ' CD ' HG21 ' A' ' 12' ' ' THR . 33.3 mtm180 -125.77 119.34 27.64 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 57.55 41.62 25.53 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.773 0.671 . . . . 0.0 109.984 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.72 13.29 74.92 Favored Glycine 0 CA--C 1.52 0.395 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.202 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 43.8 tp -112.81 125.01 30.57 Favored Pre-proline 0 C--N 1.326 -0.433 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.728 ' HA ' HG22 ' A' ' 23' ' ' THR . 18.9 Cg_exo -63.5 142.31 84.11 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.344 2.03 . . . . 0.0 112.088 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.7 t . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.378 -179.935 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.119 0 N-CA-C 112.227 0.454 . . . . 0.0 112.227 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.83 22.56 75.62 Favored Glycine 0 N--CA 1.453 -0.224 0 CA-C-N 115.483 -0.78 . . . . 0.0 113.33 179.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.566 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.8 tp10 -115.42 112.37 22.21 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 46.5 p -107.58 151.74 25.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.011 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.7 t -119.32 41.81 3.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.022 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.9 t -62.42 -39.63 85.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.694 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.36 12.87 61.54 Favored Glycine 0 N--CA 1.453 -0.222 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.891 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.41 21.87 74.52 Favored Glycine 0 C--N 1.321 -0.301 0 C-N-CA 121.453 -0.403 . . . . 0.0 112.614 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.86 147.66 27.51 Favored 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 110.614 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 15.7 m -114.74 167.01 11.14 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.14 0.495 . . . . 0.0 110.219 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -90.63 -34.71 15.35 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.788 178.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.3 m -67.88 126.06 92.15 Favored Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.398 -1.274 . . . . 0.0 111.326 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.88 133.45 33.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.439 2.092 . . . . 0.0 112.137 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 31.63 74.37 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.714 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.96 139.21 34.95 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.615 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.48 149.02 23.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.559 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.4 t -88.88 135.6 33.45 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.27 0.557 . . . . 0.0 111.379 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.6 m -141.03 59.71 1.52 Allowed 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.3 t90 -32.01 127.16 0.34 Allowed Pre-proline 0 N--CA 1.464 0.227 0 O-C-N 124.649 1.218 . . . . 0.0 112.496 -177.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.2 Cg_endo -96.02 31.08 12.91 Favored 'Cis proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.175 0.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.584 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.5 m -127.77 175.79 8.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.506 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 87.3 m -117.37 143.17 46.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.175 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.675 HG22 ' HA ' ' A' ' 28' ' ' PRO . 38.8 p -135.8 159.27 42.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.484 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -150.14 126.47 10.74 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.0 t30 60.03 34.8 21.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.518 0.675 . . . . 0.0 110.193 -178.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.59 14.07 79.87 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.995 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.431 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.5 mt -122.89 127.51 25.7 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.5 Cg_exo -65.82 142.1 68.15 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.415 2.076 . . . . 0.0 112.188 -179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.566 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.7 t . . . . . 0 C--N 1.317 -0.815 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.493 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.88 0.371 . . . . 0.0 111.837 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.63 -31.58 3.87 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.899 -0.591 . . . . 0.0 112.787 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.486 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 6.1 tp10 -72.1 109.97 6.25 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.149 0.499 . . . . 0.0 110.3 -179.617 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.9 p -107.88 153.0 23.67 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.983 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.411 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.4 t -120.7 40.49 3.51 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.049 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -61.94 -40.13 86.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.585 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.91 12.44 61.86 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.762 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.04 21.61 75.54 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 121.557 -0.354 . . . . 0.0 112.739 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.13 147.12 26.67 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 122.427 0.291 . . . . 0.0 110.939 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 18.5 m -112.07 167.36 10.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.038 0.447 . . . . 0.0 109.953 179.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -88.68 -35.64 16.65 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 26.9 m -68.7 125.38 91.74 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 114.282 -1.326 . . . . 0.0 111.586 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 15.2 Cg_exo -66.17 133.37 32.79 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.554 2.169 . . . . 0.0 111.447 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.76 31.68 70.36 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.719 -0.673 . . . . 0.0 112.724 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -99.54 141.33 32.48 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.85 0.357 . . . . 0.0 110.468 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.1 m -89.45 149.1 23.09 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.656 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -90.81 136.32 33.15 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.279 0.562 . . . . 0.0 110.996 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 56.9 m -142.66 60.42 1.43 Allowed 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.58 127.89 0.36 Allowed Pre-proline 0 N--CA 1.463 0.213 0 O-C-N 124.627 1.205 . . . . 0.0 112.45 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.2 Cg_endo -94.83 29.27 15.92 Favored 'Cis proline' 0 N--CA 1.46 -0.477 0 C-N-CA 123.238 -1.567 . . . . 0.0 114.22 0.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.0 m -126.88 179.88 3.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.985 0.422 . . . . 0.0 112.095 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.483 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 96.9 m -117.95 148.37 42.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.065 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.631 HG22 ' HA ' ' A' ' 28' ' ' PRO . 13.4 p -131.95 157.03 45.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 0.0 110.74 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.719 ' O ' ' HG ' ' A' ' 27' ' ' LEU . 53.7 ttp180 -150.31 130.56 13.67 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.6 t30 57.71 33.48 23.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 110.938 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.74 16.81 80.41 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.819 -0.628 . . . . 0.0 113.941 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.719 ' HG ' ' O ' ' A' ' 24' ' ' ARG . 3.9 pp -133.88 135.66 25.03 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.404 0.602 . . . . 0.0 109.871 178.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.631 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.2 Cg_exo -64.93 141.83 72.64 Favored 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.599 2.199 . . . . 0.0 112.722 -178.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.486 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 43.9 t . . . . . 0 C--N 1.317 -0.823 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.13 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.165 0 N-CA-C 112.126 0.417 . . . . 0.0 112.126 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.86 24.05 74.26 Favored Glycine 0 N--CA 1.452 -0.264 0 CA-C-N 115.459 -0.791 . . . . 0.0 113.613 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.624 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.9 tp10 -112.48 114.92 27.85 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.109 0.481 . . . . 0.0 110.363 179.47 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.1 p -108.44 152.04 25.23 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.863 179.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.6 t -119.0 40.81 3.21 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.098 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 26.6 t -62.23 -40.37 87.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 13.24 62.49 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.728 179.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.5 24.55 73.81 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 121.529 -0.367 . . . . 0.0 112.694 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 147.84 27.68 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 122.459 0.304 . . . . 0.0 110.927 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.5 m -118.28 164.11 15.69 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -88.76 -35.33 16.74 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.091 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.431 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 24.6 m -67.9 125.49 91.45 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 114.574 -1.194 . . . . 0.0 111.361 -179.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.72 133.74 35.24 Favored 'Trans proline' 0 N--CA 1.46 -0.476 0 C-N-CA 122.694 2.263 . . . . 0.0 111.797 179.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.64 27.67 72.13 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.968 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -97.71 136.32 38.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.827 0.346 . . . . 0.0 110.31 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 149.94 22.82 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -86.16 136.61 33.13 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.299 0.571 . . . . 0.0 111.393 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 40.9 m -142.89 59.56 1.42 Allowed 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.0 t90 -32.08 127.38 0.34 Allowed Pre-proline 0 N--CA 1.465 0.288 0 O-C-N 124.675 1.234 . . . . 0.0 112.598 -177.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.9 Cg_endo -95.6 30.32 14.14 Favored 'Cis proline' 0 N--CA 1.459 -0.506 0 C-N-CA 123.432 -1.487 . . . . 0.0 114.132 0.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 10.5 m -127.27 176.73 6.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 97.0 m -119.29 140.54 50.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.383 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.527 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.5 p -130.68 131.93 45.12 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.277 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.4 ttp85 -98.67 106.64 18.93 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.8 t30 60.16 37.68 20.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.552 0.692 . . . . 0.0 109.399 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.26 -12.17 65.41 Favored Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.466 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -96.92 111.75 58.55 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 117.239 0.52 . . . . 0.0 110.396 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.527 ' HA ' HG22 ' A' ' 23' ' ' THR . 0.9 OUTLIER -49.14 138.47 28.4 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.943 2.428 . . . . 0.0 113.56 -179.111 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.624 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 44.6 t . . . . . 0 C--N 1.317 -0.834 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.541 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.178 0 CA-C-O 120.814 0.34 . . . . 0.0 111.447 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.82 -35.25 3.68 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 121.126 -0.559 . . . . 0.0 112.413 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.446 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 14.7 tp10 -71.74 109.38 5.59 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.3 p -108.22 152.41 24.63 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.134 0.492 . . . . 0.0 111.074 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.437 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 13.9 t -119.67 39.37 3.65 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.02 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 25.8 t -62.48 -40.42 88.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.443 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.05 3.84 84.73 Favored Glycine 0 C--O 1.227 -0.326 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.764 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.96 14.61 81.8 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.999 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.6 p -148.35 141.86 25.39 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.148 0.179 . . . . 0.0 110.928 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.7 m -106.19 167.6 9.71 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -90.86 -33.9 15.47 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.645 0.736 . . . . 0.0 109.051 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 34.9 m -63.88 126.99 91.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 114.834 -1.076 . . . . 0.0 111.018 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.39 128.83 23.54 Favored 'Trans proline' 0 C--O 1.237 0.446 0 C-N-CA 122.549 2.166 . . . . 0.0 112.4 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.38 31.77 79.89 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.186 -0.916 . . . . 0.0 112.781 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.473 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.82 143.34 26.88 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.871 0.367 . . . . 0.0 110.825 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.55 148.01 23.63 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.586 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -91.71 136.12 33.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.201 0.524 . . . . 0.0 110.883 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.8 m -142.34 59.96 1.45 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.56 127.91 0.36 Allowed Pre-proline 0 N--CA 1.463 0.186 0 O-C-N 124.625 1.203 . . . . 0.0 112.473 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -94.47 27.76 18.22 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.293 -1.545 . . . . 0.0 114.178 0.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.59 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.9 m -124.78 -179.25 2.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.026 0.441 . . . . 0.0 111.959 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.437 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.9 m -119.79 150.34 40.58 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.299 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.708 HG22 ' HA ' ' A' ' 28' ' ' PRO . 7.6 p -130.26 154.13 47.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.631 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.465 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 14.7 tpt85 -142.14 124.22 15.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 24.3 t30 57.09 38.94 29.38 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.261 0.553 . . . . 0.0 110.793 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.62 16.97 76.18 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.342 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.1 mt -126.48 131.16 23.82 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.708 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.7 Cg_exo -63.41 140.83 78.47 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.107 1.871 . . . . 0.0 112.214 -179.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.446 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 33.9 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.814 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.094 0 CA-C-O 120.872 0.368 . . . . 0.0 111.835 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.44 -33.82 4.41 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.935 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.639 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 5.5 mm-40 -72.11 120.85 18.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.251 0.548 . . . . 0.0 111.827 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -115.01 147.93 39.48 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.546 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.436 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.2 t -117.71 39.8 3.25 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.222 0.534 . . . . 0.0 110.091 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 32.2 t -64.05 -40.7 89.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.008 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.25 12.68 68.5 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.595 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.436 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 65.8 31.04 78.51 Favored Glycine 0 C--N 1.319 -0.381 0 CA-C-N 115.467 -0.366 . . . . 0.0 112.786 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.79 148.54 28.63 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.602 -0.299 . . . . 0.0 110.971 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 23.5 m -125.2 167.87 14.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.081 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -90.3 -33.62 16.04 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.41 -0.813 . . . . 0.0 109.201 178.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.45 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 18.8 m -68.14 124.27 89.28 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.987 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -64.89 129.53 23.51 Favored 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.478 2.119 . . . . 0.0 111.87 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 37.33 86.03 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.488 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.45 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -97.08 144.24 27.14 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.927 0.394 . . . . 0.0 110.915 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.31 150.65 22.49 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.696 178.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.5 t -93.94 135.43 35.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.21 0.529 . . . . 0.0 111.329 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 66.9 m -141.63 61.92 1.46 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -32.56 126.99 0.37 Allowed Pre-proline 0 N--CA 1.462 0.159 0 O-C-N 124.554 1.159 . . . . 0.0 112.371 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.5 Cg_endo -97.18 32.77 10.51 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.585 -1.423 . . . . 0.0 114.171 0.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 8.7 m -130.34 169.95 20.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.639 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 88.7 m -106.51 148.3 28.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.748 HG22 ' HA ' ' A' ' 28' ' ' PRO . 15.7 p -133.44 157.29 45.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.357 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 26.9 ttt-85 -150.35 130.54 13.61 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 58.68 31.43 21.13 Favored 'General case' 0 C--N 1.328 -0.354 0 O-C-N 123.509 0.505 . . . . 0.0 110.943 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.98 18.83 80.17 Favored Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.859 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.454 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.0 mt -129.41 132.04 24.01 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.748 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.4 Cg_exo -64.83 140.85 68.92 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 122.18 1.92 . . . . 0.0 112.27 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.44 HG11 ' HG3' ' A' ' 3' ' ' GLU . 25.2 t . . . . . 0 C--N 1.314 -0.943 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.455 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.14 0 CA-C-O 120.832 0.349 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.65 -29.39 4.52 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 121.072 -0.585 . . . . 0.0 113.133 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.503 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.7 tp10 -73.11 112.88 9.56 Favored 'General case' 0 C--O 1.241 0.636 0 CA-C-O 121.317 0.58 . . . . 0.0 110.71 -179.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.663 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.6 p -111.88 152.95 27.38 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.586 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.475 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 33.0 t -115.88 37.54 3.6 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.349 0.595 . . . . 0.0 110.28 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.436 HG23 ' HB ' ' A' ' 4' ' ' THR . 24.2 t -64.91 -38.36 82.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.024 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.12 2.48 87.63 Favored Glycine 0 C--O 1.227 -0.321 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.894 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.52 3.01 90.01 Favored Glycine 0 C--N 1.317 -0.489 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.175 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.2 p -146.18 142.57 28.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.635 0.218 . . . . 0.0 110.839 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.4 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.5 m -101.06 160.25 14.54 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.14 0.495 . . . . 0.0 110.571 179.507 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -84.49 -37.75 20.93 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.34 178.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.409 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 92.7 m -65.48 125.66 90.02 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.239 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.2 Cg_exo -62.83 133.05 39.87 Favored 'Trans proline' 0 C--O 1.237 0.452 0 C-N-CA 122.787 2.325 . . . . 0.0 112.489 -179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.4 29.88 71.55 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.278 -0.874 . . . . 0.0 113.092 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.59 135.81 39.58 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.545 179.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 150.01 22.66 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.804 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.2 t -82.54 135.72 35.02 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.303 0.573 . . . . 0.0 111.444 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.2 m -143.57 59.03 1.39 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.7 OUTLIER -32.88 128.57 0.37 Allowed Pre-proline 0 N--CA 1.462 0.167 0 O-C-N 124.605 1.19 . . . . 0.0 112.793 -177.295 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 49.6 Cg_endo -93.05 25.66 22.16 Favored 'Cis proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.072 -1.637 . . . . 0.0 114.242 0.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.663 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.4 m -125.01 -173.79 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.475 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 96.0 m -126.25 144.72 50.68 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.346 -179.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.758 HG22 ' HA ' ' A' ' 28' ' ' PRO . 40.3 p -134.36 153.03 52.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.453 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttp180 -141.11 126.03 18.19 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.8 t30 58.75 36.21 24.73 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.612 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.91 14.23 80.29 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 113.003 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 45.1 tp -123.07 124.24 26.55 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.758 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -63.74 140.62 75.13 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.147 1.898 . . . . 0.0 112.334 -179.472 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.503 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 38.8 t . . . . . 0 C--N 1.314 -0.951 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.21 179.328 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.238 0 CA-C-O 120.778 0.323 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 72.58 37.08 58.29 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.894 -0.594 . . . . 0.0 112.947 179.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.596 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.6 tp10 -138.63 114.48 9.98 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.222 0.534 . . . . 0.0 109.95 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.7 p -110.85 151.23 28.09 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.237 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.47 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 12.0 t -118.01 39.26 3.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.979 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.5 t -62.2 -40.8 88.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.473 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.97 13.63 60.79 Favored Glycine 0 N--CA 1.452 -0.298 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.39 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.0 20.96 75.18 Favored Glycine 0 C--N 1.32 -0.324 0 CA-C-N 115.398 -0.401 . . . . 0.0 112.694 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.38 26.26 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.108 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 m -115.16 165.11 13.28 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -86.24 -36.89 19.13 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.401 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 28.0 m -61.11 125.54 84.04 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.959 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -63.38 130.93 30.01 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.729 2.286 . . . . 0.0 112.578 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 63.19 33.17 86.53 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.229 -0.896 . . . . 0.0 113.141 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.401 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -89.16 145.98 25.08 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.837 0.351 . . . . 0.0 110.503 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.15 147.55 24.13 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -92.31 135.99 33.56 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.289 0.566 . . . . 0.0 111.074 -179.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 41.2 m -143.28 59.82 1.4 Allowed 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.436 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.2 t90 -32.14 127.5 0.34 Allowed Pre-proline 0 N--CA 1.463 0.224 0 O-C-N 124.587 1.179 . . . . 0.0 112.572 -177.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.436 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 51.5 Cg_endo -95.18 28.71 16.78 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.402 -1.499 . . . . 0.0 114.157 0.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 11.7 m -125.15 177.89 4.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.969 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.596 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 95.3 m -118.67 149.05 42.06 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.216 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.72 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.2 p -132.75 166.06 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.338 0.589 . . . . 0.0 111.368 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -150.31 120.37 7.2 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.374 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.0 t30 57.14 38.48 29.02 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.275 0.56 . . . . 0.0 110.874 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.65 10.6 84.77 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-N 115.83 -0.623 . . . . 0.0 113.522 179.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.0 mt -121.55 131.95 24.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.72 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.9 Cg_exo -62.87 141.66 85.46 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.222 1.948 . . . . 0.0 112.312 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.451 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 48.0 t . . . . . 0 C--N 1.319 -0.731 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.916 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.51 -36.96 3.57 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.602 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.566 ' HG2' ' SG ' ' A' ' 22' ' ' CYS . 25.3 tt0 -80.4 111.37 16.74 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.092 0.473 . . . . 0.0 110.311 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 47.8 p -103.21 151.98 22.01 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.6 t -117.92 40.12 3.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.215 0.531 . . . . 0.0 109.865 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -62.29 -40.99 89.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.541 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.65 13.31 60.95 Favored Glycine 0 N--CA 1.452 -0.285 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.557 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.81 23.57 74.13 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.559 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.92 146.84 26.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.624 -0.288 . . . . 0.0 111.058 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.4 m -111.51 167.54 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.831 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -83.73 -34.27 24.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.11 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.454 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.1 m -81.6 128.08 70.7 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.206 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 22.3 Cg_exo -63.43 137.67 61.43 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.714 2.276 . . . . 0.0 111.814 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.95 29.59 66.83 Favored Glycine 0 N--CA 1.453 -0.21 0 CA-C-N 115.868 -0.605 . . . . 0.0 112.714 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.91 144.97 24.97 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.845 0.355 . . . . 0.0 110.647 179.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.412 ' HB ' ' OG1' ' A' ' 23' ' ' THR . 1.0 OUTLIER -89.51 147.88 23.73 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.016 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -97.04 136.38 37.67 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.297 0.57 . . . . 0.0 111.208 -179.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 49.8 m -142.79 60.64 1.43 Allowed 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.524 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.61 127.65 0.36 Allowed Pre-proline 0 N--CA 1.463 0.188 0 O-C-N 124.567 1.167 . . . . 0.0 112.475 -177.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.524 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -95.55 29.62 15.27 Favored 'Cis proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.365 -1.514 . . . . 0.0 114.16 0.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 13.2 m -125.42 175.3 7.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 120.936 0.398 . . . . 0.0 112.007 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.566 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 68.0 m -113.5 148.17 36.53 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.202 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.73 HG22 ' HA ' ' A' ' 28' ' ' PRO . 4.6 p -128.55 156.88 42.62 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.828 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.4 ttp-105 -150.11 128.12 11.89 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 m120 58.75 32.69 22.45 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.668 0.605 . . . . 0.0 110.796 -178.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.68 20.46 79.8 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.849 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.409 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.4 mt -129.37 133.04 24.67 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.73 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.8 Cg_exo -64.79 141.09 70.33 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.23 1.953 . . . . 0.0 112.009 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 C--N 1.315 -0.899 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.126 179.909 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.068 0 CA-C-O 120.914 0.388 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -90.76 35.89 3.75 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.647 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.559 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.9 tp10 -160.15 123.74 3.58 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-O 121.378 0.608 . . . . 0.0 110.868 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.62 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 45.0 p -113.72 153.25 29.31 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.938 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.592 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 16.2 t -121.52 38.9 3.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.241 0.543 . . . . 0.0 110.349 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -63.29 -37.95 80.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.5 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.51 11.56 50.86 Favored Glycine 0 C--O 1.228 -0.232 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.066 179.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.23 2.06 82.41 Favored Glycine 0 C--N 1.317 -0.502 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.857 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.78 145.43 25.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.576 0.227 . . . . 0.0 110.7 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.7 m -91.86 163.39 14.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.995 0.426 . . . . 0.0 109.869 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 t30 -85.94 -36.21 20.0 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.487 -0.779 . . . . 0.0 108.965 178.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 25.9 m -69.02 124.64 90.81 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.055 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.76 132.43 28.58 Favored 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.344 2.029 . . . . 0.0 111.992 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.49 34.44 50.03 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.747 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -110.93 143.11 42.1 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.686 0.279 . . . . 0.0 110.263 179.331 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.2 148.52 23.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.115 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.2 t -89.7 138.59 31.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.234 0.54 . . . . 0.0 111.509 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.4 m -146.72 60.1 1.2 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.427 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.7 t90 -32.32 128.19 0.34 Allowed Pre-proline 0 N--CA 1.464 0.261 0 O-C-N 124.515 1.134 . . . . 0.0 112.618 -177.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.427 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.1 Cg_endo -94.01 25.88 21.7 Favored 'Cis proline' 0 N--CA 1.46 -0.445 0 C-N-CA 123.196 -1.585 . . . . 0.0 113.957 0.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.8 m -124.49 -174.86 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 O-C-N 122.111 -0.368 . . . . 0.0 111.692 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 92.6 m -125.6 153.13 44.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.985 0.421 . . . . 0.0 111.277 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.961 HG22 ' HA ' ' A' ' 28' ' ' PRO . 20.9 p -134.69 162.39 32.48 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.916 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 59.3 ttt180 -150.42 126.03 10.27 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 59.76 31.37 20.78 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.843 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.67 13.25 83.37 Favored Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.857 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.42 HD13 ' HA ' ' A' ' 27' ' ' LEU . 3.5 mm? -117.94 130.52 24.66 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.15 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.961 ' HA ' HG22 ' A' ' 23' ' ' THR . 13.0 Cg_exo -65.86 139.91 58.94 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.247 1.965 . . . . 0.0 112.576 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.315 -0.901 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.267 179.262 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.204 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.64 -27.76 4.16 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.866 -0.607 . . . . 0.0 113.507 179.145 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.537 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.9 tp10 -70.73 113.22 7.6 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 121.315 0.579 . . . . 0.0 110.82 -179.19 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.68 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 20.8 p -113.1 153.67 27.82 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.824 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.542 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 27.4 t -119.1 37.37 4.15 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.285 0.564 . . . . 0.0 110.223 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.405 HG23 ' HB ' ' A' ' 4' ' ' THR . 23.8 t -63.3 -38.34 81.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.216 179.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.65 10.88 60.81 Favored Glycine 0 N--CA 1.453 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.825 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.54 4.68 85.09 Favored Glycine 0 C--N 1.318 -0.442 0 C-N-CA 121.366 -0.445 . . . . 0.0 112.911 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.79 145.72 25.92 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.519 0.2 . . . . 0.0 110.744 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 m -94.26 159.85 14.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.207 0.527 . . . . 0.0 110.267 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -80.05 -39.98 28.65 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.231 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 36.0 m -80.42 121.69 81.79 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.812 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.62 142.14 76.05 Favored 'Trans proline' 0 C--O 1.235 0.375 0 C-N-CA 122.839 2.36 . . . . 0.0 112.721 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.47 2.26 87.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 121.06 -0.591 . . . . 0.0 113.163 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.3 137.97 31.92 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.05 149.37 23.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.882 0.373 . . . . 0.0 110.002 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.6 t -80.51 136.84 36.37 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.29 0.567 . . . . 0.0 111.586 -179.124 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.3 m -145.92 59.12 1.24 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.9 OUTLIER -32.63 128.57 0.35 Allowed Pre-proline 0 N--CA 1.463 0.208 0 O-C-N 124.677 1.236 . . . . 0.0 112.657 -177.246 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.2 Cg_endo -92.72 25.35 22.65 Favored 'Cis proline' 0 N--CA 1.461 -0.423 0 C-N-CA 123.108 -1.622 . . . . 0.0 114.231 0.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.68 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 16.6 m -125.19 -172.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 C-N-CA 120.495 -0.482 . . . . 0.0 112.259 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.542 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 76.2 m -128.1 143.63 51.07 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.824 HG22 ' HA ' ' A' ' 28' ' ' PRO . 67.6 p -134.13 145.14 49.01 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.587 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 60.9 ttm-85 -111.73 109.49 19.37 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.58 35.84 22.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.34 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.53 -16.48 58.98 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.405 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.0 tp -89.42 119.07 69.6 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 117.112 0.456 . . . . 0.0 109.856 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.824 ' HA ' HG22 ' A' ' 23' ' ' THR . 23.3 Cg_exo -59.28 139.11 88.52 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 122.063 1.842 . . . . 0.0 112.547 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 41.9 t . . . . . 0 C--N 1.314 -0.936 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.063 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.138 0 CA-C-O 120.779 0.323 . . . . 0.0 111.566 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 86.83 -32.03 4.12 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.115 -0.564 . . . . 0.0 112.82 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.448 ' CG ' ' HB2' ' A' ' 22' ' ' CYS . 9.8 tp10 -72.88 113.65 10.15 Favored 'General case' 0 C--O 1.241 0.636 0 CA-C-O 121.157 0.504 . . . . 0.0 110.479 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.636 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 21.0 p -112.31 152.68 28.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.79 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.538 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 22.6 t -117.2 38.92 3.39 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.209 0.528 . . . . 0.0 110.332 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.28 -39.97 87.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.06 179.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.7 11.77 65.45 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.642 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.26 19.02 75.53 Favored Glycine 0 C--N 1.319 -0.371 0 C-N-CA 121.623 -0.322 . . . . 0.0 112.852 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.12 147.45 27.08 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 122.407 0.283 . . . . 0.0 110.83 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 m -115.4 158.81 21.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.997 0.427 . . . . 0.0 110.315 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -82.12 -38.16 25.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.479 178.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.411 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 98.1 m -64.42 125.27 88.12 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.959 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 21.4 Cg_exo -64.01 132.68 35.35 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.772 2.315 . . . . 0.0 112.016 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.33 28.36 71.45 Favored Glycine 0 N--CA 1.452 -0.252 0 CA-C-N 115.546 -0.752 . . . . 0.0 112.818 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -94.18 136.61 34.29 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.031 0.443 . . . . 0.0 110.521 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -89.36 147.74 23.9 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.568 179.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.2 t -82.59 135.15 35.14 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.189 0.519 . . . . 0.0 111.175 -179.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 45.0 m -143.09 58.83 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -32.88 128.54 0.37 Allowed Pre-proline 0 N--CA 1.463 0.191 0 O-C-N 124.673 1.233 . . . . 0.0 112.705 -177.295 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 50.4 Cg_endo -93.31 25.56 22.38 Favored 'Cis proline' 0 N--CA 1.461 -0.409 0 C-N-CA 123.071 -1.637 . . . . 0.0 114.144 0.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.636 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.4 m -123.75 -174.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.068 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.538 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.6 m -126.11 146.85 49.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.747 HG22 ' HA ' ' A' ' 28' ' ' PRO . 18.4 p -127.57 166.33 18.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.15 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 43.3 ttp85 -151.18 119.15 6.22 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 57.15 41.25 27.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.506 0.669 . . . . 0.0 110.354 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.75 11.9 77.97 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.565 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.5 mt -121.57 127.58 26.01 Favored Pre-proline 0 C--N 1.325 -0.5 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.747 ' HA ' HG22 ' A' ' 23' ' ' THR . 17.4 Cg_exo -62.98 141.9 85.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.2 1.934 . . . . 0.0 112.416 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.442 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 39.8 t . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.448 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.146 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 70.15 16.17 72.8 Favored Glycine 0 N--CA 1.453 -0.188 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.598 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.672 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 9.6 tp10 -107.06 110.32 22.41 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.079 0.466 . . . . 0.0 110.372 179.563 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 43.4 p -107.71 151.42 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.485 179.443 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.524 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 14.8 t -116.92 40.86 2.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.108 0.48 . . . . 0.0 110.367 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.2 t -62.93 -40.58 89.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.377 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 13.1 62.58 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.778 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 22.2 74.78 Favored Glycine 0 C--N 1.319 -0.386 0 C-N-CA 121.593 -0.337 . . . . 0.0 112.804 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.08 147.49 27.15 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.384 0.274 . . . . 0.0 110.797 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.0 m -117.79 159.64 22.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.058 0.456 . . . . 0.0 110.224 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -82.26 -37.89 25.23 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.354 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.4 m -65.43 125.79 90.23 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.069 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.55 131.99 29.64 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 122.546 2.164 . . . . 0.0 112.413 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.64 34.99 73.6 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.888 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.36 137.8 38.29 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.57 146.24 25.25 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -86.16 130.62 34.47 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 121.293 0.568 . . . . 0.0 111.706 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 75.1 m -137.52 62.1 1.59 Allowed 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -32.99 127.88 0.38 Allowed Pre-proline 0 N--CA 1.462 0.131 0 CA-C-N 114.619 -1.173 . . . . 0.0 112.581 -177.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 55.4 Cg_endo -95.95 30.49 13.82 Favored 'Cis proline' 0 N--CA 1.46 -0.493 0 C-N-CA 123.493 -1.461 . . . . 0.0 114.112 0.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 14.1 m -126.92 177.06 5.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.524 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 84.3 m -119.98 141.42 49.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.164 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.557 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.4 p -132.41 141.66 48.96 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.89 -179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 44.1 ttt85 -131.1 127.71 38.69 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.4 t30 57.77 37.14 27.08 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.335 0.588 . . . . 0.0 110.54 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.52 18.2 76.9 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.778 -0.646 . . . . 0.0 113.001 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 37.6 tp -129.74 128.02 22.95 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.557 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.1 Cg_exo -61.5 141.01 90.4 Favored 'Trans proline' 0 N--CA 1.46 -0.491 0 C-N-CA 121.988 1.792 . . . . 0.0 111.932 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.672 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.3 t . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.755 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.161 0 CA-C-O 120.887 0.375 . . . . 0.0 111.619 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.24 -38.03 3.24 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.418 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.539 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 12.4 mm-40 -73.07 119.11 16.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.089 0.471 . . . . 0.0 111.189 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 22.7 p -113.11 148.21 35.75 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.743 178.291 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.521 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 11.2 t -118.03 40.0 3.25 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.057 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 31.5 t -64.37 -41.67 93.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.29 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.3 6.58 78.31 Favored Glycine 0 C--O 1.227 -0.283 0 CA-C-N 115.683 -0.689 . . . . 0.0 112.395 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.521 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 73.32 29.49 64.11 Favored Glycine 0 C--N 1.319 -0.399 0 CA-C-N 115.329 -0.436 . . . . 0.0 112.891 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.8 p -145.84 142.36 28.76 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 122.219 0.208 . . . . 0.0 111.073 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 20.9 m -122.13 169.05 11.26 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 178.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -94.02 -33.4 13.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.497 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 18.2 m -64.13 122.52 78.1 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.031 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 16.6 Cg_exo -65.09 128.46 20.67 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.461 2.107 . . . . 0.0 111.753 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 37.23 84.48 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.437 -179.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.497 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -96.45 143.86 27.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.999 0.428 . . . . 0.0 110.904 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -89.57 150.9 22.21 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.567 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.8 t -92.81 135.21 34.32 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.116 0.484 . . . . 0.0 111.368 -179.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 64.7 m -141.67 62.47 1.45 Allowed 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.8 t90 -32.6 126.78 0.37 Allowed Pre-proline 0 N--CA 1.463 0.184 0 O-C-N 124.57 1.169 . . . . 0.0 112.374 -177.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 53.1 Cg_endo -97.62 32.78 10.37 Favored 'Cis proline' 0 N--CA 1.457 -0.621 0 C-N-CA 123.639 -1.4 . . . . 0.0 114.21 0.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.586 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.1 m -130.04 169.13 21.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.539 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 96.4 m -105.48 147.52 28.22 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.687 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.839 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.7 p -133.24 158.63 42.41 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.844 0.354 . . . . 0.0 110.535 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 28.6 ttt-85 -150.36 130.18 13.3 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.3 m120 59.01 31.54 21.46 Favored 'General case' 0 C--N 1.328 -0.331 0 O-C-N 123.541 0.526 . . . . 0.0 110.884 -178.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.81 17.94 80.11 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.766 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.455 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 96.4 mt -126.45 131.41 23.92 Favored Pre-proline 0 C--N 1.326 -0.444 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.839 ' HA ' HG22 ' A' ' 23' ' ' THR . 14.4 Cg_exo -65.26 140.83 66.17 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.275 1.983 . . . . 0.0 112.278 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.493 HG11 ' HG3' ' A' ' 3' ' ' GLU . 29.6 t . . . . . 0 C--N 1.316 -0.88 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.532 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.804 0.335 . . . . 0.0 111.356 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.51 -37.99 3.25 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.296 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.557 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 64.3 mm-40 -74.69 120.54 20.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.157 0.504 . . . . 0.0 111.266 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.632 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.9 p -115.33 150.38 36.38 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.733 178.243 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.5 t -120.4 38.14 4.07 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.243 0.544 . . . . 0.0 109.981 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 23.6 t -64.13 -41.75 93.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.075 179.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.62 6.21 83.86 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.49 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.35 20.43 77.08 Favored Glycine 0 C--N 1.318 -0.444 0 CA-C-N 115.331 -0.435 . . . . 0.0 112.971 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 20.7 p -147.05 141.76 26.72 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 122.1 0.16 . . . . 0.0 110.919 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.3 m -108.07 165.36 11.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.123 0.487 . . . . 0.0 110.445 179.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -83.12 -38.15 22.81 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.838 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 89.7 m -73.55 122.23 87.09 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.804 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.3 Cg_exo -64.96 133.55 36.34 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.744 2.296 . . . . 0.0 112.168 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 25.66 70.92 Favored Glycine 0 CA--C 1.519 0.284 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.036 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -92.17 147.38 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.659 0.266 . . . . 0.0 110.342 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -88.86 149.6 23.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.949 179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.6 t -91.55 136.56 33.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.167 0.508 . . . . 0.0 111.352 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.1 m -144.9 61.78 1.31 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.1 t90 -32.2 127.14 0.35 Allowed Pre-proline 0 N--CA 1.465 0.277 0 O-C-N 124.608 1.193 . . . . 0.0 112.594 -177.407 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 44.4 Cg_endo -96.53 30.24 14.12 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.547 -1.439 . . . . 0.0 114.002 0.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.632 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 6.2 m -128.4 175.13 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.557 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 89.1 m -112.94 150.74 31.41 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.845 0.355 . . . . 0.0 111.204 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.827 HG22 ' HA ' ' A' ' 28' ' ' PRO . 13.0 p -131.67 160.61 34.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.633 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -150.54 127.96 11.42 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.7 m-20 58.99 33.72 23.19 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 123.655 0.597 . . . . 0.0 110.841 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.35 16.65 79.79 Favored Glycine 0 C--N 1.33 0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 112.863 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.442 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 95.7 mt -126.59 133.86 25.44 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.827 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.5 Cg_exo -63.26 141.18 81.07 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.313 2.009 . . . . 0.0 112.154 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 3' ' ' GLU . 39.7 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.918 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.174 0 CA-C-O 120.92 0.391 . . . . 0.0 111.893 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 86.3 -30.99 4.24 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.128 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.498 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 11.4 tp10 -72.09 113.65 9.35 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.301 0.572 . . . . 0.0 110.727 -179.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.678 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 23.2 p -113.04 152.65 29.25 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.723 179.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.515 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 28.5 t -116.54 36.69 4.02 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.328 0.585 . . . . 0.0 110.222 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.445 HG23 ' HB ' ' A' ' 4' ' ' THR . 22.7 t -65.03 -37.89 81.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.92 179.453 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.1 3.38 86.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.768 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.42 1.75 90.24 Favored Glycine 0 C--N 1.318 -0.444 0 C-N-CA 121.348 -0.454 . . . . 0.0 113.306 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.7 p -147.3 141.69 26.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.697 0.248 . . . . 0.0 111.012 179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.42 ' HB3' ' CG ' ' A' ' 3' ' ' GLU . 3.2 m -98.62 161.2 13.79 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.336 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -87.93 -35.83 17.45 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.509 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 83.1 m -64.86 126.09 90.34 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.7 Cg_exo -62.39 132.64 39.29 Favored 'Trans proline' 0 C--O 1.238 0.487 0 C-N-CA 122.785 2.323 . . . . 0.0 112.446 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 69.45 30.33 71.27 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.995 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -98.52 135.06 40.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.556 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.55 148.83 23.16 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.828 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -81.31 135.89 35.73 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.285 0.564 . . . . 0.0 111.381 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.5 m -144.24 59.03 1.35 Allowed 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.7 OUTLIER -32.97 128.75 0.37 Allowed Pre-proline 0 N--CA 1.462 0.169 0 O-C-N 124.63 1.206 . . . . 0.0 112.76 -177.256 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.6 Cg_endo -92.7 24.91 23.6 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.066 -1.639 . . . . 0.0 114.209 0.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.678 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 15.5 m -124.97 -172.32 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 O-C-N 121.988 -0.445 . . . . 0.0 112.168 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.515 ' SG ' ' HB2' ' A' ' 5' ' ' CYS . 94.5 m -127.74 146.79 50.47 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.084 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.842 HG22 ' HA ' ' A' ' 28' ' ' PRO . 39.9 p -134.22 162.64 31.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.453 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.5 ttp180 -150.17 125.86 10.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.3 t30 60.03 33.4 21.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.418 0.628 . . . . 0.0 110.567 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.53 9.05 87.09 Favored Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.696 -0.684 . . . . 0.0 113.288 179.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.406 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 9.2 mp -118.78 129.79 25.19 Favored Pre-proline 0 C--N 1.327 -0.396 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.842 ' HA ' HG22 ' A' ' 23' ' ' THR . 15.1 Cg_exo -64.97 140.81 67.81 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.247 1.965 . . . . 0.0 112.331 -179.612 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 40.4 t . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.107 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 120.848 0.356 . . . . 0.0 111.809 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 70.7 32.52 67.08 Favored Glycine 0 N--CA 1.451 -0.348 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.271 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.696 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 2.6 mm-40 -130.16 123.2 29.72 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 121.124 0.488 . . . . 0.0 111.388 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.585 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 33.0 p -116.92 147.45 42.21 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.037 178.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 13.5 t -117.27 40.22 3.08 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.866 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.442 HG23 ' HB ' ' A' ' 4' ' ' THR . 33.8 t -64.2 -42.35 95.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.385 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.78 7.83 76.84 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.395 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.515 ' HA2' ' SG ' ' A' ' 5' ' ' CYS . . . 72.04 31.03 64.65 Favored Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.405 -0.397 . . . . 0.0 112.774 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.3 p -144.92 142.89 30.25 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.646 -0.277 . . . . 0.0 110.89 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 17.6 m -124.94 165.22 18.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.985 0.421 . . . . 0.0 110.018 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -87.21 -33.98 19.15 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.766 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.447 ' HB ' ' HB2' ' A' ' 15' ' ' ALA . 19.7 m -70.29 125.84 92.13 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.176 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -65.94 129.97 23.32 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.456 2.104 . . . . 0.0 111.865 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.2 37.86 87.22 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.327 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.447 ' HB2' ' HB ' ' A' ' 12' ' ' THR . . . -94.78 144.78 25.36 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.899 0.38 . . . . 0.0 110.713 179.783 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.26 148.96 23.3 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.508 178.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.8 t -93.64 134.14 36.26 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.238 0.542 . . . . 0.0 111.325 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 50.6 m -140.03 61.77 1.52 Allowed 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.0 t90 -32.16 126.36 0.35 Allowed Pre-proline 0 N--CA 1.463 0.185 0 O-C-N 124.504 1.128 . . . . 0.0 112.481 -177.462 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.489 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 52.1 Cg_endo -98.36 33.81 9.16 Favored 'Cis proline' 0 N--CA 1.458 -0.595 0 C-N-CA 123.675 -1.385 . . . . 0.0 114.167 0.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.585 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 4.3 m -130.32 163.11 36.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.696 ' HB2' ' HB3' ' A' ' 3' ' ' GLU . 81.7 m -102.44 145.62 29.27 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.814 -0.354 . . . . 0.0 110.984 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.753 HG22 ' HA ' ' A' ' 28' ' ' PRO . 30.6 p -133.42 164.03 28.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.118 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 30.5 ttt-85 -150.85 123.59 8.58 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.4 t30 58.84 34.65 23.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.426 0.631 . . . . 0.0 110.678 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.35 9.43 87.01 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.602 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.419 ' HA ' HD13 ' A' ' 27' ' ' LEU . 3.4 mm? -120.48 130.79 24.68 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 117.126 0.463 . . . . 0.0 109.917 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.753 ' HA ' HG22 ' A' ' 23' ' ' THR . 16.5 Cg_exo -63.76 141.71 79.93 Favored 'Trans proline' 0 N--CA 1.46 -0.462 0 C-N-CA 122.26 1.974 . . . . 0.0 112.253 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.491 ' CG1' ' HG3' ' A' ' 3' ' ' GLU . 37.2 t . . . . . 0 C--N 1.318 -0.786 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.857 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 120.859 0.362 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.91 -35.9 4.46 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.431 179.299 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.641 ' OE2' ' HB3' ' A' ' 10' ' ' CYS . 48.2 tt0 -81.81 121.94 27.07 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.247 0.546 . . . . 0.0 111.05 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 24.4 p -108.69 152.63 24.55 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.607 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.2 t -119.19 41.34 3.1 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.156 0.503 . . . . 0.0 109.704 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.5 t -62.66 -39.64 85.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.687 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.76 11.61 59.08 Favored Glycine 0 N--CA 1.452 -0.241 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.726 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.74 19.28 73.09 Favored Glycine 0 C--N 1.319 -0.369 0 C-N-CA 121.532 -0.366 . . . . 0.0 112.558 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.9 146.25 26.18 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 122.559 0.343 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.641 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . 39.3 m -106.83 172.11 7.0 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.028 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -96.8 -29.84 13.52 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.975 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.436 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.3 m -79.93 124.84 82.97 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.574 -179.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 36.2 Cg_exo -60.35 135.97 65.04 Favored 'Trans proline' 0 C--O 1.234 0.318 0 C-N-CA 122.905 2.403 . . . . 0.0 112.913 -179.37 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.56 32.75 79.42 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.543 -0.753 . . . . 0.0 113.437 179.423 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -100.74 147.11 26.4 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -89.52 150.28 22.52 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.1 t -98.0 138.09 35.84 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.214 0.531 . . . . 0.0 111.04 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.8 m -144.2 62.92 1.34 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 2.6 t90 -33.01 127.26 0.39 Allowed Pre-proline 0 N--CA 1.465 0.296 0 O-C-N 124.563 1.164 . . . . 0.0 112.32 -177.551 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 54.3 Cg_endo -97.08 33.11 10.13 Favored 'Cis proline' 0 N--CA 1.459 -0.528 0 C-N-CA 123.505 -1.456 . . . . 0.0 114.24 0.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.4 m -129.8 169.99 19.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.436 ' SG ' ' HG2' ' A' ' 3' ' ' GLU . 99.4 m -107.33 148.08 29.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.475 179.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.955 HG22 ' HA ' ' A' ' 28' ' ' PRO . 33.1 p -137.3 168.7 19.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.101 0.476 . . . . 0.0 110.664 -179.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -151.09 120.0 6.64 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 m120 57.85 36.64 26.54 Favored 'General case' 0 N--CA 1.467 0.417 0 O-C-N 123.41 0.444 . . . . 0.0 111.331 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.15 7.0 88.74 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 121.095 -0.574 . . . . 0.0 113.188 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.447 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 94.1 mt -113.34 126.17 28.57 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.462 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.955 ' HA ' HG22 ' A' ' 23' ' ' THR . 12.2 Cg_exo -67.5 140.94 53.88 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.395 2.064 . . . . 0.0 112.879 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.9 t . . . . . 0 C--N 1.318 -0.8 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.129 178.789 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.206 0 CA-C-O 120.922 0.391 . . . . 0.0 111.486 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.93 33.77 75.56 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.552 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 6.2 tp10 -129.43 114.08 15.71 Favored 'General case' 0 C--O 1.241 0.656 0 CA-C-O 121.224 0.535 . . . . 0.0 110.182 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 44.7 p -111.45 151.64 28.33 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.057 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.492 ' HB2' ' SG ' ' A' ' 22' ' ' CYS . 15.3 t -118.04 39.5 3.38 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.101 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.4 t -62.87 -40.6 89.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.475 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.57 4.81 85.19 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.76 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.21 13.56 82.72 Favored Glycine 0 C--N 1.317 -0.527 0 C-N-CA 121.433 -0.413 . . . . 0.0 113.03 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.4 p -147.82 142.04 26.16 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.155 0.182 . . . . 0.0 110.858 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 m -106.98 163.05 13.3 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 178.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 t30 -87.62 -35.73 17.89 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.719 0.771 . . . . 0.0 109.286 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 32.2 m -65.85 126.01 90.97 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 114.76 -1.109 . . . . 0.0 111.213 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -64.45 133.77 38.76 Favored 'Trans proline' 0 C--O 1.237 0.45 0 C-N-CA 122.519 2.146 . . . . 0.0 112.472 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.9 29.51 72.51 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.307 -0.86 . . . . 0.0 113.02 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -95.94 137.11 35.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.811 0.339 . . . . 0.0 110.621 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -89.3 149.43 23.05 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.585 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.5 t -86.61 136.2 33.14 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.352 0.596 . . . . 0.0 111.6 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.5 m -143.48 59.44 1.39 Allowed 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 1.8 t90 -31.94 127.43 0.33 Allowed Pre-proline 0 N--CA 1.464 0.245 0 O-C-N 124.506 1.129 . . . . 0.0 112.543 -177.297 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 49.3 Cg_endo -95.29 29.28 15.86 Favored 'Cis proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.352 -1.52 . . . . 0.0 114.134 0.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.597 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 9.9 m -126.92 179.31 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.552 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 92.9 m -120.9 144.31 48.49 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.243 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.676 HG22 ' HA ' ' A' ' 28' ' ' PRO . 34.7 p -134.85 155.92 49.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.642 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -148.19 130.36 15.49 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.0 m120 59.74 30.99 20.58 Favored 'General case' 0 N--CA 1.465 0.3 0 O-C-N 123.589 0.556 . . . . 0.0 110.934 -178.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.19 17.58 80.2 Favored Glycine 0 N--CA 1.451 -0.306 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.753 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 36.4 tp -129.59 129.06 23.13 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.676 ' HA ' HG22 ' A' ' 23' ' ' THR . 20.5 Cg_exo -62.19 142.7 92.74 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.195 1.93 . . . . 0.0 111.854 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.539 ' HB ' ' HB3' ' A' ' 3' ' ' GLU . 46.0 t . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.702 179.794 . . . . . . . . 1 1 . 1 stop_ save_